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Ora até que enfim..., perfeitamente...  
Cá está ela! 
Tenho a loucura exactamente na cabeça. 
 
Meu coração estoirou como uma bomba de pataco, 
E a minha cabeça teve o sobressalto pela espinha acima... 
 
Graças a Deus que estou doido! 
Que tudo quanto dei me voltou em lixo, 
E, como cuspo atirado ao vento, 
Me dispersou pela cara livre! 
Que tudo quanto fui se me atou aos pés, 
Como a sarapilheira para embrulhar coisa nenhuma! 
Que tudo quanto pensei me faz cócegas na garganta 
E me quer fazer vomitar sem eu ter comido nada! 
Graças a Deus, porque, como na bebedeira, 
Isto é uma solução. 
Arre, encontrei uma solução, e foi preciso o estômago! 
Encontrei uma verdade, senti-a com os intestinos! 
 
Poesia transcendental, já a fiz também! 
Grandes raptos líricos, também já por cá passaram! 
A organização de poemas relativos à vastidão de cada assunto 
resolvido em vários –  
Também não é novidade. 
 
Tenho vontade de vomitar, e de me vomitar a mim... 
Tenho uma náusea que, se pudesse comer o universo para o despejar 
na pia, comia-o. 
Com esforço, mas era para bom fim. 
Ao menos era para um fim. 
E assim como sou não tenho fim nem vida... 
 
Álvaro de Campos, in Poesia 
 
Aos meus pais.
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ABSTRACT 
Transthyretin (TTR) is a plasma- and cerebrospinal fluid (CSF)-circulating tetrameric 
protein synthesized mainly by liver hepatocytes, brain choroid plexus (CP) and retinal 
epithelium. The TTR monomer is composed of 127 amino acids with a molecular weight of 
14kDa, and is secreted as a 55kDa homotetramer. TTR is mostly associated with 
transport of thyroxine and retinol but recent studies have uncovered important functions in 
the physiology of the nervous system. 
Over 100 point mutations have been identified in TTR gene, most of which are disease-
associated. Mutations in TTR gene can cause a destabilization effect in the tetramer 
structure, decreasing its thermodynamic and kinetic stability, which leads to dissociation 
into partial unfolded monomers preceding amyloid formation. The variants presenting 
lowest thermodynamic and kinetic stability are usually associated with leptomeningeal 
amyloidosis, as for example L12P or D18G. However the most common TTR variant is 
V30M; this variant is associated with familial amyloidotic polyneuropathy (FAP), an 
autosomal dominant neurodegenerative disease affecting particularly the peripheral 
nervous system (PNS) and characterized by the extracellular deposition of amyloid fibrils 
composed essentially of mutated TTR. A more benign form of FAP is found in compound 
heterozygotes patients carrying TTR V30M and T119M alleles. Thus the latter TTR variant 
is considered protective. 
Currently, liver transplantation is the only efficient therapy available for FAP, to suppress 
the expression of mutated protein and avoid further amyloid deposition; however, it has 
major disadvantages as it is a very invasive therapy with risk for the patients, with limited 
availability of organs, it only suppresses TTR mutant synthesized by liver and secreted to 
blood, with no effect on CSF-circulating protein that potentially compromises the central 
nervous system (CNS). Therefore, the development of alternative treatments for TTR 
amyloidosis is of great importance, as well as the establishment of new models of study to 
identify important molecules and pathways to target by therapeutic approaches. 
Here we report our study on the secretion pattern of the TTR L12P variant both in vivo 
and in vitro. Using a fluorescent small tetracysteine (TC) tag, we directly visualized the 
secretion pathway of TTR L12P in hepatocyte- and CP-derived cells, as well as 
intracellular degradation patterns. Furthermore, we accomplished liver-specific adeno-
associated virus (AAV) gene transfer to establish a new somatic transgenic mouse model, 
bypassing the laborious transgenesis process. We found that hepatocytes exhibit 
decreased secretion levels of TTR L12P both in vitro and in vivo compared to WT and 
V30M variants. Most importantly, we found a differential N-glycosylation pattern of L12P 
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variant in both conditioned media from cells and in mouse serum from scAAV8-TTR L12P 
infected mouse; this finding represents escape from endoplasmic reticulum-associated 
degradation (ERAD) to be further investigated. In addition, none of these findings were 
observed in CP-derived cells, suggesting the existence of particular secretion/quality 
control mechanisms that might contribute to leptomeningeal amyloidosis associated with 
TTR L12P. Moreover, we noticed the presence of intracellular protein aggregates in 
cultured hepatoma cell lines and in mouse liver, which were localized mainly in 
lysosomes. 
Also localized in lysosomes, we found TTR-V30M-TC aggregates upon incubation with a 
neuroblastoma cell line. Previous work has shown that soluble WT TTR is internalized by 
a variety of cell types. To our knowledge the work presented here is the first to analyze 
and demonstrate internalization of TTR aggregates. In the present work, we infected 
HEK293 cells with a lentivirus expressing TTR-V30M-TC to obtain TTR V30M aggregates 
in the conditioned media and further use this media for internalization studies; this 
approach allowed us to follow by live-cell imaging its internalization and intracellular fate. 
We found that TTR aggregates were indeed internalized by a neuroblastoma cell line by a 
process involving both dynamin- and lipid rafts-dependent mechanisms; upon 
internalization, aggregates were rapidly translocated to lysosomes for degradation. 
Additional studies will be needed to uncover the intracellular trafficking pathway(s) that 
regulate transport of TTR aggregates from the cell surface to lysosomes. 
Several treatments for FAP have been attempted, as for example gene therapy using anti-
sense oligonucleotides (ASOs) to suppress TTR expression or the use of small molecules 
to bind TTR and stabilize the tetramer structure preventing dissociation. We took 
advantage of AAV-mediated gene transfer to deliver TTR T119M to liver of human TTR 
V30M transgenic mice. Expression of TTR T119M together with V30M led to protein 
stabilization and significant reduction of TTR deposits in the gastrointestinal (GI) tract of 
the animals, as well as to decreased levels of biomarkers associated with pathology. 
However, these results were only observed in animals injected at younger ages, with no 
therapeutic effect observed when TTR deposition was already evident. Besides the 
observed stabilization effect, the impact on other molecular mechanisms associated with 
changed TTR deposition was investigated by proteomic (2D-DIGE) and transcriptomic 
analysis (gene expression arrays) of dorsal root ganglia (DRG). The proteomics approach 
revealed decreased levels of a modified form of TTR with higher molecular weight in 
scAAV8-TTR T119M injected animals that may correspond to N-glycosylated TTR, but the 
significance of this finding has yet to be addressed; on the other hand, transcriptomic 
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analysis suggested that the protective effect of T119M may be mediated through changes 
in expression levels of extracellular matrix (ECM) remodeling genes. 
The data presented in this thesis suggests that AAV-mediated gene transfer is an 
excellent platform to establish new mouse models of TTR amyloidosis and develop new 
therapies for FAP. Our finding that cellular uptake of TTR aggregates occurs via endocytic 
lipid-raft dependent mechanisms, and most likely is responsible for ER stress and 
apoptotic events previously described by our lab, opens new avenues for research and 
therapeutic intervention. 
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SUMÁRIO 
A transtirretina (TTR) é uma proteína tetramérica que circula no plasma e no líquido 
cefalorraquidiano (LCR), produzida principalmente pelos hepatócitos do fígado, pelo 
plexo coróide (PC) no cérebro e pelo epitélio da retina. Cada monómero de TTR é 
composto por 127 aminoácidos com o peso molecular de 14kDa, sendo a proteína 
secretada como um homotetrâmero de 55kDa. A TTR está essencialmente associada ao 
transporte de tiroxina e de retinol, mas estudos mais recentes revelaram que possui 
funções importantes na fisiologia do sistema nervoso. 
Foram já identificadas mais de 100 mutações pontuais no gene da TTR, a maioria das 
quais está associada com doenças. Mutações na TTR podem provocar uma 
destabilização na estrutura do tetrâmero, diminuindo as suas estabilidades 
termodinâmica e cinética, o que conduz à sua dissociação em monómeros com 
conformação parcialmente alterada, o que precede a formação de amilóide. As variantes 
de TTR que apresentam estabilidades termodinâmica e cinética mais baixas estão 
normalmente associadas com amiloidose leptomeningeal, como é o caso das variantes 
L12P ou D18G. No entanto, a variante de TTR mais comum é V30M; esta variante está 
associada a polineuropatia amiloidótica familiar (PAF), uma doença neurodegenerativa 
autossómica dominante que afecta em particular o sistema nervoso periférico (SNP) e 
que é caracterizada pela deposição extracelular de fibras de amilóide compostas 
essencialmente por TTR mutada. Uma forma mais benigna de PAF pode ser encontrada 
em doentes heterozigóticos que possuam os alelos de TTR V30M e T119M, pelo que 
esta última variante pode ser considerada como protectora. 
Actualmente, o transplante hepático é a única terapia eficiente para PAF, de forma a 
suprimir a expressão da proteína mutada e evitar a deposição adicional de amilóide; 
contudo, esta terapia acarreta inúmeras desvantagens, pois é uma terapia invasiva com 
risco para os doentes, e disponibilidade limitada de órgãos, alem de apenas suprimir a 
TTR mutante que é sintetizada pelo fígado e secretada para o sangue, não produzindo 
qualquer efeito na proteína que circula no LCR e que poderá potencialmente 
comprometer o sistema nervoso central (SNC). Desta forma, é de grande importância que 
se desenvolvam tratamentos alternativos para as amiloidoses provocadas por TTR, bem 
como que se estabeleçam novos modelos de estudo que permitam identificar moléculas 
e vias importantes que possam ser alvos terapêuticos.  
Nesta tese reportamos o nosso estudo no padrão de secreção da variante de TTR L12P 
tanto in vivo como in vitro. Usando uma pequena marcação na proteína composta por 
tetracisteína fluorescente, visualizámos directamente o padrão de secreção da TTR L12P 
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em células derivadas de hepatócitos e do PC, bem como as suas vias de degradação 
intracelular. Além disso, utilizando vírus associados a adenovírus (AAV), efectuámos 
transferência genética específica para o fígado de forma a estabelecer um novo modelo 
animal somático em murganho, evitando assim o processo laborioso de produção de 
animais transgénicos. Estes estudos permitiram observar que os hepatócitos possuem 
níveis mais baixos de secreção de TTR L12P tanto in vivo como in vitro quando 
comparado com as variantes WT ou V30M. Para além disso, foi também possível 
observar a existência de um padrão de N-glicosilação na variante L12P tanto nos meios 
condicionados das células como também no soro de murganhos injectados com scAAV8-
TTR L12P, o que poderá representar uma fuga aos mecanismos de degradação 
associada ao retículo endoplasmático (RE) necessitando de mais investigação. 
Adicionalmente, nenhum destes resultados foi observado nas células derivadas de PC, o 
que sugere a existência de mecanismos específicos de secreção e controlo de qualidade 
que possam contribuir para a amiloidose leptomeningeal associada com TTR L12P. Foi 
também documentada a existência de agregados proteicos intracelulares, tanto nos 
hepatócitos em cultura celular como também no fígado dos murganhos, que se 
encontravam maioritariamente em lisossomas. 
De forma semelhante, também encontrámos agregados de TTR-V30M-TC depois de 
estes terem sido incubados com uma linha celular de neuroblastoma. Estudos anteriores 
mostraram que a proteína solúvel TTR WT é internalizada por vários tipos de células. 
Para o nosso conhecimento, o trabalho que aqui apresentamos é o primeiro a analisar e 
demonstrar a internalização de agregados de TTR. Neste trabalho, infectámos células 
HEK293 com lentivírus para expressar TTR-V30M-TC, de forma a obter agregados 
proteicos formados por TTR V30M no meio condicionado das células e seguidamente 
utilizar este meio para efectuar estudos de internalização; esta abordagem permitiu seguir 
através de imagiologia de células vivas em tempo real a internalização e o destino 
intracelular desses agregados. Este sistema permitiu observar que os agregados de TTR 
são de facto internalizados por uma linha celular de neuroblastoma por processos que 
envolvem mecanismos dependentes de dinamina e de lipi-rafts; depois de internalizados, 
os agregados foram rapidamente translocados para os lisossomas por forma a serem 
degradados. São ainda necessários estudos adicionais para melhor compreender as vias 
de tráfico intracelular que regulam o transporte dos agregados de TTR desde a superfície 
da células até aos lisossomas. 
Até à data, têm sido tentados vários tratamentos para PAF, como por exemplo terapia 
génica utilizando oligonucleótidos de cadeia complementar para suprimir a expressão de 
TTR, ou a utilização de pequenas moléculas que se ligam à TTR e estabilizam a sua 
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estrutura tetramérica prevenindo a dissociação. Nós tirámos partido da transferência 
genética mediada por AAV para expressar TTR T119M no fígado de murganhos 
transgénicos que expressam a variante humana TTR V30M. A expressão conjunta de 
TTR T119M e V30M conduziu à estabilização da proteína e à redução significativa dos 
depósitos de TTR no tracto gastrointestinal dos animais, bem como à redução de 
biomarcadores associados a esta patologia. No entanto, estes resultados foram apenas 
observados em animais injectados em idades jovens, não tendo sido observado qualquer 
efeito terapêutico nos animais em que a deposição de TTR era já pronunciada. Para além 
do efeito estabilizador observado, também foi analisado o efeito da introdução desta 
variante de TTR noutros mecanismos moleculares associdos com a deposição de TTR, 
utilizando análises proteómica (2D-DIGE) e transcriptómica (arrays de expressão génica) 
de gânglios dorsais dos murganhos injectados. A análise proteómica revelou diminuição 
dos níveis de uma forma modificada de TTR com elevado peso molecular nos animais 
injectados com scAAV8-TTR T119M que poderá corresponder à forma N-glicosilada de 
TTR, contudo o significado desta descoberta necessita de ser melhor investigado; por 
outro lado, da análise transcriptómica sirgiu a sugestão de que o efeito protector da TTR 
T119M pode estar associado a alterações nos níveis de expressão de genes envolvidos 
na remodelação da matriz extracelular. 
De um modo geral, os dados apresentados nesta tese sugerem que a transferência 
genética mediada por AAV é uma excelente plataforma para  criação de novos modelos 
animais de amiloidoses relacionadas com TTR em murganhos, bem como para o 
desenvolvimento de novas terapias para PAF. Os nossos resultados acerca da 
internalização de agregados de TTR por outras células, descrevendo que esta ocorre 
através de mecanismos endocíticos dependentes de lipid-rafts e que será muito 
provavelmente esta a via responsável pelo stresse do RE e mecanismos de apoptose 
descritos anteriormente pelo nosso laboratório, poderão abrir novas avenidas para a 
investigação de estratégias e terapias nesta patologia. 
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TRANSTHYRETIN 
It was back in 1942 that two different research teams detected the presence of a 
component with an electrophoretic mobility slightly greater than albumin both in serum 
(Seibert and Nelson, 1942) and in cerebrospinal fluid (CSF, Kabat et al., 1942). This new 
plasma- and CSF-circulating protein was then called “prealbumin”, a term that lasted for 
many years until a new name that reflected its physiological roles was proposed: 
transthyretin (TTR), as in transporter of thyroxine and retinol (Biochemistry, 1981; Raz 
and Goodman, 1969). 
In a phylogenetic view, TTR is a highly conserved protein among vertebrate species, 
including mammals, birds, reptiles, amphibians and fish (Power et al., 2000; Schreiber 
and Richardson, 1997). More recently, an increasing number of proteins with functional 
roles identical to TTR, called TTR-like, are being reported in prokaryotes and lower 
eukaryote organisms (Eneqvist et al., 2003; Hennebry et al., 2006). 
Nowadays, new functions of TTR continue to be uncovered in several biochemical 
processes (for a review see Oliveira et al., 2012) and it is also implicated in different 
disorders, namely Familial Amyloidotic Polyneuropathy (FAP), when associated with 
several point mutations (Saraiva, 2001). 
 
 
Transthyretin expression 
TTR is codified by a single copy gene located in chromosome 18 (Whitehead et al., 1984). 
TTR gene spans 6.9kb, comprising 4 exons (E1 to E4) and 3 introns (I1 to I3) (Figure I.1); 
E1 (95bp) encodes for a signal peptide of 20 aminoacids and the 3 first aminoacids of the 
mature protein; E2 (131bp), E3 (136bp) and E4 (253bp) encode for the remaining mature 
protein aminoacid residues 4–47, 48–92bp and 93–127, respectively (Sasaki et al., 1985; 
Tsuzuki et al., 1985). A particularity in this gene is the existence of 2 independent open 
reading frames (ORF) in I1 and I3, with the same transcription direction, but with unknown 
function, since they are neither transcribed to be expressed as independent polypeptides 
nor integrated to fully translated mRNAs (Soares et al., 2003; Tsuzuki et al., 1985). 
Expression of the gene requires a 6kb upstream region that retains all the cis-elements 
required for developmental, tissue-specific and quantitatively normal expression (Nagata 
et al., 1995). 
CHAPTER I⏐General Introduction 
4 
 
Figure I.1. Schematic representation of human TTR gene structure. E1 to E4 represent exons 1 to 
4; AATAAA, polyadenylation signal (adapted from Sasaki et al., 1985). 
 
TTR mRNA is found as early as the 10th day of gestation in mice, indicating that its 
synthesis is initiated at early stages of fetal development (Murakami et al., 1987). Studies 
conducted using rat tissues showed that the liver is the organ with highest levels of TTR 
mRNA (Felding and Fex, 1982), followed by the brain with 30% of liver mRNA levels; low 
amounts of the gene were also detected in stomach, heart, skeletal muscle and spleen 
(Soprano et al., 1985). It was later revealed that only a specific area in the brain 
expresses ttr; the choroid plexus epithelium was described as the major site of TTR 
synthesis, since the ratio tissue mass / expression levels is 25-fold higher in these cells 
than in liver (Aleshire et al., 1983; Dickson et al., 1985; Sousa et al., 2007a). Notice that 
synthesis and secretion of TTR are regulated independently in the liver and choroid 
plexus (Dickson et al., 1986). In addition, ttr gene expression was also found in the 
visceral yolk sac (Soprano et al., 1986), retinal pigment epithelium in the eye (Cavallaro et 
al., 1990; Martone et al., 1988), islets of Langerhans in the pancreas (Jacobsson, 1989) 
and, more recently, in human placenta (McKinnon et al., 2005). TTR expression has been 
suggested to also occur in brain neurons, particularly in cortex and hippocampus 
(Buxbaum et al., 2008; Stein et al., 2004); however these observations are based on 
intraneuronal TTR protein staining, which may be a result of protein uptake from CSF and 
not necessarily TTR synthesis. It has also been reported that TTR is expressed both in 
dorsal root ganglia (DRG) neurons (Murakami et al., 2008) and in Schwann cells of 
peripheral nerves (Murakami et al., 2010); however another report clarified that TTR 
expression in DRG was an artifact (Sousa and Saraiva, 2008). 
TTR produced in liver is secreted into the bloodstream, where the protein concentration 
normally ranges between 200 to 400µg/mL (Goldsmith and Munson, 1987); it is gender 
and age dependent, with serum concentration levels showing a progressively increasing 
concentration from newborn to adult beginning to decline at age 50 (Ingenbleek and De 
Visscher, 1979; Stabilini et al., 1968). The epithelial cells of the choroid plexus secrete 
TTR into the CSF, where its concentration varies from 5 to 20µg/mL, with no significant 
correlation with age (Vatassery et al., 1991) and it represents 20% of the total CSF 
proteins (Weisner and Roethig, 1983). 
AATAAA
E1 E2 E3 E4
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Many studies have been performed regarding TTR metabolism and turnover, determining 
that the biological half-life of this molecule in serum is approximately 2–3 days in humans 
(Socolow et al., 1965), 22–23h in primates (Vahlquist, 1972) and 10–13h in rats (Peterson 
et al., 1974). Makover and colleagues further investigated TTR turnover and determined 
that the entire CSF TTR pool turned over in about 2.5–3.5h in rat; this same study also 
revealed kidney and liver as the most active organs in TTR degradation (Makover et al., 
1988). However, little is known about TTR catabolism. 
 
 
Transthyretin structure 
TTR molecule is a stable tetramer composed of 4 identical or nearly identical subunits 
(Blake et al., 1974). Each monomer contains 127 aminoacids and its molecular weight is 
13,745Da, calculated from its composition; therefore the overall molecular weight of the 
assembled tetramer is 54,890Da (Kanda et al., 1974). 
X-ray diffraction studies on protein crystals clarified the main elements of secondary, 
tertiary and quaternary structures of TTR at a resolution of 1.8Å (Blake et al., 1978). Each 
TTR subunit has an extensive β-sheet structure composed of 8 strands (A through H), 
organized into 4-stranded sheets (DAGH and CBEF); there is also a short α-helix. The β-
sheets are linked by seven loops and a small helical region involving residues 75 to 83 
located in the E strand. All, with the exception of A and G strands, display an antiparallel 
orientation and are arranged in a topology similar to the classic Greek key barrel; β-
strands are 6–9 aminoacids long, except the D strand that only contains 3 residues. 
Strands F and H of each monomer can interact through hydrogen bonds and form a dimer 
(Figure I.2A). To form the tetramer, 2 dimers interact through hydrophobic contacts 
involving residues situated in the AB and GH loops. Assembly of the tetramer forms one 
large hydrophobic channel between the 2 dimers, where thyroxin (T4) binds (Figure I.2B). 
TTR has a globular shape and an overall size of 70Å x 55Å x 50Å (Blake et al., 1978; 
Blake et al., 1974; Hornberg et al., 2000). 
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Figure I.2. Ribbon drawing of the TTR structure. (A) The structure of the dimer with monomer A 
colored in dark gray and monomer B in light gray. Each monomer contains 2 β-sheets composed of 
strands DAGH and CBEF, extending to two 8-stranded β-sheets when two monomers associate 
forming a dimer. The strand arrangement is DAGHH’G’A’D’ and CBEFF’E’B’C’; strands A-H belong 
to one monomer while A’-H’ represent the equivalent monomer in the other subunit. The 2 paths of 
the FG loop in the B monomer are shown in red (adapted from Hornberg et al., 2000). (B) 
Representation of TTR quaternary structure complexed with T4 in the central hydrophobic channel. 
Note the 2 dimers slightly rotated in relation to each other along the y-axis. Adapted from PDB 
entry 2ROX. 
 
From a structural point of view, tetrameric TTR is extremely stable, and is unusually 
resistant to subunit dissociation and to denaturation with acid, alkali, urea, guanidine, or 
detergents (Kanda et al., 1974). However the existence of point mutations may alter the 
structural stability of the molecule. For instance, Hamilton and colleagues reported in 1993 
that the valine for methionine substitution at position 30 (V30M variant) forces the β-
sheets of the monomer as much as 1Å apart, resulting in a distortion of the T4 binding 
cavity (Hamilton et al., 1993). Later on, in 1998, Sebastião and colleagues described that 
the substitution of leucine for proline at position 55 results in the disruption of the 
monomer strand D, causing a potentially less stable L55P TTR tetramer compared to wild 
type (WT) (Sebastiao et al., 1998); the same result had already been documented for 
V122I TTR variant (Damas et al., 1996). 
 
 
 
A B
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Transthyretin physiological functions 
From an historical point of view, TTR owes its name to its physiological role as a 
transporter of thyroxine (Hollander et al., 1962) and retinol (Alvsaker et al., 1967). 
However, several other functions are associated with this molecule. For instance, TTR 
can be used as a useful clinical indicator to evaluate the presence of an acute systemic 
disease, particularly malnutrition or an infectious disease, due to its sensitivity to both 
nutritional status and inflammation (Ingenbleek and Bernstein, 1999; Myron Johnson et 
al., 2007). Moreover, recent findings suggest that TTR has an important physiological role 
in the nervous system. 
 
TTR as a transporter molecule 
Thyroid hormones are essential for normal mammalian development and for normal 
metabolism. T4 is the principal product synthesized and secreted by the thyroid follicles, 
while tri-iodothyronine (T3), the biologically active hormone, derives mainly from local 
deiodination of T4 in tissues (Palha, 2002). Once secreted, thyroid hormones bind to 
plasma transport proteins. In human serum, about 75% of the total circulating T4 is carried 
by thyroid binding globulin (TBG), with 10–15% bound to both TTR and albumin, while in 
rodents this value increases to about 50%; under most circumstances TTR binds virtually 
no T3. As for CSF, in humans, TTR is the main carrier of T4, transporting up to 80% of T4 
in the CSF. Less than 1% of TTR tetramers transport T4 in human serum, due to the high 
affinity of T4 to TBG and because the serum concentration of T4 is low compared to that of 
TTR, therefore the stoichiometry of T4 binding to tetrameric TTR is higher in the CSF as 
compared to that in serum (Bartalena and Robbins, 1993; Hagen and Elliott, 1973; Palha, 
2002). 
Retinol (vitamin A) is essential for several physiological functions, namely for vision, 
reproduction, growth and development. TTR is a retinol plasma carrier, through binding to 
retinol-binding protein (RBP) (Kanai et al., 1968). Retinol-RBP complex binds to TTR on 
the exterior of the molecule, having 4 binding sites available; however, under 
physiological conditions TTR only binds 2 holo-RBP molecules due to steric hindrance 
and RBP binding does not compete with T4 binding (Monaco et al., 1995; Nilsson et al., 
1975). The TTR:retinol-RBP complex is formed in the endoplasmic reticulum (ER) of 
hepatocytes and is secreted into serum, usually in a 1:1:1 equimolar ratio, preventing the 
glomerular filtration of the low molecular weight RBP in the kidneys (Monaco, 2000). 
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The role of TTR in tissue distribution of thyroid hormones and retinol is controversial. 
Given that both thyroid hormones and retinol are essential for normal embryonic 
development, it was thought that lack of TTR could result in development impairment and 
in a severe phenotype. However, this is not the case, as TTR knockout (KO) mice display 
no obvious phenotypic abnormalities (Episkopou et al., 1993). In TTR KO mice, T4 plasma 
and CSF levels are strongly reduced compared to WT mice; nevertheless, TTR is not 
needed for thyroid hormone to be delivered to tissues, as a normal T4 distribution both in 
brain and other tissues was observed (Episkopou et al., 1993; Palha et al., 1994; Palha et 
al., 2000; Palha et al., 1997; Wei et al., 1995). Thus TTR most likely is a redundant protein 
in thyroid hormone homeostasis. Similarly, TTR KO mice do not show signs of retinol 
deficiency in tissues (Wei et al., 1995) but present lower circulation levels of RBP possibly 
due to increased renal filtration of the RBP-retinol complex (van Bennekum et al., 2001). 
Therefore, other proteins and/or alternative pathways for tissue delivery might overcome 
TTR function as a carrier. It is possible that the major function of TTR remains to be 
elucidated. 
 
TTR roles in lipid metabolism and as a novel protease 
TTR was found associated to a small portion of low density proteins (LDL) and also to 
high density proteins (HDL) in the serum of FAP patients (Tanaka et al., 1994). 
Association of TTR with HDL is achieved through interaction with apolipoprotein A-I 
(apoA-I) in a non-RBP bound form; 1–2% of total TTR in plasma is bound to HDL (Sousa 
et al., 2000a). Later, Liz and colleagues reported apoA-I as a substrate in the just 
described proteolytic activity of TTR (Liz et al., 2004); TTR was able to proteolytically 
process the C-terminus of apoA-I, leading to decreased capacity of HDL to promote 
cholesterol efflux and thus affecting the development of atherosclerosis (Liz et al., 2007). 
TTR was also reported to be able to in vitro cleave amidated neuropeptide Y (NPY) and 
thus promote neurite outgrowth (Liz et al., 2009). Only a small fraction of TTR is active as 
a metallopeptidase (Liz et al., 2012). 
More substrates for TTR proteolytic activity have been recently described. Costa and 
colleagues showed that TTR has the ability to cleave in vitro amyloid-β peptide (Aβ), 
generating peptides with decreased amyloidogenic potential and toxicity when compared 
to full length Aβ; TTR was also shown to degrade in vitro aggregate forms of the peptide, 
thus suggesting a TTR participation in its catabolism and in Aβ plaque removal in the 
brain (Costa et al., 2008a; Costa et al., 2008b). 
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TTR roles in nervous system biology 
Apart from its relation to the neurodegenerative disorder FAP (which will be further 
discussed in the next sections), recent findings have implicated TTR as an important 
molecule in the peripheral nervous system (PNS) as well as in central nervous system 
(CNS) biology. 
Studies involving sciatic nerve crush in TTR KO and WT mice, showed a role for TTR in 
nerve regeneration, as TTR KO animals showed decreased capacity of sciatic nerve 
regeneration, as well as slower recovery of locomotor activity, slower nerve conduction 
velocity and decreased number of myelinated and unmyelinated axons, when compared 
to their WT littermates, also TTR delivered locally to crushed sciatic nerve was shown to 
rescue the regeneration capacity of TTR KO mice (Fleming et al., 2009; Fleming et al., 
2007). 
Regarding the roles in the CNS, Sousa and colleagues showed that TTR KO mice present 
reduced signs of depressive- and anxiety-like behavior, together with increased 
exploratory activity, suggesting the modulation of the noradrenergic system by TTR 
(Sousa et al., 2004). Further supporting a role of TTR in cognition, it was shown that age-
related worsening of cognitive performance observed in WT animals is associated with 
reduced TTR levels in CSF (Sousa et al., 2007b). Moreover, the neuropeptide NPY, which 
among others possesses anti-depressant properties, shows increased levels in TTR KO 
mice, due to regulation-dependent mechanism of TTR on down-regulating peptidylglycine 
α-amidating monooxygenase (PAM), the rate-limiting enzyme in NPY maturation (Nunes 
et al., 2006). 
TTR has been suggested to play a key role in the modulation of Aβ aggregation, by 
forming in vitro stable complexes with soluble Aβ and preventing it from forming amyloid 
fibrils (Schwarzman et al., 1994). In addition, TTR levels are decreased both in CSF 
(Serot et al., 1997) and plasma (Ribeiro et al., 2012) of Alzheimer’s disease (AD) patients, 
the later seen at a very early stage of disease, turning TTR to a potential biomarker of AD. 
Studies involving a transgenic mouse model of AD crossed with TTR KO mice showed 
elevated levels and deposition of brain Aβ in the presence of reduced TTR levels (Choi et 
al., 2007); in a different model, decreased levels of Aβ brain deposition and improved 
cognition were reported upon TTR overexpression (Buxbaum et al., 2008); recent studies 
have shown that, TTR modulation of brain Aβ levels in AD mouse models is only observed 
in females (Oliveira et al., 2011). Altogether, these reports corroborate the idea of a 
protective role of TTR in AD. Also, CSF-derived TTR appears to have a role in attenuating 
neuronal cell death, edema and inflammation in brain injury caused by ischemia in 
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surgically-induced permanent middle cerebral artery occlusion (pMCAO) in a mouse 
model with a compromised heat shock response (HSR) background (Santos et al., 
2010b). 
Nowadays, TTR is no longer considered a simple transport molecule, as recent studies 
have uncovered an important role of TTR in nervous system physiology, namely in 
peripheral nerve regeneration, development of AD pathology, and prevention of neuronal 
cell death. 
 
 
Transthyretin molecular variants 
Over 100 mutations in the primary sequence of TTR have been identified, most of which 
are associated with amyloidosis. Table I.1 lists 98 amyloid-associated TTR mutations, 13 
non-amyloidogenic mutations and 12 double mutations; an up-to-date list of TTR 
mutations can be found at http://amyloidosismutations.com/mut-attr.php. The majority of 
the amyloidogenic TTR variants are associated with peripheral neuropathy as the main 
clinical manifestation. Often, cardiomyopathy, carpal tunnel syndrome and vitreopathy 
occur as well. Several TTR mutations without clinical manifestations have also been 
described. Also, several compound heterozygotes, carriers of two different TTR 
mutations, have been reported. 
 
Table I.1. TTR mutations (adapted from Saraiva, 2001 and Benson and Kincaid, 2007). 
Mutation Codon change Predominant clinical 
features 
Pathological mutations 
C10R TGT CGT PN, AN, Eye 
L12P CTG CCG LM, PN, AN 
D18E GAT GAG PN, AN 
D18G GAT GGT LM 
D18N GAT AAT Heart 
V20I GTC ATC Heart 
S23N AGT AAT Heart 
P24S CCT TCT Heart, CTS, PN 
A25S GCC TCC Heart, CTS, PN 
A25T GCC ACC LM, PN 
V28M GTG ATG PN, AN 
V30M GTG ATG PN, AN, Eye 
V30A GTG GCG Heart, AN 
V30L GTG CTG PN, AN 
V30G GTG GGG LM, Eye 
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V32A GTG GCG PN 
F33I TTC ATC PN, Eye 
F33L TTC CTC PN, AN 
F33V TTC GTC PN, AN 
F33C TTC TGC CTS, Heart, Eye, Kidney 
R34T AGA ACA PN, Heart 
R34G AGA GGA Eye 
K35N AAG AAC PN, AN, Heart 
K35T AAG ACG Eye 
A36P GCT CCT PN, Eye 
D38A GAT GCT PN, Heart 
W41L TGG TTG Eye, PN 
E42G GAG GGG PN, AN 
E42D GAG GAT Heart 
F44S TTT TCT PN, AN, Heart 
A45D GCC GAC Heart 
A45S GCC UCC Heart 
A45T GCC ACC Heart 
G47R GGG CGG PN, AN 
G47A GGG GCG Heart, PN, AN 
G47V GGG GTG PN, AN, Heart 
G47E GGG GAG PN 
T49A ACC GCC Heart, PN 
T49I ACC ATC PN, Heart 
T49P ACC CCC Heart, PN 
S50R AGT AGG PN, AN 
S50I AGT ATT Heart, PN, AN 
E51G GAG GGG Heart 
S52P TCT CCT PN, AN, Heart 
G53E GGA GAA LM, Heart 
E54G GAG GGG PN, AN, Eye 
E54K GAG GAA PN, AN, Heart, Eye 
E54L a GAG CTG ND 
L55R CTG CGG LM, PN 
L55P CTG CCG PN, Heart, AN 
L55Q CTG CAG Eye, PN 
L55E CTG CAG Heart, PN, AN 
H56R CAT CGT Heart 
G57R GGG AGG Heart 
L58H CTC CAC CTS, Heart 
L58R CTC CGC CTS, AN, Eye 
T59K ACA AAA Heart, PN 
T60A ACT GCT Heart, CTS 
E61K GAG AAG PN 
E61G GAG GGG Heart, PN 
F64L TTT CTT PN, CTS, Heart 
F64S TTT TCT LM, PN, Eye 
I68L ATA TTA Heart 
Y69H TAC CAC Eye 
Y69I a TAC ATC Heart, CTS, AN 
K70N AAA AAC CTS, PN, Eye 
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V71A GTG GCG PN, Eye 
I73V ATA GTA PN, AN 
S77F TCT TTT PN 
S77Y TCT TAT PN 
Y78F TAC TTC PN, CTS, skin 
A81T GCA ACA Heart 
A81V GCA GTA Heart 
I84S ATC AGC Heart, CTS, Eye 
I84N ATC AAC Eye, Heart 
I84T ATC ACC Heart, PN, AN 
H88R CAT CGT Heart 
E89Q GAG CAG PN, Heart 
E89K GAG AAG PN, Heart 
H90D CAT GAT Heart 
A91S GCA TCA PN, CTS, Heart 
E92K GAG AAG Heart 
V94A GTA GCA Heart, PN, AN, Kidney 
A97G GCC GGC Heart, PN 
A97S GCC TCC PN, Heart 
I107V ATT GTT Heart, CTS, PN 
I107M ATT ATG PN, Heart 
I107F ATT TTT PN, AN 
A109S GCC TCC PN 
L111M CTG ATG Heart 
S112I AGC ATC PN, Heart 
Y114C TAC TGC PN, AN, Eye 
Y114H TAC CAC CTS 
Y116S TAT TCT PN, CTS 
A120S GCT TCT Heart, PN, AN 
V122I GTC ATC Heart 
V122Δ GTC deletion Heart, PN, CTS 
V122A GTC GCC Heart, Eye, PN 
Non-pathological mutations 
G6S GGT AGT  
M13I ATG ATC  
D74H GAC CAC  
H90N CAT AAT  
G101S GGC AGC  
P102R CCC CGC  
R104C CGC TGC  
R104H CGC CAC  
A108A b GCC GCT  
A109T GCC ACC  
A109V GCC GCT  
T119M ACG ATG  
P125S CCC TCC  
Compound heterozygotes 
G6S/V30M    
G6S/F33I c    
G6S/A45D    
G6S/S77Y    
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G6S/Y114C    
G6S/T119M    
G6S/V122A    
H90N/V30M    
H90N/E42G    
H90N/T119M    
R104H/V30M    
T119M/V30M    
AN, autonomic neuropathy; CTS, carpal tunnel syndrome; Eye, vitreous deposition; PN, peripheral 
neuropathy; LM, leptomeningeal amyloid; Heart, cardiomyopathy; a Double nucleotide substitution; 
b Silent mutation; c Mutations on the same allele 
 
Most of the affected individuals are heterozygous for a pathogenic mutation and express 
both normal and variant TTR. One of the most common TTR variants is V30M, prominent 
in northern Portugal, northern Sweden, Japan and also present in many other countries 
(Andrade, 1952; Benson and Kincaid, 2007; Saraiva et al., 1984). Interestingly, the 
combination of non-amyloidogenic and amyloidogenic mutations, usually present in 
different alleles, sometimes influences the clinical outcome. For example, the polymorphic 
G6S mutation in V30M patients does not influence the clinical manifestation of the 
disease (Jacobson et al., 1995), whereas the T119M and the R104H non-pathogenic 
variants exert a significant protective effect among Portuguese and Japanese V30M 
patients, respectively (Alves et al., 1997b; Terazaki et al., 1999). The study of pathogenic 
and non-pathogenic TTR variants is important for the understanding of TTR-related 
amyloidosis and also to establish a relationship between the structure and function of the 
molecule. 
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TRANSTHYRETIN AMYLOIDOSES 
Amyloidoses are a large group of diseases in which normally soluble proteins accumulate 
in the extracellular space of various tissues as insoluble deposits of 7–10nm wide fibrils 
that are rich in β-sheet structure and have characteristic optical behavior and dye binding 
properties, such as apple-green birefringence upon binding Congo red dye (Dobson, 
2003; Selkoe, 2003). TTR is one of the human proteins associated with systemic 
amyloidosis. Aggregation of WT TTR is associated with senile systemic amyloidosis 
(SSA), occurring later in life, typically over 60 years of age; SSA is a common disease, 
affecting to some degree 25% of the population greater than 80 years old, and presenting 
amyloid deposits primarily in the heart and lungs and occasionally in carpal ligaments 
(Westermark et al., 1990). Other TTR amyloidosis typically present earlier symptoms and 
are often more severe (Selkoe, 2003), with several protein variants exhibiting tissue-
selective deposition and pathology, including familial amyloidotic polyneuropathy (FAP) 
(Andrade, 1952), familial amyloidotic cardiomyopathy (FAC) (Jacobson et al., 1997; 
Nordlie et al., 1988) and familial CNS amyloidosis (Brett et al., 1999; Sekijima et al., 2003; 
Vidal et al., 1996).  
Although amyloidoses are modulated by numerous environmental and genetic factors, 
single point mutation in the TTR gene often influence disease phenotype. For example, 
TTR V30M causes FAP (Saraiva et al., 1984), with the onset of clinical symptoms 
generally around age 40 and fatal in about 10-20 years (Coutinho et al., 1980). TTR L55P 
is also related with FAP, but presents a more severe phenotype and early onset (before 
20 years of age) (Jacobson et al., 1992). A few TTR mutations are related predominantly 
to FAC, the most common is V122I, described in 3.9% of the African-American population 
and over 5% of the population in some areas of West Africa (Jacobson et al., 1997). 
Furthermore, patients with mutations such as L12P (Brett et al., 1999), D18G (Vidal et al., 
1996) or A25T (Sekijima et al., 2003), considered the most aggressive variants (Sekijima 
et al., 2005), present CNS involvement. 
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FAMILIAL AMYLOIDOTIC POLYNEUROPATHY 
In 1952, Corino de Andrade, neurologist working at Santo António General Hospital, 
identified for the first time what he called “a peculiar form of peripheral neuropathy” 
particularly present in fishermen kindreds in Póvoa de Varzim (in the Northern area of 
Portugal, near Porto). In his initial observations, Corino de Andrade described the clinical 
aspects of a number of patients affected by “Mal dos Pézinhos” (“Foot disease”), as it was 
known in the area, characterized histologically by generalized atypical amyloidosis, 
involving especially the peripheral nerves. This form of amyloidosis was the first form of 
hereditary amyloidosis identified (Andrade, 1952). Later it was known as familial 
amyloidotic polyneuropathy. 
The disease was subsequently reported in subjects of non-Portuguese origin throughout 
the world, particularly in Sweden, Japan, Italy, Spain and Greece (Saraiva et al., 2012). 
However, within this population there is some heterogeneity in FAP both in age of onset 
and clinical presentation (Sousa and Saraiva, 2003) 
 
 
FAP pathological features 
The first patients that Corino de Andrade described developed the initial clinical symptoms 
in the third or fourth decade of life and ultimately leading to death within 10–20 years 
(Andrade, 1952; Coutinho et al., 1980). The chemical nature of the amyloid protein 
involved in FAP remained unknown until 1978, when Costa and colleagues reported that 
the amyloid fibril protein accumulated in tissues of Portuguese FAP patients consisted of 
an abnormal form of TTR (Costa et al., 1978). Later, Saraiva and colleagues identified the 
molecular abnormality in TTR as a substitution of methionine for valine at position 30 of 
the polypeptide chain (Saraiva et al., 1984); this variant has become a biochemical marker 
for FAP (Saraiva et al., 1985). 
FAP is associated with the systemic extracellular deposition of amyloid fibrils throughout 
the connective tissue, leading to general organ dysfunction, with exception of brain, the 
central nervous system and liver parenchyma (Coimbra and Andrade, 1971a, b). Among 
first symptoms of the disease is sensory impairment, with pain and temperature 
sensations being the most severely affected, and eventually all sensory modalities are 
impaired; motor involvement occurs later in the course of the disease, causing wasting 
and weakness; there is also a progressive loss of reflexes with upper limb involvement 
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occurring months to years after lower limb manifestations. The majority of FAP patients 
have early and severe autonomic nervous system dysfunction, involving gastrointestinal 
(GI), urogenital and cardiovascular system (manifested mainly by impotence, urinary 
bladder dysfunction, motility disturbances of the GI tract and postural hypotension; 
malabsorption, cardiac insufficiency and vitreous opacities are also frequent) (Sousa and 
Saraiva, 2003).  
In peripheral nerves, TTR deposits as amyloid in the epineurium, perineurium and more 
prominently in the endoneurium (Figure I.3), with fibrils present near the Schwann cells 
basal membrane, but without penetrating the cell membrane or cytoplasm, and causing 
axonal fiber degeneration mainly in the unmyelinated fibers. In DRG, amyloid deposition 
occurs in the stroma in close contact with satellite cells and there is severe neuronal loss 
(with smaller neurons preferentially lost), which correlates well with clinical loss of pain 
and temperature sensations and autonomic functions. The causes of neurodegeneration 
in FAP are not yet fully understood and, based on pathological features, several 
hypotheses have been proposed, namely lesions in DRG neurons, compression of 
nervous tissue by amyloid deposits and ischemia caused by amyloid deposits around 
blood vessels. However, none of these hypotheses can fully explain neurodegeneration in 
FAP. 
 
Figure I.3. TTR deposition in the nerve of a FAP patient. (A) TTR immunohistochemistry using an 
anti-TTR specific antibody. (B) Apple-green birefringence characteristic of amyloid under polarized 
light upon Congo red staining (adapted from Sousa et al., 2001a). 
 
 
Amyloidogenesis in FAP 
Mechanism of TTR aggregation 
Although remarkable progress has been made over the last 15 years in understanding the 
biology and structural basis of TTR amyloidogenesis in FAP, the precise mechanisms 
A B
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underlying TTR amyloid fibril formation are still unknown and constitute a major activity in 
TTR amyloidosis research. Nowadays it is accepted that amyloid formation might involve 
diverse molecular pathways, with formation of an amyloidogenic intermediate occurring 
prior to fibril formation, whether it results from a destabilization of the TTR tetramer 
leading to dissociation into monomers or from a proteolytic event is still open to debate 
(Damas and Saraiva, 2000). 
Amyloid formation is often considered to be a nucleation-dependent process, where fibril 
growth requires the formation of an oligomeric structure before monomer addition become 
energetically favorable (Naiki and Gejyo, 1999); however in TTR amyloidosis there is no 
evidence of inducible amyloid formation by this type of events (Wei et al., 2004). 
Another hypothesis for amyloid fibrils formation is related to proteolytic cleavage. This 
hypothesis is supported by findings of the presence of TTR peptide fragments as well as 
the full-length protein in amyloid fibrils extracted from FAP patients and composed by TTR 
V30M; however not all studies detected the presence of the referred proteolytic fragments 
(Saraiva et al., 1984; Tawara et al., 1983). Therefore the role of proteolysis in TTR 
amyloidogenesis needs further studies to be understood; it appears that release of small 
peptides may contribute to the initiation or progression of the pathology, but are not the 
essential mechanism behind TTR amyloid formation. 
Currently, the conformational change hypothesis of TTR amyloidosis is the most 
supported theory. Biophysical studies have provided strong evidence for this theory, 
particularly by structural studies using X-ray diffraction of TTR L55P, an aggressive TTR 
variant, which led to the proposal of a model where monomers are the building blocks of 
amyloid (Sebastiao et al., 1998). Moreover, stability studies have shown a correlation 
between amyloidogenic potential and decrease in the tetrameric stability, thus leading to 
the hypothesis that amyloid fibril formation might be triggered by tetramer dissociation to a 
compact non-native monomer with low conformational stability, resulting in partially 
unfolded monomeric species with a high tendency for ordered aggregation into amyloid 
fibrils (Figure I.4; Quintas et al., 2001). Furthermore, it has been shown that TTR 
tetramers in serum of FAP patients with various variants are less stable than in normal 
subjects (Tojo et al., 2006). Both amyloidogenic and non-amyloidogenic TTR variants may 
dissociate into non-native monomers, yet only the amyloidogenic variants produce large 
amounts of partially unfolded monomeric species as a consequence of the marginal 
conformational stability of the non-native monomer. 
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Figure I.4. Hypothetical model for TTR amyloid fibril formation. Native tetrameric TTR may 
dissociate into a non-native monomer, which may undergo partial unfolding (depending on its 
conformational stability), and may self-assemble originating non-fibrillar aggregates, protofibrils and 
eventually mature amyloid fibrils (adapted from Quintas et al., 2001). 
 
 
Dynamics of TTR aggregation 
In FAP patients, TTR amyloid deposits are not composed entirely of the amyloidogenic 
protein. In human V30M FAP nerves the presence of non-fibrillar aggregates in early 
stages of disease progression suggested that these may precede protofibrils and fibrils 
formation (Sousa et al., 2001a; Sousa et al., 2001b).  
Different TTR species have been proposed to explain how the native soluble protein loses 
its normal fold and aggregates into fibrils. Using recombinant TTR variants with different 
quaternary structure stability, Redondo and colleagues concluded that dimmers resulting 
from disulfide-linked monomers could not form amyloid in vitro, while the respective 
monomers under reducing conditions immediately formed fibrils capable of binding the 
Thioflavin T dye (Redondo et al., 2000). This study suggests that monomers, rather than 
dimmers or tetramers, are the building blocks comprising amyloid fibrils. More recently, a 
different study showed that TTR amyloidogenesis is a dynamic process, with modified 
monomers being added to growing fibrils, and not any other TTR subunit, such as 
dimmers or tetramers (Cardoso et al., 2002). 
Amyloid fibrils also contain other components, such as serum amyloid P component 
(SAP), proteoglycans (either heparan sulfate type or chondroitin sulfate type), 
apolipoprotein E (apoE) and several basement membrane constituents, like fibronectin, 
laminin or collagen type IV (Kisilevsky, 2000). The role of these components in 
Tetramer
Non-­Native
Monomer Partially  Unfolded
Monomeric  Species
Soluble
Aggregates
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amyloidogenesis is not entirely clear, however it is possible that they may affect in vivo 
fibril turnover and dynamics. For instance, extracellular matrix (ECM) components 
including proteoglycans have been demonstrated to be significant components of amyloid 
deposits and to favor fibrillogenesis by increasing fibril stability and protecting fibrils from 
proteolysis (Dember, 2005; Magnus et al., 1991). In its turn, SAP is a plasma glycoprotein 
always present in amyloid deposits, contributing to amyloidogenesis, most likely due to 
stabilization of amyloid fibrils and retardation of their clearance (Pepys, 2001); very 
recently, a new role for SAP has been suggested – protection against the toxicity of early 
amyloidogenic aggregates (Andersson et al., 2013). Both SAP and proteoglycans 
(heparan sulfate and chondroitin sulfate types) have been found as components of 
amyloid deposits extracted from nerves of FAP patients (Inoue et al., 1998). 
 
 
FAP animal models 
Generation of animal models that mimic pathology of diseases of protein conformation is 
extremely important, since most protein misfolding diseases are experimentally difficult to 
study in detail except from autopsy and biopsy specimens. Therefore, in order to study in 
vivo the molecular mechanisms related to FAP amyloidogenesis and to search for 
pharmacological therapies for pathogenesis, several FAP animal models have been 
generated. 
The first FAP mouse model was generated in 1986 using cDNA with the coding sequence 
for TTR V30M driven by the mouse metallothionein promoter. Gene expression was 
induced by zinc but the plasma levels were low (2.5–12µg/mL) and amyloid deposition 
was not detected (Sasaki et al., 1989; Sasaki et al., 1986). 
Later on, other transgenic mice containing a DNA fragment composed of about 6kb of the 
upstream region and the entire human TTR V30M gene was generated. These mice 
showed TTR protein levels in plasma similar to what is found in humans and the protein 
was expressed in liver, yolk sac and the choroid plexus. Amyloid deposition started at 9 
months of age in the GI tract, cardiovascular system and kidneys, extending to other 
organs and tissues with aging. At 24 months the pattern of amyloid deposition was similar 
to FAP autopsied cases, except for the absence of TTR deposition in the peripheral and 
autonomic nervous systems (Nagata et al., 1995; Takaoka et al., 1997). 
In 1993, a TTR KO mouse was generated (Episkopou et al., 1993) and, in a collaborative 
effort between different research groups, a new mouse model later emerged carrying the 
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human TTR variant V30M but lacking the endogenous ttr gene. The authors suggested 
that the presence of endogenous murine TTR does not affect the human TTR pattern of 
deposition, as it was comparable to the previous described models (Kohno et al., 1997). 
Nonetheless, there is evidence suggesting that the presence of murine TTR in animals 
expressing both murine and human protein can influence TTR deposition (Sousa et al., 
2002); therefore the use of a mouse model for FAP expressing TTR variant V30M in a 
TTR null background should be favored. Although amyloid deposition in the PNS has not 
been observed in this new transgenic model, these animals still provide means to define 
the factors that modulate the onset and progression of disease, as well as being a 
valuable resource in the search of drugs and treatments that could prevent amyloid 
deposition. 
Transgenic animals carrying TTR variants other than V30M have also been generated, 
such as L55P (Teng et al., 1995) and I84S (Waits et al., 1995), however both strains failed 
to present deposition phenotype even at late ages and after multiple generations. 
Because L55P is a very aggressive TTR variant with patients presenting very early and 
severe symptoms (Jacobson et al., 1992), a new attempt to generate a model expressing 
this variant was performed, but in animals with TTR KO background, with transgene 
expression driven by the metallothionein promoter and induced by zinc. In these animals, 
early non-fibrillar deposition was observed at age 1–3 months and at age 4–8 months 
animals presented fibrillar deposits both in the GI and in skin; however, once again, no 
deposition was found in peripheral nerves (Sousa et al., 2002). 
All the FAP mice models presented so far lack the human phenotype of peripheral and 
autonomic nervous system involvement. But in 2010 a new mouse model was generated 
by crossing the previous existent model carrying TTR variant V30M in a TTR null 
background with mice in a heat shock transcription factor 1 (Hsf1) KO background 
(Santos et al., 2010a). For the first time, non-fibrillar TTR deposits were observed in the 
autonomic and peripheral nervous system, as well as an earlier and more extensive non-
fibrillar deposition, as compared to the other available models; this new animal model also 
replicates the activation of inflammation and oxidative stress pathways found in FAP 
patients. Data collected from this new model implicate the involvement of genes related to 
HSR in FAP pathology. 
To study the process of age-related fibrillogenesis and TTR deposition in the heart, a 
feature of SSA, a different transgenic mice model was generated by overexpressing 
human WT TTR. Most animals older than 18 months developed non-fibrillar and non-
congophilic TTR deposits primarily in heart and kidney, but 20% of the animals older than 
18 months had TTR cardiac amyloid deposits identical to the lesions seen in SSA. Further 
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analysis of the deposits showed intact human TTR with no evidence of proteolysis neither 
co-deposition of murine TTR, the authors suggested that non-fibrillar deposits can be 
either a precursor of amyloid fibrils or an alternate form of tissue deposition (Teng et al., 
2001). 
In addition to the mouse models above described, other animal models for FAP are also 
available, namely in rat and flies. While mouse models offer numerous advantages 
particularly in manipulation of their genome, their small size can make certain types of 
manipulation and studies difficult. Therefore, in 2007 a rat model expressing human TTR 
V30M under the action of mouse albumin promoter was generated. This model only 
presented non-fibrillar deposits in large intestine and at late ages (24 months), but 
nonetheless is a good model for the study of liver transplantation therapies particularly 
concerning to effects in retina and brain (Ueda et al., 2007). 
Also, transgenic Drosophila melanogaster models have been generated expressing WT, 
L55P and V30M TTR variants. Flies expressing mutated TTR variants showed protein 
aggregation, reduced lifespan and neurological impairment, while the WT transgenic 
presented a mild phenotype with similarities to SSA patients. Overall, the Drosophila 
system can be used as an invertebrate model to complement studies on TTR amyloid 
formation, studies addressing correlations between mutants amyloidogenicity and 
phenotypes and may also enable genetic manipulation to investigate modifying genes 
(due to availability of vast genetic tools) as well as allowing to screen for pharmacological 
agents (Berg et al., 2009; Pokrzywa et al., 2007). 
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CELLULAR TOXICITY INDUCED BY TTR 
It was suggested in the past that amyloid fibrils themselves induce tissue damage in TTR 
amyloidosis by direct compression and local blood circulation failure. Nonetheless, early 
descriptions of FAP by electron microscopy mentioned fibrillar and non-fibrillar aggregates 
(Coimbra and Andrade, 1971a, b). More recently, Sousa and colleagues demonstrated 
the presence of non-fibrillar TTR aggregates in nerve biopsies from FAP patients at an 
early stage of disease before detection of amyloid fibrils, while at later stages co-existence 
of both fibrillar and non-fibrillar aggregates was observed; the authors also showed that 
mature amyloid fibrils were unable to cause cellular toxicity in cell culture while non-fibrillar 
aggregates did (Sousa et al., 2001a). Moreover, Reixach and colleagues later 
demonstrated that TTR amyloid fibrils with size higher than 100kDa were not toxic, 
whereas monomeric or very low molecular mass TTR aggregates were cytotoxic (Reixach 
et al., 2004). Altogether, these results suggest that cellular toxicity in FAP is a 
consequence of non-fibrillar aggregates and it starts at early stages of fibril formation; it 
has been hypothesized that the presence of mature fibrils in tissues might represent an 
inert end stage that might even serve as a rescue mechanism (Andersson et al., 2002). 
However the mechanisms that mediate non-fibrillar aggregates induced cytotoxicity are 
not yet fully understood, but several pathways, including ER stress, oxidative stress and 
inflammation, have been implicated. 
 
 
Mechanisms of cytotoxicity in FAP 
Cellular quality control systems: ER stress and structural destabilization 
The inability to meet protein folding demands within the ER leads to the activation of the 
unfolded protein response (UPR), a signaling pathway with both adaptive and apoptotic 
outputs (Shore et al., 2011). Most of the adaptive outcomes involve activation of 
transcription factors to enhance the folding capacity of ER, promote ER-associated 
degradation (ERAD) and inhibit mRNA translation, with the ultimate goal of restoring the 
normal ER function (Määttänen et al., 2010; Xu et al., 2005). The most abundant ER 
resident chaperone is BiP (Grp78); it is usually the first chaperone to bind the nascent 
chain of a misfolded protein, mediated by ERdj1 and 2, triggering the ER stress response 
(Määttänen et al., 2010). 
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The ER stress response is activated in FAP, as proved by several different studies. 
Teixeira and colleagues showed that BiP levels were increased in tissues both from FAP 
patients and from FAP mice models; they also demonstrated activation of ATF6, a 
transcription factor activated by BiP that induces UPR-related genes expression leading to 
apoptosis, and eIF2-α (eukaryotic initiation factor 2 subunit alpha) phosphorylation, an 
initiation factor that when phosphorylated by the ER transducer PERK attenuates mRNA 
translation (Figure I.6; Teixeira et al., 2006).  
That same study also showed the existence of calcium mobilization to the cytosol 
(Teixeira et al., 2006). Calcium release from ER stores can modulate cell death in several 
ways, including activation of caspases (via activation of Bax and Bid and inhibition of Bcl-
2), induction of mitochondrial dysfunction or autophagy (via Bcl-2 activation) (Figure I.6A; 
Pinton et al., 2008; Xu et al., 2005). The intervention of apoptosis in FAP toxicity has been 
demonstrated, as the effector caspase-3 was seen activated in nerve biopsies of FAP 
patients (Sousa et al., 2001a); there is no evidence for an important role of mitochondria 
in FAP supporting the idea of a secondary role for mitochondria; Macedo and colleagues 
described that levels of both Bcl-2 and Apaf-1 (apoptotic protease activating factor 1) were 
not altered in tissues of TTR deposition (Macedo et al., 2007). Therefore the role of 
calcium release in FAP toxicity is yet to be clarified. 
Recent studies have suggested that highly unstable TTR variants are retained in the ER 
and subjected to ERAD and proteasomal degradation (Sato et al., 2007; Sekijima et al., 
2005). Amyloidogenic mutations in the TTR sequence destabilize the native tetrameric 
structure, induce conformational changes leading to aggregates and amyloid fibrils 
formation; Sekijima and colleagues analyzed the thermodynamic and kinetic stability of 
several TTR variants and concluded that all the pathogenic variants are energetically less 
stable than WT TTR (Sekijima et al., 2005); it has been suggested that thermodynamic 
and kinetic stability can explain disease severity (Figure I.6C; Hammarstrom et al., 2002). 
Most of TTR variants, even the ones associated with disease, are secreted from the cell 
with a near-WT efficiency, because they are only modestly destabilized – they present a 
relatively high score of combined thermodynamic and kinetic stability that results in normal 
serum concentrations and modest extracellular amiloidogenicity. On the other hand, some 
of the most destabilized TTR variants, such as L12P, D18G or A25T, present very low 
concentration in serum and are associated with CNS involvement; hypotheses have been 
raised that these variants can be degraded by ERAD, depending on the extent of 
destabilization (Figure I.5; Sekijima et al., 2005). 
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Figure I.5. Schematic relationship between disease phenotype and combined thermodynamic and 
kinetic stability of TTR variants. Combined thermodynamic and kinetic stability showed strong 
correlations with amyloidogenicity in vitro. In slightly and modestly destabilized variants, the 
combined score also correlated with clinical severity of amyloidosis. Variants with stability below 
the threshold are thought to be degraded by ERAD. Highly destabilized mutations like large 
deletions, frameshift mutations or nonsense mutations, are not usually found in TTR, most likely 
due to the cellular quality control mechanisms (adapted from Sekijima et al., 2008). 
 
Recently, Sato and colleagues demonstrated that the highly destabilized TTR variant 
D18G, but not WT or V30M, is subjected to prolonged residence time in the ER lumen in 
an unfolded manner before degradation, thus exposing a cryptic N-glycosylation site and 
triggering STT3B-dependent post-translational N-glycosylation; therefore the protein is 
targeted for an alternative pathway for degradation, which is EDEM3-mediated N-glycan-
dependent ERAD, an alternative to the traditional BiP-mediated ERAD (Sato et al., 2012). 
On the other hand, a study by Teixeira and colleagues showed that TTR variant V30M is 
present in serum of FAP patients in an N-glycosylated form, being post-translationally 
modified and secreted, escaping ERAD (Teixeira and Saraiva, 2013). Because N-
glycosylation can improve the thermodynamic and kinetic stability of proteins, it is yet to 
be clarified the role of this post-translational modification in TTR amyloidosis. 
 
Inflammation and oxidative stress 
In many neurodegenerative disorders, like AD or Parkinson’s disease (PD), there is 
activation of inflammatory processes, such as macrophage and microglia activation and 
up-regulation of cytokines or complement proteins (Rogers, 1995; Veerhuis et al., 1999). 
In the case of AD, it has even been considered that inflammation is not simply a response 
to already existing pathology, but ultimately can turn to a significant source of pathology 
(Rogers, 1995). In contrast, in FAP, there is no strong evidence of macrophages 
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intervention, as infiltration of tissues with inflammatory cells has only been reported in a 
short number of cases, but never in nerves (Nakamura et al., 1999). 
Pro-inflammatory cytokines, such as TNF-α (tumor necrosis factor-alpha), IL-1β 
(interleukin-1 beta) and M-CSF (macrophage colony-stimulating factor), were assessed in 
nerves from FAP patients at early stages with the disease and were found up-regulated; 
expression of these cytokines was also increased in later stages of the disease (Figure 
I.6B; Sousa et al., 2001a; Sousa et al., 2001b). Furthermore, up-regulation of the anti-
inflammatory cytokine IL-10 (interleukin-10) in axons and Schwann cells of FAP nerves 
correlated with TTR deposits (Sousa et al., 2005), thus suggesting a balance between 
pro- and anti-inflammatory mechanisms in FAP. 
Oxidative stress related to the generation of reactive oxygen and nitrogen species has 
also been implicated in the pathogenesis of neurodegenerative disorders in which the 
nervous system is especially susceptible to oxidative stress (Contestabile, 2001). In FAP, 
different studies support the notion of oxidative stress involvement. First, the levels of 
HNE (hydroxynonenal) and TBARS (thiobarbituric acid reactive substances), markers of 
lipid peroxidation, as well as the levels of protein carbonyls, a marker of protein 
modifications by free radicals, were found increased in human colon biopsy samples of 
FAP patients (Ando et al., 1997); this study co-localized HNE and TBARS with amyloid 
deposits, suggesting that toxicity might be related to injury on surrounding tissues. In view 
of the known link between cytokines and expression of iNOS (inducible form of nitric oxide 
synthase), FAP nerves were examined and increased levels of iNOS were observed in 
axons even at pre-symptomatic stages of disease (Sousa et al., 2001b); also the levels of 
3-NT (3-nitrotyrosine), a marker of protein nitration, are increased in FAP nerves, 
suggesting that deposited TTR was subjected to nitration (Sousa et al., 2001b). 
Subsequent studies showed increased levels in FAP tissues of other markers of oxidative 
stress, such as 8-OHdG (8-hydroxydeoxyguanosine), marker of nuclear and mitochondrial 
DNA oxidative damage, and GRx1 (glutaredoxin 1), that measures cellular redox 
homeostasis and acts as regulator of oxidative stress and apoptosis (Macedo et al., 
2007).  
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Figure I.6. Schematic representation of the mechanisms involved in TTR aggregates induced 
cytotoxicity (adapted from Hou et al., 2007; Sekijima et al., 2008; and Saraiva et al., 2012). 
Extracellular non-fibrillar TTR aggregates interact with the cell membrane and with membrane 
receptors like Fas or RAGE, leading to the activation of several pathways that may result in 
neurodegeneration. (A) Interaction of TTR aggregates with Fas may activate a caspase cascade, 
leading to apoptosis and cell death, while interaction with cell membrane (and its possible 
disruption) may conduct to calcium dysregulation (calcium influx from the ER) and activation of ER 
stress pathways, both also activating caspase cascades and leading to apoptosis. (B) TTR 
aggregates interact with RAGE, triggering kinase cascades and activation of NF-κB, which in turn 
activates the transcription of inflammatory cytokines and oxidative stress molecules; consequent 
increase of oxidized molecules may contribute to extracellular matrix components dysregulation 
and fibril formation. (C) Most TTR variants are secreted at nearly-WT efficiency, forming 
aggregates in the extracellular milieu, which may be internalized by other cells and targeted for 
lysosomal degradation; on the other hand, highly destabilized TTR variants are detected by the ER 
quality control system and degraded via ERAD in the proteasome. 
 
 
Signal transduction by extracellular aggregates versus internalization  
The mechanisms underlying induced cytotoxicity by non-fibrillar extracellular TTR 
aggregates remain unclear. Hou and colleagues reported that low molecular mass TTR 
aggregates, but not high molecular mass (fibrillar) species, induced calcium influx via 
voltage-gated calcium channels upon binding to the membrane disrupting the membrane 
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fluidity (Hou et al., 2007; Hou et al., 2005). This suggests a role of TTR extracellular 
aggregates in cytotoxicity by disruption of lipid rafts. 
In recent studies, the receptor for advanced glycation end products (RAGE) has been 
implicated in the triggering of intracellular events in FAP (Monteiro et al., 2006a; Sousa et 
al., 2001b). The activation of RAGE upon binding of TTR non-fibrillar aggregates activates 
signal transduction mechanisms that ultimately culminate in the activation of NF-κB and 
consequent inflammatory cascades (Figure I.6B); a correlation between RAGE distribution 
and expression and TTR deposits in nerves from FAP patients was also observed 
(Monteiro et al., 2006a; Sousa et al., 2001b). Another membrane receptor, the death 
receptor Fas, has also been implicated in FAP, as Fas and caspase-8 are up-regulated in 
tissues from animal models for FAP with non-fibrillar TTR deposition, as well as in salivary 
glands from FAP patients (Macedo et al., 2007). 
Other possible receptors might also be involved, particularly membrane receptors, which 
could contribute for the clearance of extracellular aggregates, as aggregates may be 
internalized and degraded intracellularly. To date, there is no evidence on the 
internalization of non-fibrillar TTR aggregates. Nonetheless, there is evidence of the 
internalization of soluble TTR, implicating a number of membrane receptors. Megalin, a 
member of the LDL receptor family capable of mediating endocytosis via clathrin coated 
pits, has been previously described to mediate soluble TTR uptake both in kidney (Sousa 
et al., 2000b) and in sensory neurons (Fleming et al., 2009); also another yet unidentified 
receptor associated protein (RAP)-sensitive receptor was described to mediate TTR 
uptake in liver (Sousa and Saraiva, 2001). These results suggested the hypothesis that 
TTR aggregates could be internalized in a similar way to soluble TTR. 
In other neurodegenerative disorders, like AD, there is increasing evidence of 
accumulation of intracellular Aβ originated either from the cleavage of amyloid precursor 
protein (APP) within neurons, or from Aβ internalization, despite the traditional hallmark of 
extracellular accumulation of Aβ peptide and intracellular neurofibrillar tangle of 
hyperphosphorylated tau (Haass and Selkoe, 2007).  
Most studies on Aβ uptake rely on data obtained from soluble proteins, but recently a 
study by Chafekar and colleagues showed that oligomeric, but not fibrillar Aβ, is 
internalized via endocytosis and transported to lysosomes (Chafekar et al., 2008). 
Moreover, Omtri and colleagues described different routes of internalization for Aβ40 and 
Aβ42, with Aβ40 using an energy-independent route, while Aβ42 internalization is via a 
dynamin-dependent and sensitive to cholesterol pathway that targets the peptides to the 
CHAPTER I⏐General Introduction 
28 
lysosomes (Omtri et al., 2012). Together, these data opens the door to different pathways 
and mechanisms of internalization depending on size or conformation. 
The involvement of several membrane receptors and/or pathways have been described in 
Aβ internalization, namely lipoprotein receptors, RAGE, lipid rafts, heparan sulfate 
proteoglycans or macropinocytosis, among others (LaFerla et al., 2007; Lai and Mclaurin, 
2010; Mohamed and Posse De Chaves, 2011). All these can potentially lead to signal 
transduction and/or internalization and traffic through endosomes and lysosomes for final 
degradation.  
Overall the studies on mechanisms of Aβ uptake allow us to speculate about possible 
pathways on how TTR aggregates interact with cells, and one of which can be 
internalization. Thus, based on the available data, we can hypothesize possible pathways 
involved in TTR aggregates uptake (Figure I.7). 
 
Figure I.7. Schematic representation of alternative portals of entry into the mammalian cell. The 
endocytic pathways differ with regard to the size of the endocytic vesicle, the nature of the cargo 
(ligands, receptors and lipids) and the mechanism of vesicle formation (adapted from Conner and 
Schmid, 2003). 
 
 
Tissue selectivity in TTR amyloidosis 
TTR amyloidosis present characteristic tissue-selective deposition and pathology, 
dependent on the mutation, such as polyneuropathy (for example V30M), cardiomyopathy 
(V122I) or leptomeningeal amyloidosis (L12P, D18G, A25T); however, the mechanisms 
causing tissue selectivity remain unclear. Sekijima and colleagues showed that highly 
destabilized TTR variants were more prone to induce CNS-related amyloidosis (Sekijima 
et al., 2005). It has been hypothesized that highly destabilized variants do not exhibit 
severe systemic disease because of efficient degradation in liver, whereas the choroid 
plexus efficiently secrete the highly destabilized TTR variants into the CSF, which may 
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potentially be related with high T4 concentrations acting as a stabilizing chaperone 
(Dickson et al., 1987; Sekijima et al., 2003; Sekijima et al., 2005). 
While the mechanisms above described may explain tissue selectivity for TTR-related 
CNS amyloidosis, it cannot be applied for the selectivity between polyneuropathy and 
cardiomyopathy, as in these cases amyloid fibrils appear to derive from serum TTR. It has 
recently been hypothesized to be related with diversity in the cellular components of the 
different tissues; therefore the affinity between TTR aggregates and tissue components, 
such as gangliosides, glycosaminoglycans, and proteoglycans, might pose as a crucial 
factor for the mechanisms of tissue selectivity in TTR amyloidosis (Sekijima et al., 2008). 
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THERAPIES FOR FAP 
An effective medical treatment of patients with TTR amyloidosis requires an accurate 
diagnosis, which may include the use of various parameters. In FAP, the presence of TTR 
variant V30M is considered a biomarker (Saraiva et al., 1985). The most common 
methods for diagnose of FAP include genetic tests and proteomic analysis. The point 
mutation V30M in exon 2 of TTR gene creates a restriction site for the enzyme NsiI, 
facilitating the molecular diagnosis of TTR V30M FAP (Sasaki et al., 1984); also using 
qPCR genotyping assays based on melting curve analysis is a possible method for 
diagnosis, together with TTR gene sequencing analysis. Complementary to genetic 
methods, it is also possible to use proteomic tests; by employing mass spectrometry 
analysis of serum, it is possible to detect variant TTR because the substitution of one 
amino acid results in a known mass shift in the protein molecular weight (Ando and Ueda, 
2012). 
Currently a definitive treatment for FAP is still unavailable. The strategies put forward so 
far as potentially therapeutic for FAP follow for most aspects directions generally taken for 
other amyloidosis, such as inhibiting aggregation and/or disrupting TTR amyloid by 
selective molecules (Figure I.8; for review see Ando and Ueda, 2012). In the following 
paragraphs different strategies adopted to prevent, retard or eliminate FAP are described. 
CHAPTER I⏐General Introduction 
31 
 
Figure I.8. Potential points of intervention in therapies for FAP (adapted from Saraiva, 2002). 
 
 
Elimination of variant TTR in blood circulation 
Plasma exchange, affinity column binding with a monoclonal antibody and use of a 
special column with affinity for TTR had been considered as possible methods for 
elimination of amyloidogenic TTR from the blood circulation. However these methods 
were concluded not to be an effective treatment for FAP mostly because TTR is a rapid 
turnover protein whose plasma half-life is approximately 2 days (and therefore rapidly 
returns to normal levels after the procedure) and also due to a vast variety of secondary 
effects (Ando, 2005). 
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Liver transplantation 
The best possible treatment for FAP is, so far, liver transplantation; if performed in the 
early stage of disease, it has been reported to halt the progression of clinical 
manifestations, since it eliminates more than 95% of the variant amyloidogenic TTR from 
circulation. Excellent outcomes have been described, including improvement in autonomic 
and to a lesser extent peripheral nerve function coupled with regression of visceral 
amyloid deposits. However, acceleration of TTR amyloid deposition following liver 
transplantation may occur in the heart and other sites (Holmgren et al., 1993; Stangou 
and Hawkins, 2004). The long-term outcome of patients with FAP who have undergone 
this procedure remains to be determined. 
Also, the use of sequential liver transplantation with resected livers from FAP patients 
(called domino liver transplants) became a relatively common practice. However, FAP 
liver recipients show amyloid deposits with or without clinical manifestations of FAP in less 
than 10 years after the surgery (Stangou et al., 2005). 
Unfortunately, this therapy encompasses several problems: (i) it is extremely expensive; 
(ii) patients with liver transplantation must continue lifelong administration of 
immunosuppressants; (iii) both carriers of TTR mutations who do not show clinical 
symptoms and patients in advanced stage of FAP cannot undergo liver transplantation; 
(iv) limited organ availability; (v) some patients develop ocular and CNS problems, since 
transplantation only suppresses TTR production of liver, not affecting the other sites of 
production (Ando, 2005). 
 
 
Fibril disrupters 
Several molecules have been described as having the ability of disrupt TTR amyloid 
fibrils. IDOX (4'-iodo-4'-deoxydoxorubicin) was described as an agent that could bind to 
different types of amyloid fibrils increasing their solubility (Merlini et al., 1995). In vitro 
studies by Sebastião and colleagues presented a theoretical model of the strong 
interaction between IDOX and TTR L55P crystals and proved that IDOX was able to 
disrupt the crystals (Sebastiao et al., 2000). Subsequent studies showed that, under 
physiological conditions, IDOX was not capable of inhibit TTR fibril formation but instead 
was able of completely disaggregate TTR amyloid fibrils into non-toxic species (Cardoso 
et al., 2003). 
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Doxycycline was also studied for its ability to disrupt TTR fibrils. In vitro studies showed it 
to be the most effective fibril disrupter, with no toxicity side effect, being a potential useful 
drug for FAP treatment (Cardoso et al., 2003). Moreover, in vivo studies using transgenic 
mice for FAP revealed that doxycycline was able to disaggregate Congo red positive 
amyloid deposits and to decrease biomarkers associated with the pathology (Cardoso and 
Saraiva, 2006). Currently, a phase 2 clinical trial is ongoing to evaluate whether 
doxycycline reduces amyloid deposits and improves organ function in patients with 
systemic or localized amyloidosis (clinicaltrials.gov, identifier NCT01677286). 
More recently, in vitro and in vivo studies have shown the potential of EGCG 
(epigallocatechin-3-gallate), the most abundant catechin in green tea, to disrupt TTR 
amyloid fibrils (Ferreira et al., 2011, 2012), as well as to inhibit fibril formation (Ferreira et 
al., 2009). 
 
 
TTR tetramer stabilization by small molecules 
The currently accepted amyloid formation hypothesis states that TTR tetrameric 
destabilization and dissociation into amyloidogenic intermediate species is the first step in 
TTR fibrillogenesis. Therefore, stabilizing the TTR tetramer posed as a possible method to 
prevent amyloidosis.  
Considering also the available data concerning the stabilization effect exerted by the 
presence of TTR variant T119M in compound heterozygotes and that it leads to milder 
FAP pathology (Alves et al., 1997b); Alves, 1997 #1084}, it is likely that small molecule 
kinetic stabilization strategies could be effective in FAP patients. It has been shown that 
TTR binding to its natural ligand T4 stabilizes the tetramer against dissociation and 
subsequent conformational changes required for amyloid fibril formation, thus paving the 
way to the design of small molecules that could bind to the T4 unoccupied binding sites 
and stabilize the TTR native tetrameric form (Miroy et al., 1996). Several small molecules 
that are able to stabilize the TTR native state have been described, however because 
many of these molecules exhibit high serum binding selectivity and are potent amyloid 
fibril inhibitors in vitro, most of the studies need in vivo validation to assess toxicity, 
bioavailability and pharmacological properties (Sekijima et al., 2008). 
Non-steroidal anti-inflammatory drugs (NSAIDs) have a molecular structure similar to T4 
and are, therefore, able to bind TTR in the 2 available T4 binding sites (Baures et al., 
1999). Diflunisal, one of the tested NSAIDs, was reported to stabilize serum TTR in 
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amyloidosis patients without adverse effects (Sekijima et al., 2006; Tojo et al., 2006). A 
phase 2/3 clinical trial is now underway to determine whether diflunisal is capable of 
altering the progression of FAP (clinicaltrials.gov, identifier NCT00294671); preliminary 
data from the trial indicate the drug is being well tolerated and with few recognized 
complications (Berk et al., 2012). More studies showed that the iodinated diflunisal 
derivative IDIF preferentially binds TTR rather than albumin and TBG both in human and 
mice plasma, in clear contrast to diflunisal and other NSAIDs, and is also more efficient in 
stabilizing the TTR tetramer (Almeida et al., 2004). 
More recently, a new small molecule that binds the TTR tetramer selectively and potently 
has been designed and developed as a TTR kinetic stabilizer to ameliorate TTR 
amyloidosis known as Tafamidis or Fx-1006A (www.foldrx.com). Initial studies showed 
that Tafamidis is well tolerated and proved to exert strong stabilization effects in plasma of 
participants, a slowing disease progression in patients heterozygous for the V30M TTR 
mutation (Bulawa et al., 2012; Coelho et al., 2012; Sekijima et al., 2008). A phase 3 
clinical trial is now in progress to evaluate the usefulness of the drug in FAP patients 
(clinicaltrials.gov, identifier NCT01435655). Tafamidis became the first pharmacological 
treatment to be approved for FAP, with its market authorization in the European Union in 
November 2011 (Said et al., 2012). 
Additionally, metal ions have also been suggested to stabilize TTR structure. High 
concentrations of trivalent chromium (Cr3+) increased tetramer stability of both WT and 
variant TTR and inhibit TTR amyloidogenesis in vitro (Sato et al., 2006), however at 
physiological concentrations Cr3+ showed no effect on TTR stabilization (Tojo et al., 2006).  
 
 
Immune therapy 
Immune therapies are major candidate methods for the treatment of TTR amyloidosis. It 
has been hypothesized that active immunization with a destabilized TTR variant with 
exposed cryptic epitopes might have a therapeutic effect in FAP (Terazaki et al., 2006). In 
this study, the authors used TTR variant Y78F to immunize transgenic mice for FAP and 
observed reduction of both amyloid and non-fibrillar deposition in mice intestine together 
with infiltration of lymphocytes and macrophages at the TTR deposition site. 
Recently, administration of anti-SAP antibodies to mice depleted of SAP in circulation 
resulted in complete removal of serum amyloid A (SAA) deposits by macrophages (Bodin 
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et al., 2010; http://pentraxin.wordpress.com). Since SAP is also a component of TTR 
amyloid deposits, this could be a general therapy to further investigate. 
 
 
Anti-oxidative and anti-apoptotic treatments 
Several studies have implicated oxidative stress in amyloid formation (Ando et al., 1998). 
Free radical scavenger therapy was attempted for the treatment of FAP by administrating 
N-acetylcysteine, α-tocopherol and vitamin C to Swedish FAP patients; however 
prevention of amyloid deposition was not confirmed nor change in levels of deposited 
amyloid (Suhr et al., 2001). Nonetheless, this type of treatment could be effective in 
preventing deposition, as it has been shown in vitro that the stability of TTR is increased 
by oxidative stress reduction and maintenance of its reduced state (Altland and Winter, 
1999). 
Macedo and colleagues investigated the possible therapeutical application in FAP of 
tauroursodeoxhycholic acid (TUDCA), a natural compound derived from bile acids that act 
as a strong anti-oxidant and anti-apoptotic agent, reducing cytotoxicity in several 
neurodegenerative disorders. In a different study, the authors proposed to address the 
effects of another anti-oxidative compound, carvedilol, a lipophilic non-selective β-
adrenoreceptor antagonist with strong anti-oxidative effect and commonly used for 
cardiovascular therapies. Both drugs had no effect in TTR aggregation mechanism in 
vitro; using transgenic mice for FAP, both TUDCA and carvedilol were shown to decrease 
non-fibrillar TTR deposition, as well as oxidative and apoptotic biomarkers associated with 
the disease (Macedo et al., 2008; Macedo et al., 2010). Moreover, a recent study 
combined the action of doxycycline with TUDCA in treating transgenic mice for FAP and 
showed that mutual action of both compounds was more effective in reducing both TTR 
deposition and associated biomarkers than either of the compounds alone (Cardoso et al., 
2010). A phase 2 clinical trial is being conducted to evaluate efficacy, tolerability, safety 
and pharmacokinetics of doxycycline in combination with TUDCA in TTR amyloidosis 
(clinicaltrials.gov, identifier NCT01171859); preliminary results indicate that the 
combination of doxycycline / TUDCA stabilizes the disease for at least 1 year (Obici et al., 
2012). 
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Gene therapy 
Gene therapy has arisen as a new non-invasive method for gene replacement and/or 
correction. Gene therapy approaches to TTR amyloidosis have, to date, focused on 
suppressing TTR variant expression, either by inhibiting mRNA expression or by repairing 
the variant TTR gene. 
The use of ribozymes has been reported to reduce the level of variant TTR mRNA not 
altering levels of WT TTR; however the suppression of gene expression was only partial 
most likely due to the rapid TTR turnover (Tanaka et al., 2001). Benson and colleagues 
reported that the reduction of a specific mutated TTR gene expression (I84S) was 
achieved using antisense nucleotides (ASOs) in liver, by as much as 80% (Benson et al., 
2006), and in the choroid plexus, albeit to lower extent (Benson et al., 2010). 
In a different strategy, Nakamura and colleagues reported the conversion of mutated 
V30M TTR to WT TTR in cell culture and in the liver of a transgenic mouse using single-
stranded oligonucleotides (SSOs) (Nakamura et al., 2004). This method is considered 
more attractive than the previously described since it is suitable for proteins with rapid 
turnover and can have a permanent effect; however in the experiments reported the level 
of gene conversion was not significantly high. 
Currently, clinical trials to evaluate safety and tolerability of systemically delivered small 
interfering RNA (siRNA) (www.alnylam.com; phase 2 trial; clinicaltrials.gov identifier 
NCT01617967) or an antisense drug (www.isispharm.com; phase 2/3 trial; 
clinicaltrials.com identifier NCT01737398), both aiming to reduce the amount of mutant 
and normal TTR made by the liver are progressing. Preliminary results from the siRNA 
trial showed suppression of TTR mRNA and protein levels in plasma, as well as reduction 
of TTR deposition in extra-hepatic tissues (Alvarez et al., 2010). 
Also, a gene therapy approach had already been suggested for the synthesis of T119M 
trans suppressor subunits in the liver, which would likely stabilize the TTR tetramers and 
inhibit amyloid formation (Hammarström et al., 2001; Hammarström et al., 2003b). 
Gene therapy is considered a promising future therapeutic strategy for TTR amyloidosis in 
substitution of liver transplantation; however many questions remain to be addressed, 
including delivery, suppression efficiency, safety, ethics and cost issues. 
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GENE THERAPY USING ADENO-ASSOCIATED VIRUS 
Gene therapy is, very often, considered the last option to treat some diseases, such as 
genetic disorders or neurodegenerative disorders; it consists of the introduction of a 
nucleic acids into a target cell in order to repair a defective gene, increase or reduce gene 
expression, with the ultimate goal of preventing, halting or reversing a pathological 
process. Successful gene therapy is highly dependent on efficient gene delivery; since the 
early days of gene therapy viruses have been recognized for their potential as vectors for 
gene delivery. However, great efforts have been put in the creation of non-viral gene 
delivery vehicles, such as naked DNA (or RNA), liposomes or nanoparticles, mainly due to 
their low cost and ability to deliver large cargos. Nonetheless, none of these vectors 
contain the mechanisms that viruses use to insert their genetic material into host cells and 
to alter cell functions. Therefore, the most common gene delivery vehicles available for 
somatic gene delivery are virus-based vector systems, such as: adenoviral vectors, 
adeno-associated virus (AAV) vectors, retroviral vectors (both murine and lentiviral) and 
herpes simplex virus (HSV-1) vectors (for review see Lentz et al., 2012 and Simonato et 
al., 2013). The properties and features of each viral vector system are summarized in 
Table I.2 and indicate the respective range of uses for in vivo gene delivery. 
 
Table I.2. Properties of the most commonly used virus-based vector systems (adapted from 
Simonato et al., 2013). 
Characteristic Adenoviral vector AAV vector 
Retroviral vector 
HSV-1 vector Murine 
vector 
Lentiviral 
vector 
WT virus ds linear DNA (36kb) 
ss DNA 
(4.7kb) 
diploid positive strand 
RNA (9.2kb) 
 
ds linear DNA 
(152kb) 
Derived from 
pathogenic 
virus 
Yes No Yes Yes 
Maximum size 
of gene insert ~ 7.5kb ~ 4.5kb ~ 8kb ~ 20–40kb 
Integration into 
host-cell 
genome 
No No a Yes No 
Duration of 
transgene 
expression 
Transient 
(days to 
weeks) 
Long-lasting 
(months to 
years) 
Long-lasting (months to 
years) 
Transient 
(days to 
weeks) b 
Target cells Dividing and non-dividing 
Dividing and 
non-dividing Dividing 
Dividing 
and non-
dividing 
Dividing and 
non-dividing 
Safety issues 
Immune and 
inflammatory 
response 
Insertional 
mutagenesis c Insertional mutagenesis 
Immune and 
inflammatory 
response 
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ds, double-stranded; ss, single-stranded; a some integration at a very low frequency; b years in the 
PNS; c minimal compared with other vectors. 
 
Recently, progresses have been made using AAV in diseases such as Leber’s congenital 
amaurosis (a retinal degenerative disorder) and severe hemophilia B, placing AAV as the 
vectors that achieved the most promising results to date, with currently ~50 ongoing 
studies (clinicaltrials.org) and directing gene therapy closer to a clinical application (for a 
review on the therapeutic usage of AAV vectors for genetic diseases see Mingozzi and 
High, 2011). 
 
 
AAV biology 
AAVs are small (22–26nm) non-enveloped viruses, with an icosahedral capsid, that were 
first discovered as contaminants of adenovirus preparations. They belong to the family 
Parvoviridae and are placed in the genus Dependovirus because they require co-infection 
with a helper virus, either adenovirus or herpesvirus, to complete their replication cycle; in 
the absence of the helper virus, the WT AAV can integrate into a specific site in 
chromosome 19, the AAV1S locus (q13.4) (Daya and Berns, 2008; Hoggan et al., 1966; 
McCarty et al., 2004; Xie et al., 2002). 
The AAV genome is a linear single-stranded (ss) DNA of about 4.7kb, of either plus or 
minus polarity, each one packaged with equal frequency into AAV capsids. Structurally, 
the genome contains two ORFs, denominated rep (replication) and cap (capsid), flanked 
by two inverted terminal repeats (ITR) at each end of the viral genome (Srivastava et al., 
1983). The rep ORF encodes for the non-structural proteins rep78, rep68, rep52 and 
rep40 that have roles in viral replication, transcriptional regulation, genomic integration 
and virion assembly. The cap ORF encodes the structural capsid proteins VP1, VP2, VP3. 
Recently, a third ORF has been reported as an alternate ORF within the cap gene 
encoding for a newly identified chaperone called assembly-activating protein, which is a 
viral protein that localizes AAV capsid proteins to the nucleus and is necessary for the 
capsid assembly process (Linden and Berns, 2000; Sonntag et al., 2011; Sonntag et al., 
2010; Srivastava et al., 1983). 
Recombinant versions of AAV have a gene of interest (therapeutic gene) inserted 
between the two ITRs substituting rep and cap. The ITRs are the only cis-elements of the 
AAV genome necessary for DNA replication and packaging, while the entire rep and cap 
genes may be provided in trans, along with helper viral genes, during vector production 
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(Figure I.9B). The resulting vector can stably transduce both dividing and non-dividing 
cells reported to last years in post-mitotic tissues; also no viral genes are encoded by the 
vector, thus reducing the potential for immune response (Flotte, 2004; Schaffer et al., 
2008). 
A major requirement is that the inserted therapeutic gene does not exceed ~ 4.7kb in size, 
which is the packaging capacity of the viral capsid. This packaging capacity is very strict, 
as vectors that exceed this size can be packaged as truncated forms. Single-stranded 
AAV (ssAAV) vectors were the first vectors to be developed and simply consist of a 
transgene cassette flanked by the ITR sequence and packaged as ssDNA (Samulski et 
al., 1989), what becomes a rate-limiting step in cell transduction, since second-strand 
synthesis is still required (Ferrari et al., 1996). To overcome this limitation, self-
complementary (scAAV) vectors were developed with the goal of shortening the lag time 
before transgene expression and potentially increase the biological efficiency of the vector 
(McCarty et al., 2001). scAAV vectors contain a mutated ITR positioned centrally between 
two copies of the transgene sequence, one inverted and complementary to the other, 
allowing the genome to self-anneal to form a double-stranded molecule (Figure I.9C). 
However, the maximal size of the transgene is reduced by ~ 50% to ~ 2.2kb, preventing a 
broader use of these vectors. To circumvent this, a trans-splicing AAV approach has been 
developed that can increase transgene capacity up to ~ 9kb (Yan et al., 2000). This 
technology consists in splitting the transgene cassette between two AAV vectors 
containing splicing sequences, which after co-infection of a single cell and subsequent 
recombination and transcription result in a functional gene product. Despite having been 
used successfully, trans-splicing vectors are less efficient than scAAV vectors. 
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Figure I.9. Schematic representation of viral particles and viral genomes. (A) 3-D representation of 
the AAV2 capsid. Adapted from PDB entry 1LP3. (B) Simplified schematic representation of the 
AAV2 genome. Top panel: WT AAV2 genome; middle panel: a typical therapeutic vector; bottom 
panel: helper plasmid, which may exist as a stand alone plasmid, a combined adenoviral gene/AAV 
gene plasmid or integrated within a helper cell line. Pro, promoter/enhancer for expression of the 
transgene; pA, polyadenylation signal (adapted from Flotte, 2004). (C) Comparison between 
ssAAV and scAAV (adapted from Daya and Berns, 2008). 
 
 
AAV serotypes and host-cell receptors 
AAV vectors for gene therapy are mostly based on AAV2, as it was the first AAV 
infectious clone (Samulski et al., 1982). Therefore, the AAV2 ITR is the most widely used 
to flank a transgene cassette, but it can be packaged into the capsid of any AAV serotype, 
a process named pseudotyping. This is of particular interest since many clinically relevant 
tissues are not susceptible to infection by AAV2 and different AAV serotypes show 
different tissue tropisms, which are determined by the capsid proteins, including binding to 
a variety of cell surface receptors and co-receptors (summarized in table I.3; Asokan et 
al., 2012; Ding et al., 2005; Grimm and Kay, 2003; Wu et al., 2006; Zincarelli et al., 2008). 
 
 
ITR ITRRep Cap
ITR ITRPro Transgene pA
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Table I.3. AAV receptors and their preferential tissue tropism (adapted from Nonnenmacher and 
Weber, 2012). 
Virus Glycan receptor Co-receptor Tissue tropism a 
AAV1 N-linked sialic acid Unknown SM, CNS, retina, 
pancreas 
AAV2 HSPG FGFR1, HGFR, LamR, 
CD9 tetraspanin 
VSMC, SM, CNS, 
liver, kidney 
AAV3 HSPG FGFR1, HGFR, LamR Hepatocarcinoma, SM 
AAV4 O-linked sialic acid Unknown CNS, retina 
AAV5 N-linked sialic acid PDGFR SM, CNS, lung, retina 
AAV6 N-linked sialic acid, 
HSPG 
EGFR SM, SM (iv), heart, 
lung 
AAV7 Unknown Unknown SM, retina, CNS 
AAV8 Unknown LamR Liver, SM, CNS, retina, 
pancreas, heart 
AAV9 N-linked galactose LamR Liver, heart (iv), brain 
(iv), SM (iv), lung, 
pancreas, kidney (iv) 
EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; HGFR, 
hepatocyte growth factor receptor; HSPG, heparan sulfate proteoglycan; PDGFR, platelet-derived 
growth factor receptor; SM, skeletal muscle; VSMC, vascular smooth muscle cell; iv, intravenous 
injection.  a Preferential tissue tropism following local delivery, unless otherwise indicated.  
 
 
Infectious pathway 
The virus ability to transduce cells is determined by the initial step of cell surface receptor 
binding, as well as by the relative abundance of AAV receptors and co-receptors. Upon 
binding, AAV vectors are internalized by receptor-mediated endocytosis, which may be 
either through clathrin-coated pits in a dynamin-dependent pathway (Lux et al., 2005) or 
through a clathrin-independent carriers/GPI-enriched endocytic compartment 
(CLIL/GEEC) endocytic pathway (Nonnenmacher and Weber, 2011). Following cellular 
entry, the virus escape from early endosomes and traffics to the perinuclear area, entering 
the nucleus. There is evidence suggesting that AAV traffics to nucleus prior to uncoating 
and that AAV uncoating takes place prior to viral DNA entry in the nucleus (Lux et al., 
2005). All these stages appear to be related and pose as potential rate-limiting steps for 
many AAV serotypes in transduction (for review see Ding et al., 2005). 
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Immune responses to AAV 
AAV vectors induce almost no innate immune response in the host, which contributes to 
long-term stability of transgene expression (Zaiss et al., 2002). The host immune 
response to AAV vectors administration is primarily a humoral response, consisting in the 
production of neutralizing antibodies (Chirmule et al., 2000). This response may interfere 
with the ability of AAV to infect cells. Because there is a high prevalence of neutralizing 
antibodies anti-AAV2 in humans (Chirmule et al., 1999), the immunization status of human 
subjects is an important factor in designing clinical trials (Mingozzi and High, 2007). 
In addition, cell-mediated responses to AAV vectors have also been reported, but this 
response appears to be dependent on the route of administration and AAV serotype 
(Brockstedt et al., 1999; Dobrzynski et al., 2004). For instance, it has been described that 
AAV2 infection can activate a cytotoxic-T-lymphocyte response, while AAV7 and AAV8 do 
not (Wang et al., 2007). Moreover, liver-directed AAV transfer results in induction of 
immune tolerance to otherwise antigenic proteins resulting in sustained gene expression 
(Dobrzynski and Herzog, 2005; Mingozzi et al., 2003; for review see Nayak and Herzog, 
2010). 
 
Barriers to repeated injection of AAV 
The potential for repeated dosing of AAV vectors has been studied in a number of pre-
clinical models and utilizing a number of different modes of administration. It has been 
reported that successive injections of the same vector in rabbits result in lower efficiency 
of gene transfer, while using a different serotype was relatively unaffected (Flotte, 2004). 
However, results from studies with humans indicate that T-cells are likely to cross-react 
between serotypes (Mingozzi et al., 2007). Therefore new strategies are needed to control 
the escape or limit T-cell responses to AAV in humans, in order to improve the quality of 
clinical trials. Such strategies may include modulation of T-cell response to the capsid (by 
use of immunosupressants), to alter the half-life of virus capsid within the transduced cells 
(after complete understanding of the intracellular traffic and fate of AAV capsid) or to 
reduce the antigenic load (using lower vector doses or scAAV) (Mingozzi and High, 2007). 
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AAV as a tool for basic studies 
Gene transfer for liver 
AAV has demonstrated to be a promising vector for gene transfer in non-dividing tissues 
in vivo. In clinical settings, there is particular interest in AAV-mediated gene expression of 
liver, since it has been proved that a single dose of AAV2 can successfully treat 
hemophilia B (deficiency in blood coagulation factor IX) for years in mice and dogs 
(Snyder et al., 1999). However, this success has yet to be achieved in humans. 
Hemophilia B is an attractive target for gene transfer to the liver, because it has a wide 
therapeutic window and availability of animal models of the disease. Based in robust 
results from gene therapy trials in animal models, that showed sustained expression and 
tolerance to the transgene product (Mingozzi et al., 2003; Wang et al., 2005a), advances 
were made towards the first AAV-factor IX liver trial in humans, using an AAV2 vector with 
a liver-specific promoter (Manno et al., 2006). However, the goal of long-term expression 
failed and destruction of transduced hepatocytes, possibly because of a CD8+ T cell 
response, was observed. It became clear that many differences between humans and the 
available animal models in respect to the immune responses elicited upon AAV injection 
exist (Li et al., 2007; Wang et al., 2007). 
Therefore, efforts are needed in order to translate AAV-mediated gene transfer to liver a 
reality in human trials. The strategies that are being put forward include the use of scAAV, 
to achieve therapeutic levels of expression with lower vector doses, and the use of an 
AAV8 serotype from non-human origin with strong liver tropism; both approaches resulted 
in hemophilia B correction with few side-effects (clinicaltrials.gov, identifier NCT00979238; 
Nathwani et al., 2011). Nonetheless, efforts continue to develop new and improved 
strategies for safe and successful liver transduction in hemophilia B patients, as more 
efficient expression cassettes and vectors are developed (for review see Mingozzi and 
High, 2011; McIntosh et al., 2013 and Kay, 2011). 
 
Use in basic neuroscience studies 
The use of animal models is a powerful tool to understand the etiology of a disease, 
particularly in the case of neurodegenerative disease. AAV vectors have been used to 
generate animal models of neurodegenerative diseases, such as: Huntington’s disease by 
expression of truncated human huntingtin protein with extended glutamine repeats in 
striatum neurons (Senut et al., 2000); Parkinson’s disease by overexpression of mutated 
α-synuclein and tau in substantia nigra dopaminergic neurons (Kirik and Björklund, 2003; 
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Klein et al., 2005). AAV vectors can also be used to deliver Cre recombinase to specific 
targets in the brain to achieve precise gene expression in spatial- and temporal-specific 
manner thus facilitating the study of genetic modifications in the mouse brain (Kaspar et 
al., 2002). 
Another important application of AAV vectors is in the down-regulation of target genes by 
deliver of encoded siRNA or shRNA (Couto and High, 2010). This type of approach is a 
great hope in the development of effective therapies for dominant inherited neurological 
diseases. 
 
Overall, although the use of AAV vectors has some limitations, it shows great promises for 
a number of applications, ranging from clinical gene therapy to the establishment of basic 
tools for scientific research. 
 
 
 
CHAPTER I⏐Objectives of Thesis 
45 
OBJECTIVES OF THE THESIS 
Alternative strategies to approach TTR amyloidosis are needed, either to better 
understand the pathways followed by amyloidogenic aggregates or to propose alternative 
therapies.  
In the present study we propose to: 
(i) investigate tissue specificity of TTR variants expression and secretion, 
contributing to a better understanding of the pathogenesis of TTR related 
leptomeningeal amyloidosis by generating a new mouse model using AAV-
mediated gene transfer (chapter II); 
(ii) dissect the mechanisms of TTR aggregates internalization, as a possible 
mechanism of clearance (chapter III); 
(iii) propose a new therapy for FAP, using AAV-mediated gene transfer of TTR 
T119M to a transgenic mouse model and assess in vivo the effect of a protective 
TTR variant in reversing and/or preventing the pathology (chapter IV). 
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ABSTRACT 
Transthyretin (TTR) is a plasma and cerebrospinal fluid (CFS)-circulating homotetrameric 
protein. More than 100 point mutations have been identified in the TTR gene and several 
are related with amyloid diseases. Here we focused our attention in the TTR L12P variant 
associated with severe peripheral neuropathy and leptomeningeal amyloidosis. By using 
different cell lines derived from tissues specialized on TTR synthesis, such as the 
hepatocyte and the choroid plexus expressing WT, V30M, or L12P TTR variants we 
analyzed secretion, intracellular aggregation and degradation patterns. Also, we used 
liver-specific AAV gene transfer to assess expression of the L12P variant in vivo. We 
found: (i) decreased secretion with intracellular aggregation of TTR L12P in hepatoma 
cells relative to the WT and V30M variant; this differential property of TTR L12P variant 
was also observed in mice injected with L12P AAV vector; (ii) Differential N-glycosylation 
pattern of L12P variant in hepatoma cell lysates, conditioned media and mouse sera, 
which might represent an escape mechanism from ERAD degradation; (iii) intracellular 
L12P TTR aggregates mainly localized to lysosomes in cultured cells and liver; (iv) none 
of the above findings were present in choroid plexus derived cells, suggesting particular 
secretion/quality control mechanisms that might contribute to leptomeningeal amyloidosis 
associated with the L12P variant. These observations open new avenues for the 
treatment of TTR associated leptomeningeal amyloidosis. 
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INTRODUCTION 
Amyloidoses are a large group of diseases caused mainly by protein misfolding, 
aggregation and deposition. Transthyretin (TTR) is one of these amyloidogenic proteins 
involved mainly in peripheral nerve amyloidosis, as it is the case of familial amyloidotic 
polyneuropathy (FAP) (Andrade, 1952). TTR is a 127 aminoacid soluble and typical non-
glycosylated protein mainly synthesized and secreted by hepatocytes in the liver, the 
choroid plexus epithelium in the brain and retinal epithelium in the eye. It is responsible for 
the transport of thyroxine (T4) in plasma and cerebrospinal fluid (CSF). To date more than 
100 point mutations have been described in the TTR gene at 50 different codons, but not 
all are associated with disease (http://amyloidosismutations.com/mut-attr.php). The most 
common TTR mutation responsible for FAP is the substitution of valine by methionine at 
position 30 of the polypeptide chain (V30M). In FAP, extracellular mutant TTR deposits 
extracellularly systemically in the form of non-fibrillar and amyloid fibrils in most organs 
and tissues, except for liver parenchyma and the central nervous system. There are 
exceptional cases where mutated TTR leads to cerebral compromise, as a result of TTR 
amyloid deposits in the leptomeninges and subarachnoid blood vessels but almost no 
deposition in visceral organs (Benson, 1996; Brett et al., 1999; Vidal et al., 1996). The 
reason for these differences in organ targeting are still unknown, but some TTR variants 
appear to have more tendency to have CNS involvement than others, e.g. L12P, D18G or 
A25T (Benson, 1996; Sekijima et al., 2003). These leptomeningeal amyloidoses are 
uncommon but fatal and treatments are yet to be found, since the available therapies for 
TTR amyloidosis, such as liver transplantation or pharmacological approaches do not 
seem to affect the protein in the CSF (Planté-Bordeneuve and Said, 2011). However, in 
L12P-TTR amyloidosis, severe systemic amyloidosis and intracellular deposits in the liver 
were reported (Brett et al., 1999). 
TTR is produced as a monomer, assembles as a tetramer in the ER, can undergo post-
translational modifications and then is secreted. TTR amyloidogenesis occurs by rate-
limiting tetramer dissociation, followed by partial monomer unfolding, leading to aggregate 
formation and eventually amyloid fibril assembly (Quintas et al., 2001). The presence of 
mutations in the monomeric chain may lead to a decreased tetrameric folding efficiency 
within the ER and reduced export, as well as to a reduced thermodynamic stability 
(Sekijima et al., 2005). The protein thermodynamic and kinetic stabilities have a potential 
effect on secretion efficiency. Most TTR variants associated with CNS pathology have low 
scores of combined stability, which makes these proteins likely targets for ERAD 
degradation and low secretion, as shown in BHK cells (Sekijima et al., 2005). Transfection 
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experiments in rat choroid plexus cells showed that TTR variants A25T was secreted as 
efficiently as WT but not D18G (both variants are associated with CNS pathology and low 
plasma levels). This suggests that choroidal cells have higher secretion aptitude than 
other cell types (Sekijima et al., 2005).  
The main objectives of the present work were to compare the secretion efficiency of WT, 
L12P, V30M, and D18G TTR mutants in hepatocytes and choroid plexus cells. 
Additionally, we used intravenous delivery of AAV vectors to achieve liver-specific 
expression of L12P TTR variant and the WT protein in adult mice. These somatic 
transgenic mouse models were developed and characterized to investigate the different 
modes of secretion/intracellular degradation by liver to understand ethiopathogenesis and 
future treatments for TTR related leptomeningeal amyloidosis, including, among others 
the L12P variant. 
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MATERIALS AND METHODS 
TTR-TC plasmids 
Briefly, for the construction of the TC-FlAsH tag we used the following aminoacid 
sequence: Gly-Ala-Gly-Gly-Cys-Cys-Pro-Gly-Cys-Cys-Gly-Gly-Gly. This sequence was 
fused to the N-terminal of human TTR cDNA, which was then cloned into NheI and XhoI 
sites of the CSCW2-IRES-mCherry lentiviral vector (Sena-Esteves et al., 2004). 
Expression of the vector is driven by the CMV promoter. V30M, L12P and D18G TTR 
variants were generated with the QuickChange site-directed mutagenesis kit (Agilent) 
according to the manufacturer instructions and using the wild type TTR vector as a 
template. 
 
Lentiviral production 
Lentiviral vectors stocks were produced as previously described (Sena-Esteves et al., 
2004). Titers were determined on human 293T cells as transducing units (tu) using serial 
dilutions of vector stocks and infection in the presence of 8µg/ml polybrene (Millipore).  
 
Cell culture 
HEK293 cell line (human embryonic kidney, European Collection of Cell Cultures) was 
cultured in EMEM (Eagle’s minimum essential media, Lonza), supplemented with 10% 
(w/v) FBS, 2mM L-Glutamine, 100U/mL penicillin/streptomycin (all from Gibco) and 1% 
(w/v) non-essential amino acids (Sigma-Aldrich). SaHep cell line (human hepatoma 
without TTR expression, kindly provided by Dr. João Monjardino, Imperial College, 
London, UK) was cultured in DMEM (Dulbecco’s modified Eagle’s medium, Lonza), 
supplemented with 10% (w/v) FBS, 2mM L-Glutamine and 100U/mL 
penicillin/streptomycin (all from Gibco). TR-CSFB cell line (rat immortalized epithelial 
choroid plexus cells, kindly gifted by Dr. Terasaki, Tohoku University, Japan) was cultured 
in DMEM with 4.5g/L glucose, supplemented with 10% (w/v) FBS, 2mM L-Glutamine, 
100U/mL penicillin/streptomycin and 1% (w/v) sodium pyruvate (all from Gibco). All cell 
lines were routinely propagated in T-25 flasks in monolayer (SaHep were grown on flasks 
coated with collagen I) at 37°C (HEK293 and SaHep) or 33°C (TR-CSFB), in 5% CO2 
humidified atmospheres. 
Cells were plated in 24-well-plate and 24h later were infected with the lentivirus vectors at 
a multiplicity of infection (M.O.I.) = 100tu/cell in the presence of 8µg/mL polybrene. Forty-
eight hours after infection, cells were assayed for expression of the transgenes by 
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measurement of mCherry expression, yielding on average 90% of infected cells with no 
apparent toxicity. Cells were then propagated. 
 
Gene expression assessment 
Cells were plated in 6-well multiplates. Twenty-four hours later, medium was changed to 
serum-free DMEM without phenol red supplemented with 2mM L-Glutamine. After 24h, 
cells were washed with PBS and lysed in TriZol Reagent (Invitrogen). RNA extraction was 
performed following manufacturer’s instructions. cDNA synthesis was performed by 
oligod(T) with Superscript II following manufacturer’s instructions (Invitrogen). cDNA was 
then quantified in an iQ5 Bio-Rad real time PCR machine with iQ™ Sybr® Green 
Supermix (Biorad). β−actin was used for normalization. The ΔΔCT method was used for 
quantification calculations (Bustin et al., 2009). 
Primer sequences:  
hTTR Fwd: ATGGCTTCTCATCGTCTGCT 
hTTR Rev: GACCATCAGAGGACACTTGGA 
rat β-actin Fwd: CCGCCACCAGTTCGCCATGGAT 
rat β-actin Rev: GAAGCCGGCCTTGCACATGC 
human β-actin Fwd: GCGAGCACAGAGCCTCGCCTTT 
human β-actin Rev: TCATCATCCATGGTGAGCTGGCGG 
 
Protein expression assessment 
Cells were plated in multi-well plates of 6 wells. Twenty-four hours later, medium was 
changed to serum-free DMEM without phenol red supplemented with 2mM L-Glutamine. 
After 24h, conditioned media were collected and cells washed with ice-cold PBS and 
lysed in RIPA lysis buffer (50mM Tris-HCl, 150mM NaCl, 1mg/mL sodium deoxycholate, 
1% NP-40) containing 1x protease inhibitors mixture (GE Healthcare Bioscience). Total 
protein in cell lysates was determined by the Bio-Rad assay kit (Bio-Rad) using serial 
dilutions of bovine serum albumin as protein standard; 40µg of total protein were 
separated in a 15% polyacrylamide SDS-PAGE gel and then transferred onto a 0.2µm 
pore nitrocellulose membrane (Whatman) using a wet transfer system. Primary antibodies 
were rabbit polyclonal anti-hTTR (1:500, Dako) and mouse monoclonal anti-α-tubulin 
(1:10,000, Sigma-Aldrich) for normalization. The enhanced chemiluminescense method 
(ECL, GE Healthcare Bioscience) was used to develop the blots. Quantitative analysis of 
western blot images was performed using the ImageJ software (NIH). As for the media, 
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samples were centrifuged at low speed to remove cell debris, subsequently dialyzed 
against water buffered to pH 7 and then freeze-dried. Samples were resuspended in 
200µL of distilled water and TTR concentration measured by ELISA, as previously 
described (Cardoso et al., 2007).  
 
N-glycosylation and tunicamycin assays 
N-glycosylation was assessed with a glycoprotein deglycosylation kit (Calbiochem) 
according to manufacturer’s instructions. Briefly, 20µL of media or 100µg of total protein 
were incubated with or without (for control) N-glycosidase F for 3h at 37°C. Samples were 
then loaded in a 15% polyacrylamide SDS-PAGE gel and then blotted as above 
described. 
In tunicamycin assays, the different cell lines were plated on 6-well multiplates. Twenty-
four hours after plating, culture medium was replaced with serum-free DMEM without 
phenol red supplemented with 2mM L-Glutamine in the presence of 1µg/mL tunicamycin 
(Sigma-Aldrich). After 24 hours conditioned media and cell lysates were collected and 
processed as above described. In parallel control experiments, 6-well multiplates were 
incubated with vehicle alone (DMSO). 
 
Fluorescence microscopy 
For live cell imaging by fluorescence analysis, cells were plated on µ-Slide 8 well (Ibidi) 
and 24h after plating were subjected to FlAsH staining, nucleus staining and incubation 
with 75nM LysoTracker Red DND-99 (Molecular Probes, Invitrogen) for 2h for tracking of 
lysosomes, according to the manufacturer’s instructions. After labeling, cells were 
maintained in complete medium phenol red free and live-imaged under a Laser Scanning 
Confocal Microscope Leica SP2 AOBS SE, with controlled temperature and using laser 
lines of 405nm, 514nm and 561nm.  
For fluorescent and immunofluorescence analysis in fixed cells, cells were grown on glass 
coverslips coated with either poly-D-lysine (HEK293 and TR-CSFB) or collagen I (SaHep). 
Twenty-four hours after plating, FlAsH staining was performed as described (Hoffmann et 
al., 2010). Briefly, cells were incubated for 30min at 37°C with 5mM sodium 2-
mercaptoethane sulfonate and 0.5mM Tris(2-carboxyethyl) phosphine hydrochloride 
solution (both from Sigma-Aldrich) in OptiMEM (Gibco). Cells were then washed and 
incubated with 1µM FlAsH-EDT solution (Molecular Probes, Invitrogen) in HBSS for 1h at 
37°C, followed by washes with 250µM 1,2-ethanedithiol (EDT, Sigma-Aldrich) in HBSS. 
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After staining, cells were washed 3 times with HBSS and incubated with 1µM Hoechst 
3342 (Molecular Probes, Invitrogen) for nucleus stain and fixed with ice-cold acetone for 
indirect immunofluorescence. Fixed cells were blocked with 1% BSA/PBS/0.25% Triton X-
100 for 1h at room temperature and incubated overnight at 4°C with rabbit polyclonal 
antibody against calnexin (1:150, Abcam) to localize the ER, mouse monoclonal antibody 
against Golgin-97 (1:50, Invitrogen) to localize Golgi apparatus, rabbit polyclonal antibody 
against M6PR (1:100, Abcam) or rabbit polyclonal antibody against LC3A/B (1:100, Cell 
Signaling) to localize autophagosomes. For detection of primary antibodies, AlexaFluor-
647 anti-rabbit IgG or AlexaFluor-647 anti-mouse IgG (both from Molecular Probes, 
Invitrogen) were used (1:1,000, 30min RT). Coverslips were mounted in Vectashield 
(Vector Labs) and visualized under a Laser Scanning Confocal Microscope Leica SP2 
AOBS SE using laser lines 405nm, 514nm and 633nm. 
 
Co-Immunoprecipitation 
Total cell lysates (500µg) were subjected to immunoprecipitation using either anti-hTTR or 
anti-M6PR antibodies attached to IgA agarose beads. The immunoprecipitated pellet was 
resolved in a 4–15% gradient TGX gel (BioRad), and immunoblotted as described above 
using as primary antibodies rabbit polyclonal anti-M6PR (1:1,000, Abcam) or rabbit 
polyclonal anti-hTTR (1:500, Dako). 
 
Lysosomal inhibition and autophagy enhancing treatments 
The different cell lines were plated on 6-well multiplates. Twenty-four hours later, culture 
medium was replaced with serum-free DMEM without phenol red supplemented with 2mM 
L-Glutamine in the presence of either 20mM ammonium chloride (Sigma-Aldrich) or 5mM 
rapamycin (Calbiochem). After 24h, conditioned media and cell lysates were collected and 
processed as above described. Six-well multiplates were incubated in parallel as control 
experiments with respective vehicle – water (NH4Cl) or DMSO (rapamycin).  
 
Animal procedures 
Mice were handled according to European Union and National rules. TTR KO mice 
(Episkopou et al., 1993) in the 129/Sv background, were maintained at 24 ± 1°C under a 
12h light/dark cycle and fed regular chow and tap water ad libitum. Three months old 
animals were injected in the tail vein with 3x1011 viral genomes of scAAV8-AHA-TTR 
L12P. Three months after injections the animals were euthanized after anesthesia with a 
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mixture of ketamine/medetomidine and blood was collected, as well as liver, stomach and 
colon, that were fixed in 4% neutral buffered formalin and embedded for paraffin 
processing. 
 
AAV vector design and preparation 
The AAV vector used in this study was modified from pAAV-CBA-mβgal-W (Broekman et 
al., 2007) by removing the mβgal cDNA and replacing the CBA promoter with a liver 
specific enhancer-promoter combination composed of the human apolipoprotein hepatic 
control region (HCR) and human alpha-1-antitrypsin gene promoter followed by the hAAT 
5’ untranslated region and a modified SV40 intron as previously described (Nathwani et 
al., 2006). This enhancer-promoter was synthesized by PCR amplification and matches 
the sequence published by Nathwani and colleagues (Nathwani et al., 2006). The vector 
was further modified into a self-complementary design by deletion of the terminal 
resolution site (as described in Mccarty et al., 2003) in the AAV2 inverted terminal repeat 
(ITR) near the AHA promoter to generate the plasmid scAAV-AHA-W. WT or variant TTR 
cDNAs were cloned into this plasmid by PCR amplification followed by sequencing. Vector 
stocks made with AAV8 capsid were produced by transient transfection of 293T cells and 
purification by iodixanol gradient centrifugation followed by anion-exchange 
chromatography using HiTrapQ columns (GE Healthcare), as described (Broekman et al., 
2006). Titers of vector stocks were determined by real-time quantitative PCR using 
primers and probe specific for the bovine growth hormone (BGH) polyadenylation signal 
(pA) present in these vectors, and represented as genome copies/mL. 
 
Serum TTR levels and mass spectrometry 
Serum TTR was quantified by ELISA (Cardoso et al., 2007), as above described for 
conditioned media. For western blot analysis of sera, 5µL of sera was then loaded in a 
15% polyacrylamide SDS-PAGE gel and then blotted as above described. 
MALDI mass spectroscopic analysis of TTR was performed after immunoprecipitation with 
anti human TTR antibody (Dako) and band excision from a silver stained gel and digestion 
with trypsin followed by identification of the originated peptides from the SWISSPROT 
database. 
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Liver fluorescence microscopy 
Three-µm-thick sections were deparaffinated in Histoclear (National Diagnostics) and 
hydrated in a descendent alcohol series. Tissues were permeabilized with 0.25% Triton X-
100 in PBS for 10min at room temperature and then incubated with blocking buffer 
containing 1% BSA/PBS/0.25% Triton X-100 for 1h at room temperature and incubated 
overnight at 4°C with sheep polyclonal antibody against human TTR (1:50, The Binding 
Site) and rabbit antibody against Lamp-2 (1:50, Sigma) to localize lysosomes. For the 
detection of primary antibodies, AlexaFluor-488 anti-sheep IgG and AlexaFluor-647 anti-
rabbit IgG (both Molecular Probes, Invitrogen) were used (1:1,000, 30min RT). Slides 
were mounted in Vectashield with 4’,6-diamidino-2-phenylindole (DAPI, Vector Labs) and 
visualized under a Laser Scanning Confocal Microscope Leica SP2 AOBS SE using laser 
lines 405nm, 488nm and 633nm. 
 
Immunohistochemistry for assessment of TTR deposition 
Three-µm-thick sections were deparaffinated in Histoclear (National Diagnostics) and 
hydrated in a descendent alcohol series. Endogenous peroxidase activity was quenched 
with 3% hydrogen peroxide in PBS for 30min. Tissue slides were incubated with blocking 
buffer containing 4% FBS and 1% BSA in PBS for 1h at room temperature and then 
incubated overnight at 4°C with primary antibodies diluted in blocking buffer. Primary 
antibody was rabbit polyclonal antibody against human TTR (1:300, Dako). Antigen 
visualization was performed using Vectastain® Elite ABC Reagent (Vector Labs), 
according to the manufacturer’s instructions, and diaminobenzidine (Sigma-Aldrich) used 
as substrate for color development. Sections were counterstained with hematoxylin, 
dehydrated in an ascendant alcohol series and coverslipped under Entellan (Merck). On 
parallel control sections, incubation with primary antibody was replaced by blocking buffer; 
staining was absent under these conditions. Sections were examined with an Olympus 
BX50 light microscope equipped with an Olympus DP71 digital camera for image 
acquisition.  
 
Viral genome copies quantification in mice liver 
Briefly, genomic liver DNA was extracted using the automated Maxwell 16 System 
(Promega). The Maxwell 16 System uses paramagnetic-particle technology for fast 
automation of routine DNA resulting in reproducible yields and purity. The number of viral 
genome copies was quantified by qPCR of the BGH pA sequence. 
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Primer sequences: 
Forward: 5’ – TgCgATgCAATTTCCTCAT – 3’ 
Reverse: 5’ – CCTCgACTgTgCCTTCTAg – 3’ 
Probe: 6FAM – TgCCAgCCATCTgTTgTTTgCC – BBQ  
 
Image analysis 
All confocal images were processed using Fiji software (Schindelin et al., 2012) and plug-
in ROI Profiler was used in co-localization analysis. 
 
Statistical Analysis 
Experimental results shown are the average of at least 3 independent experiments and 
are presented as mean ± SEM. Statistical significance was evaluated by one-way ANOVA 
with Bonferroni post test. Differences were considered significant for p<0.05 or as 
designated. Statistical analysis was performed using GraphPad Prism 5.0 for Mac OS X. 
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RESULTS 
Establishment of stable hepatocyte and choroid plexus cell lines for the study of human 
TTR secretion after lentiviral tetracysteine TTR fusion infection 
Several studies have been performed to study the secretion pattern of different TTR 
variants (Sato et al., 2007; Sekijima et al., 2003; Sekijima et al., 2005) mostly in cell lines 
that naturally do not express the protein and thus partially mimic the expression pattern of 
TTR in vivo, such as HeLa (Sato et al., 2007) or BHK cells (Sekijima et al., 2005). In the 
present work we used cell lines derived from liver and choroid plexus, main sites of TTR 
synthesis and secretion (Dickson et al., 1985); the studies described below were carried 
out in SaHep (human hepatocytes derived cells) and TR-CSFB cell lines (rat choroid 
plexus epithelial cells immortalized) (Terasaki and Hosoya, 2001). Endogenous TTR 
expression was not detected in either cell line. A third cell line, HEK293 (human 
embryonic kidney), was used as a control cell line for protein expression, since it is widely 
recognized as an easy to transfect/infect cell line and a good model for protein expression 
studies (Thomas and Smart, 2005). 
Chimeric TTR variants (WT, V30M, L12P and D18G) carrying a C-terminus six amino 
acids tetracysteine (TC) tag (Figure 1A) (Griffin et al., 1998) were used to study 
intracellular protein trafficking after reaction with the membrane-permeable biarsenical dye 
FlAsH-EDT2 (fluorescein arsenical helix binder, bis-EDT adduct) (Griffin et al., 2000; 
Griffin et al., 1998). Lentiviral vectors encoding each variant (Figure II.1A) were used to 
stably transduce SaHep, TR-CSFB, and human HEK293 cell lines (Figure II.1B).  
Intracellular TTR protein levels were comparable for all TTR variants in HEK293 and 
SaHep cell lines; in contrast, in TR-CSFB cells the intracellular levels of TTR variants 
V30M, L12P and D18G were approximately 40% lower than in cells expressing WT TTR 
(Figure II.2A). TTR mRNA levels were comparable for all TTR variants in each cell line 
(Figure II.1C). This suggests that TTR variant turnover rate in TR-CSFB cells is altered 
compared to WT TTR.  
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FIGURE II.1. Expression of human TTR variants in different cell lines. (A) Schematic 
representation of the lentiviral vector used to transduce the different cell lines (HEK293, SaHep 
and TR-CSFB). This vector leads to expression of different human TTR variants (TTR-X, where X 
codes for WT, V30M, L12P or D18G) fused to a tetracysteine tag (TC). (B) Direct fluorescence 
analysis of L12P expressing cells. Scale bar, 5µm. (C) TTR-TC gene expression in the different cell 
lines. Error bars represent SEM. 
 
Analysis of TTR secretion into the growth medium by ELISA revealed considerable 
differences across cell types and variants (Figure II.2B). Both in HEK293 and SaHep cells, 
the D18G TTR variant was not detected by ELISA (it was detected at very low levels by 
immunoblotting) consistent with previous findings in other cell types (Hammarström et al., 
2003a; Sato et al., 2007). Relative to the WT protein, the V30M variant level in 
conditioned medium was comparable in HEK293 cells but lower in SaHep, reflecting 
differences in secretion pattern among the 2 cell types. As for the L12P protein, lower 
levels were found in both SaHep and HEK293 cell lines relative to WT and V30M proteins. 
In contrast, secreted levels of V30M or L12P TTR were comparable to WT TTR levels in 
TR-CSFB cells. Contrarily to the findings in HEK293 and SaHep cells, D18G TTR was 
ǻ  U3 R U5CCPGCC IRES mCherry WPRETTR-­XCMVCMV R  U5 gag RRE cPPT
ȥ
A
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B
HEK293 SaHep TR-­CSFB
HEK293 SaHep TR-­CSFB
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secreted from TR-CSFB cells. Based on the differential secretion of TTR L12P variant in 
hepatocytes and choroid plexus and the association of this variant with CNS amyloidosis 
(Brett et al., 1999) we decided to focus our attention on this variant, to support a model 
where TTR protein variants are processed differentially by cell types of different tissue 
origin. 
Recent work has shown that TTR might undergo N-glycosylation (Sato et al., 2012), 
especially in the case of misfolded and destabilized variants, such as the D18G variant. 
We then evaluated whether L12P was susceptible to N-glycosylation. A higher molecular 
weight band (~ 19kDa) was detected in cell lysates and conditioned media from HEK293 
and SaHep cells expressing TTR L12P or D18G with a ratio of approximately 2.3% 
relative to the monomer (Figure II.2C). No clear higher molecular weight form was 
detectable in cell extracts or conditioned media from cells expressing TTR WT or V30M 
variant, most likely because they did not expose the putative N98 residue for glycosylation 
and thus are not glycosylated. Treatment of cell extracts or supernatant from TTR L12P 
expressing HEK293 and SaHep cells with N-glycosidase F eliminated the higher 
molecular weight band (Figure II.2C). This shows that this form is due to N-glycosylation 
of TTR L12P in those cells. In addition, we treated TTR L12P expressing SaHep cells with 
tunicamycin, an N-glycosylation inhibitor, and observed that L12P secretion decreased 
considerably while intracellular level increased (Figure II.2C). However, when the 
experiments were performed in TR-CSFB cells, no evidence for L12P N-glycosylation was 
observed, in accordance with the notion that glycosylation is cell-type specific (Parekh et 
al., 1989; Parekh et al., 1987), and can lead to different glycosylated patterns for the 
same protein in different organs. 
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Figure II.2. Levels of human TTR variants in the different cell lines. (A) hTTR  levels in cell lysates. 
Plots represent quantification of hTTR relative to α-tubulin. The bottom panels depict 
representative western blots. Besides de TTR monomer, a band of higher molecular weight 
(approximately 19kDa) is observed in HEK293, and SaHep cells and it is indicated by an arrow. 
*p<0.05; **p<0.01; ***p<0.001. (B) hTTR levels measured in cell conditioned media by ELISA. In all 
plots error bars represent SEM. *p<0.05; **p<0.01; ***p<0.001. (C) Secretion of N-glycosylated 
L12P TTR. Western blot analysis of conditioned media from cells treated in vitro either with N-
glycosidase F or tunicamycin; HEK293 and SaHep secrete N-glycosylated L12P TTR, not 
observed in TR-CSFB cells; tunicamycin inhibits N–glycosylation. Arrows indicate the N-
glycosylated band (a) and TTR monomer (b). 
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Comparative L12P intracellular localization in hepatocyte and choroid plexus cell lines  
To characterize L12P protein intracellular localization throughout the regular secretory 
pathway, we assessed by confocal microscopy with appropriate markers, L12P 
distribution in the ER, Golgi apparatus, endosomes and lysosomes by either direct 
fluorescence in live cells or indirect immunofluorescence in fixed material. The behavior of 
WT and V30M, L12P and D18G TTR variants in the three different cell types used in the 
secretion studies was also compared.  
First, none of the cell lines expressing WT-TTR revealed punctate-like material suggestive 
of the existence of intracellular aggregates, which were very evident in all D18G 
expressing cells (Figure II.3A); in V30M expressing cells very few aggregates were 
present, whereas in L12P expressing SaHep and HEK293 cells clear evidence of 
aggregates was found. By contrast, there were no aggregates in TR-CSFB cells 
expressing L12P. This observation is in agreement with the secretion data in TR-CSFB 
cells (Figure II.2B). The data again support the notion that epithelial cells of choroid plexus 
may possess distinct protein secretion and quality control machineries. 
Next we assessed the sub-cellular localization of TTR protein and aggregates in all cell 
types (Figure II.3). All TTR proteins showed widespread co-localization with calnexin, an 
ER resident chaperone, since they are produced in the ER (Figure II.3A). However TTR 
aggregates did not exhibit clear co-localization with calnexin (arrowheads in Figure II.3A), 
suggesting they are not degraded in the ER. 
We investigated whether intracellular accumulation of aggregates was caused by 
disruption of the normal secretory pathway. Cells were stained for the Golgi apparatus, 
but no abnormalities in Golgi vesicles and TTR-TC aggregates were noticed, excluding 
retention of the accumulated TTR variants in this compartment (Figure II.3B). 
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Figure II.3. Intracellular distribution of human TTR variants in different cells – distinct distribution in 
TR-CSFB as compared with HEK293 and SaHep cell lines. (A) TTR-TC (green) co-localizes with 
calnexin (red). TTR aggregates (white arrow heads) appear as punctated stain in variants V30M 
(scarce distribution), L12P and D18G inside HEK293 and SaHep cells but not in TR-CSFB cells, 
indicating their retention inside the cell. Nuclei are stained with Hoechst 33342 (blue). TR-CSFB 
cells present some speckles in nuclei, result of non-specific staining. Scale bars, 5µm. (B) 
Intracellular distribution of TTR-TC (green) and Golgin-97 (red). The vast majority of TTR 
punctated aggregates do not co-localize with the Golgi structures; these structures look intact and 
TTR-TC is seen in their vicinity. Nuclei are stained with Hoechst 33342 (blue). Scale bars, 5µm. 
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It is reasonable to hypothesize that part of TTR disease-related variants pass through the 
ER quality control without being retained, since retention has only been verified to happen 
with the D18G variant (Sato et al., 2007; Sekijima et al., 2005; Sörgjerd et al., 2006; 
Susuki et al., 2009). However we hypothesize that the protein could pass through the 
Golgi apparatus and subjected to a new round of quality control at the trans-Golgi network 
(TGN); here it is likely to be sorted either to the plasma membrane for secretion or bound 
by the cation-independent mannose-6-phosphate receptor (ci-M6PR) and directed for 
lysosomal degradation. (Ghosh et al., 2003; Hille-Rehfeld, 1995; Rodriguez-Boulan and 
Musch, 2005). Our data suggests the existence of an interaction between TTR, 
particularly L12P, and ci-M6PR, assessed both by immunofluorescence and co-
immunoprecipitation assays, suggesting that this destabilized variant could be directed for 
lysosomal degradation (Figure II.4). 
 
Figure II.4. Interaction of TTR with cation-independent mannose-6-phosphate receptor. (A) TTR-
TC (green) shows some co-localization (pointed by white arrow heads) with ci-M6PR (red), 
particularly in HEK293 and SaHep cell lines. Nuclei are stained with Hoechst 33342 (blue). Scale 
bars, 5µm. (B) Co-immunoprecipitation experiments show the existence of interaction between the 
TTR and ci-M6PR. 
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TTR intracellular aggregates are targeted for degradation in the lysosomes 
We investigated the possible presence of TTR in lysosomes, which are vesicles more 
often associated with degradation, but that can also function as secretory vesicles (Blott 
and Griffiths, 2002; Wang et al., 2011). Moreover we wanted to assess the possibility of 
lysosomal-mediated degradation of TTR aggregates. For this purpose, we used 
LysoTracker, a fluorescent probe highly selective for acidic cellular organelles in live cells. 
When we overlapped the images of TTR-TC with LysoTracker Red (Figure II.5) the great 
majority of TTR protein aggregates were inside lysosomes in HEK293 and SaHep cell 
lines, especially prominent for the D18G variant in HEK293 cells. In TR-CSFB cells we 
found no overlap between TTR-TC and LysoTracker fluorescence, as we also did not 
detect intracellular protein aggregates in this cell line. 
 
Figure II.5. TTR-TC (green) is co-localized with lysosomes (red) in live cells. Protein aggregates 
inside the lysosomes (in yellow, pointed by white arrow heads), mostly in the cases of L12P and 
D18G in HEK293 and to a lesser extent in SaHep and absent in TR-CSFB cells. TR-CSFB cells 
present some speckles in nuclei, result of non-specific staining. Scale bars, 5µm. 
 
Next we examined the contribution of lysosomes to TTR aggregate degradation by 
biochemical means, in particular for the L12P variant. We made use of the lysosomal 
inhibitor ammonium chloride, which is a weak base that increases cellular pH and inhibits 
lysosomal proteolysis and phagosome-lysosome fusion (Cardelli et al., 1989). Incubation 
of L12P TTR HEK293 cells with 20mM ammonium chloride for 24h led to significantly 
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increased intracellular TTR levels (Figure II.6A) and concomitant decrease in TTR 
concentration in condition media (Figure II.6B); surprisingly in parallel experiments in 
SaHep cells, lysosome inhibition by ammonium chloride had opposite effects, i.e., lead to 
decreased L12P intracellular accumulation and increased L12P secretion levels 
(approximately 40% change). We interpret these results as an additional effect of 
ammonium chloride in the folding of the variants, acting as a chemical chaperone in 
hepatocyte-derived cells. The same trend in the pattern of intracellular accumulation 
versus secretion in HEK293 and SaHep cells also occurred for the V30M variant although 
to a lesser extent. Lysosomal inhibition had no effect on D18G variant or WT TTR 
accumulation/secretion or in WT in HEK293 or SaHep cells, or on any of the TTR proteins 
in TR-CSFB cells. In summary, in choroid plexus-derived cells TTR aggregates are not 
generated and therefore, the lysosome does not play a role in L12P disposal as it does in 
hepatocyte-derived cells. 
 
Figure II.6. Effect of ammonium chloride in TTR secretion. Plots represent hTTR levels in cell 
lysates with and without ammonium chloride treatment (A) measured by Western blot relative to α-
tubulin and in conditioned media (B) measured by ELISA. Error bars represent SEM. *p<0.05; 
**p<0.01; ***p<0.001. 
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Other degradation pathways for intracellular degradation of TTR aggregates: UPS and 
autophagy 
The ubiquitin-proteasome system (UPS) is one of the major sites for degradation of 
abnormal proteins in cells (Sherman and Goldberg, 2001). We investigated whether this 
system may be involved in removing the intracellular TTR aggregates in HEK293 and 
SaHep cells. We found no evidence of increased TTR ubiquitination in cells expressing 
any of the variants compared to wild type TTR; thus, the UPS does not appear to play a 
major role in the clearance of intracellular TTR aggregates in these systems. 
Autophagy is a way for cells to dispose of aberrant cytosolic proteins that accumulate in 
the ER, working in parallel with the UPR and the UPS (Anelli and Sitia, 2008; Kubota, 
2009). The involvement of autophagy in the degradation of intracellular generated TTR 
aggregates was investigated by immunostaining of fixed cells with an LC3-specific 
antibody. Co-localization of TTR-TC and LC3 (a marker for autophagy) was not 
particularly evident in HEK293 and TR-CSFB cells, but apparent for some TTR variants in 
SaHep cells (Figure II.7A). To further assess the potential role of autophagy, we treated 
all three TTR-expressing cell lines with rapamycin, but found no significant changes in 
TTR levels in cell lysates (Figure II.7B) or conditioned media (Figure II.7C) compared to 
vehicle (DMSO) treated cells. Altogether this data suggest that autophagy does not play a 
significant role in the clearance of TTR aggregates in the cell lines studied here. 
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Figure II.7. Effect of autophagy in TTR secretion. (A) Intracellular distribution of TTR-TC (green) 
compared to LC3 A/B (red). Note that the vast majority of TTR punctated aggregates do not co-
localize with autophagosomes, with a few exceptions in the SaHep cell line, pointed by 
arrowheads. Scale bars, 5µm. Nuclei are stained with Hoechst 33342 (blue). Plots represent hTTR 
levels in cell lysates with and without rapamycin treatment (B) relative to α-tubulin and in 
conditioned media (C) measured by ELISA. Error bars represent SEM. *p<0.05; **p<0.01; 
***p<0.001. 
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Intracellular L12P protein aggregates in mouse hepatocytes – evidence from an in vivo 
approach 
In order to further explore the selective existence of L12P TTR intracellular aggregates in 
hepatocytes in the liver, we used systemic gene delivery with adeno-associated virus 
(AAV) vectors encoding WT, V30M or L12P TTR under a liver-specific promoter. The viral 
stocks were administrated to TTR null mice through tail vein injections. Animals were 
euthanized 3 months later and characterized for infection efficiency, TTR liver expression, 
TTR serum levels and TTR deposition in the gastrointestinal (GI) tract and dorsal root 
ganglia (DRG), the major organs of TTR deposition in the available transgenic mouse 
models (Kohno et al., 1997; Santos et al., 2010a). 
AAV vector genomes were quantified in liver, stomach and in the peripheral nervous 
system by qPCR. We found that liver was the only organ where significant amounts of 
AAV vector genome copies per mouse genome were found, with identical levels of viral 
genome copies across groups of mice injected with AAV vectors encoding WT, V30M or 
L12P TTR (Figure II.8A).  
The human identity of TTR proteins in sera was evaluated by mass spectrometry following 
immunoprecipitation, and confirmed (data not shown). TTR levels were then measured by 
ELISA; whereas mice expressing human WT or V30M TTR had comparable levels of the 
protein in their sera TTR L12P levels were approximately 10-fold lower than for the other 
isoforms (Figure II.8B), despite equal levels of liver viral genome copies per mouse 
genome, as above described. We next carried out western blot analysis of sera (Figure 
II.8C); as shown in figure II.8C, in addition to the regular TTR monomer, a higher 
molecular weight band of approximately 2kDa higher was detected in the sera of L12P 
TTR expressing mice, suggesting the existence of N-glycosylated TTR L12P in sera. As 
shown above, this additional band was present in western blots of conditioned media from 
SaHep cells expressing L12P or D18G TTR variants (Figure II.2A and II.2C), which N-
glycosidase F treatment confirmed to represent a product of N-glycosylation. 
We then investigated by immunofluorescence, TTR localization in the liver of these 
animals. Animals expressing TTR L12P displayed intracellular TTR aggregates in liver 
hepatocytes (Figure II.8D), which were not present in the livers of WT and V30M-TTR 
animals that had a diffused staining owing to TTR secretion. Further confocal 
immunofluorescence analysis of the L12P aggregates with the lysosomal marker Lamp-2 
indicated co-localization in lysosomes (Figure II.8D), as earlier found in L12P expressing 
SaHep cells. We also analyzed by immunohistochemistry TTR deposition in the GI tract 
and in DRG, the principal organs targeted in available animal models for FAP (Kohno et 
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al., 1997; Santos et al., 2010a); however, no TTR deposits were observed in tissues other 
than liver, contrasting the descriptions in human patients (Brett et al., 1999). We 
hypothesize that this failure is related with the very low levels of circulating protein and the 
very short time of the experiment, placing eventual deposits below the detection limit of 
the employed technique. 
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Figure II.8. In vivo TTR expression and distribution in mice. (A) scAAV8-TTR expression in mice 
liver. Plot represents the ratio of viral genome copies in relation to the number of mouse genomes 
in each sample. (B) Human TTR concentration in sera of WT, V30M and L12P mice as measured 
by ELISA. Error bars represent SEM. *** p<0.001; (C) TTR western blot of sera from L12P and WT 
mice, showing a high molecular weight N-glycosylated L12P TTR band above the TTR monomer, 
absent from WT serum. Arrows indicate the N-glycosylated band (a) and TTR monomer (b). (D) 
TTR distribution in mice hepatocytes; TTR (green) expression is widespread in mice hepatocytes 
after transduction with AAV vectors. The presence of intracellular TTR aggregates is evident in 
hepatocytes in the TTR L12P mouse with noticeable green punctated staining. These punctuates 
are not seen in models for TTR WT and V30M. L12P aggregates localize in lysosomes (Lamp-2 
staining, red), pointed by white arrowhead. Scale bars, 10µm. Nuclei are stained with DAPI (blue). 
Plots represent extent of co-localization by measuring the distance between the highest intensity of 
the different channels on selected points of the figure. (E) TTR deposition assessment in stomach, 
colon and DRG of TTR null mice injected with scAAV8-TTR L12P. Scale bars, 100µm. 
 
Altogether, data from in vitro hepatocyte-derived cells and the newly developed L12P 
mice confirmed the unique properties of this mutant, as prone to N-glycosylation, poorly 
secreted by liver, and forming intracellular aggregates degraded by the lysosomal 
proteolytic system. 
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DISCUSSION 
In the field of amyloid diseases opinions differ considerably on how and where amyloid 
fibrils are formed. In TTR amyloidoses, it is commonly accepted that TTR variants 
aggregate in the extracellular environment (Susuki et al., 2009), since the protein is 
secreted as a correctly folded product after undergoing quality control where misfolded 
proteins are targeted for ERAD degradation (Sato et al., 2007; Sekijima et al., 2005). The 
present report concentrated on a special TTR variant previously reported to deposit in the 
liver of a L12P patient (Brett et al., 1999), in complete contrast with the most common 
V30M TTR variant, which led us to hypothesize particular and abnormal cell trafficking 
properties for the L12P variant. 
The systems used to tackle the in vitro and in vivo studies of this work were very 
advantageous because of the following: (i) were carried out on established cell lines 
derived from TTR naturally producing cells without endogenous TTR expression; as such 
the in vivo conditions are mimicked in a much better way as compared to the use of 
transient transfections (Colosimo et al., 2000); (ii) allowed in vivo labeling with a small tag, 
and lentiviral vectors generated high stable expression of WT and TTR variants in the 
different cell types used; and (iii) systemic administration of the AAV vectors resulted in 
highly selective and stable liver expression of WT and V30M or L12P variants overcoming 
the cumbersome work of transgenesis; furthermore, no adverse immunological reactions 
were noticed. 
Both approaches revealed a wealth of new data; first, cell culture experiments on the 
L12P variant, showed clear and distinct secretion properties between hepatocytes and 
choroid plexus cells. While WT-TTR and the V30M variant are secreted by both 
hepatocytes and choroid plexus cells, the D18G and the L12P leptomeningeal associated 
TTR mutants significantly differed between the two cell types with intracellular retention of 
D18G and L12P which occurred in hepatocytes as assessed by in vivo labeling and 
biochemical methods, but not in TR-CSFB cells. Previous studies on the D18G variant 
using an immortalized rat choroidal epithelial cell line (Z310 cells), showed retention of 
this variant (Sekijima et al., 2005). However, the immortalization procedures used across 
cell lines can be very different, which may explain secretion of D18G in CP-derived lines 
used in the present work; TR-CSFB cells are choroid plexus cells derived from transgenic 
rats harboring a temperature-sensitive SV40 large T-antigen gene (ts SV40), and are thus 
a conditionally immortalized cell line. In contrast, the Z310 cell line was immortalized by 
transfection with the viral plasmid psV3neo. One of the main advantages of conditionally 
immortalized cell lines derived from such transgenic animals is that transgene insertion is 
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unlikely to have disrupted essential genes as these homozygous animals are viable and 
have been maintained for many years (Terasaki and Hosoya, 2001). In contrast 
immortalization via transfection of primary cells may lead to unpredictable insertional 
mutagenesis with the potential to affect pathways important to the biology of TTR; at any 
rate, there is always the possibility that cell lines in culture display different secretion rates 
and/or protein quality control properties compared to hepatocytes in their native 
environment in the liver. Only in vivo approaches can definitely resolve and corroborate 
the cell culture data. The hepatic AAV-mediated somatic transgenesis approach we used 
here to assess the in vivo properties of L12P supports our findings in hepatocytes in 
culture, and represents a new approach to rapidly evaluate properties of TTR variants.  
Secondly, we report for the first time N-glycosylation of L12P by hepatocyte-like cells and 
secretion of a glycosylated product. Different types of post-translational modifications in 
TTR have been reported (Biroccio et al., 2006; Bunkenborg et al., 2004; Rüggeberg et al., 
2008; Terazaki et al., 1998). N-glycosylation of TTR at asparagine 118 (N118) 
(Rüggeberg et al., 2008) has been described; however the function of this post-
translational modification is yet to be clarified. More recently, Sato and colleagues (Sato et 
al., 2012) demonstrated that highly destabilized misfolded TTR variants such as D18G, 
but not the WT or V30M, can be N-glycosylated on position 98 (N98) and targeted to an 
EDEM3-mediated N-glycan dependent ERAD to maintain cellular homeostasis. TTR 
possesses a sequon for N-glycosylation at position 98 (N-D-S) (Teixeira and Saraiva, 
2013), but normal protein folding usually hides this sequence into the interior of the 
molecule, however protein unfolding might expose this sequon to the surface (Sato et al., 
2012). N-glycosylation can improve the thermodynamic and kinetic stability of a protein 
(Shental-Bechor and Levy, 2008); therefore the low ratio of glycosylated form to non-
glycosylated suggests that most protein exists as a moderately unfolded form and only a 
small fraction is severely unfolded and exposes the N-glycosylation sequon (Sato et al., 
2012). 
We hypothesize that the mechanism underlying L12P N-glycosylation is similar to what 
has been described for blood coagulation factor VII (FVII), which is post-transcriptionally 
glycosylated after accumulation in the ER followed by folding into a secretion-competent 
conformation (Ruiz-Canada et al., 2009), since in our studies increased levels of ER 
chaperones, like BiP, Herp or HRD1 were not noticeable in hepatocyte-derived cells (data 
not shown), therefore N-glycosylation of L12P TTR is most likely not targeting it for Herp-
associated ERAD degradation. Furthermore, very recently the existence of N-glycosylated 
V30M TTR in the plasma of FAP patients was described, but the authors failed to identify 
N-glycosylated protein in tissue extracts of transgenic V30M mice (Teixeira and Saraiva, 
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2013); taken together we hypothesize that severely unfolded L12P TTR is retained inside 
the cell for lysosomal degradation whereas a minute amount is N-glycosylated and 
secreted as a glycosylated product. 
The assays involving tunicamycin, an N-glycosylation inhibitor, showed a decrease in 
secretion of L12P TTR in hepatocytes (Figure II.2C) but it did not affect choroid plexus 
cells secretion (data not shown); we thus hypothesize that choroid plexus may not 
possess the necessary cellular machinery to recognize misfolded proteins, leading to their 
secretion, suggesting that N-glycosylation of this particular amyloidogenic TTR variant is 
important for protein secretion by hepatocytes but not by choroid plexus. Moreover, the 
different glycosylation patterns may also be the explanation on why the choroid plexus 
derived cells secrete TTR L12P at levels comparable to WT TTR, whereas in the other 
cell lines secretion of this variant is considerably reduced, possibly to overcome extensive 
extracellular accumulation that might cause toxicity. Description of secretion of N-
glycosylated TTR was unequivocally demonstrated in the serum of L12P mice. Whether 
this represents an escape to N-glycosylation-dependent ERAD is the subject of future 
investigation, and in this regard, the L12P mutant constitutes a model system, both by in 
vitro and in vivo approaches.  
Thirdly, the study we present here shows by in vivo labeling the targeting to the lysosome 
of intracellular produced TTR aggregates. Previous studies with the D18G mutant 
hypothesize accumulation and degradation of intracellular TTR by ERAD mechanisms, 
both independent and dependent on N-glycosylation. Most cells possess forms of protein 
degradation alternate to ERAD and the UPS. One of alternative processes is 
macroautophagy, which takes place in lysosomes. This process is involved in diseases 
where intracellular protein accumulation occurs, as it is the case in Machado-Joseph 
disease where mutant ataxin-3 is cleared in the lysosomes (Nascimento-Ferreira et al., 
2011), or Parkinson’s disease, where α-synuclein is translocated for degradation in 
lysosomes (Cuervo et al., 2004). Therefore, it is not surprising that intracellular L12P TTR 
aggregates (and D18G) can follow this pathway for degradation. Disposal of TTR 
aggregates by autophagy might also operate but only when the lysosomal degradation 
system is impaired (Anelli and Sitia, 2008). Absence of TTR aggregates in the lysosomal 
compartment of choroid plexus derived cells again stresses the possibility of still unknown 
secretion and quality control properties assigned of this cell type. Lysosomal accumulation 
of TTR aggregates in the liver of L12P mice not only corroborated the cell culture data, but 
also raises the potential to use somatic transgenesis in tests of pharmacological 
compounds to improve lysosomal clearance in instances of liver TTR intracellular 
aggregates. Such class of compounds is the subject of intense study for other protein 
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aggregation related disorders, as for instance in a rat model of Machado-Joseph disease 
overexpression of beclin-1 improved the lysosomal clearance of ataxin-3 (Nascimento-
Ferreira et al., 2011). 
Finally, a new animal model was generated using recombinant AAV vectors instead of the 
more usual transgenic mouse. Viral-vector-mediated gene transfer has the advantage of 
being targeted to a particular organ, gene expression can be induced at any time-point 
during development or in the fully mature animal and high levels of gene expression can 
be achieved (Kirik and Björklund, 2003). 
Our animal model expresses the protein only in liver, due to the liver specific promoter 
present in our constructs. Because the viral load in liver was similar among TTR variants 
and the WT protein, the 10 times lower serum found for L12P animals compared to WT or 
V30M animals is related to the unique intracellular retention/degradation of the L12P 
protein in liver; these aggregates were not present in neither WT nor V30M animals.  
Previous studies have compared TTR levels both in serum and CSF, as well as across 
variants. These have shown that V30M carriers have reduced levels of TTR in serum than 
non-carriers (Saraiva et al., 1985); the same occurring in the case of TTR variants 
associated with leptomeningeal amyloidosis (Mitsuhashi et al., 2005), and in the particular 
case of L12P carriers the reduction in TTR serum levels goes from the normal 
concentration range 0.2–0.4g/L to 0.11g/L (Altland et al., 2007), a reduction of about 50–
75%. However, in CSF no differences were observed in the TTR concentration across 
mutations (Mitsuhashi et al., 2005).  
Overall our in vivo approach replicates the data we described for the cell line model. But 
more importantly, it replicates the clinical features found in patients, in particular the 
severe protein deposition in liver (Brett et al., 1999) and opens a new door to the 
establishment of somatic transgenic animal models for different TTR variants. There are 
still many questions lacking answers, including why some particular TTR variants appear 
to cause CNS amyloidosis if all are secreted and not retained by the choroid plexus? CNS 
sensitivity or protein affinity to tissues might certainly play an important role? At any rate, 
through the in vitro system new therapeutic approaches to leptomeningeal amyloidosis 
encompassing trapping TTR inside the cell and enhancing lysosomal degradation system 
to avoid the presence of aggregates in CNS warrants further investigation. 
  
CHAPTER II⏐Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new 
somatic transgenic mouse model 
79 
ACKNOWLEDGEMENTS 
The authors thank Fundação para a Ciência e Tecnologia (FCT), Portugal, for fellowship 
SFRH/BD/40511/2007 to ARB. The authors also thank Paula Sampaio from ALM, IBMC, 
for help with confocal microscopy and helpful discussions, Paula Gonçalves from IBMC 
for tissue processing and Davide Gianni from UMass for qPCR of AAV vector genomes. 
This work was supported by FEDER funds through the Operational Competitiveness 
Programe – COMPETE and by national funding from FCT under projects FCOMP-01-
0124-FEDER-022718 (PEST-c/SAU/LA0002/2011 and PTDC/SAU-ORG/111313/2009). 
MSE is supported by National Institutes of Health grants R01NS066310, U01NS064096 
and R01HD060576. 
 
  
  
 
 
 
 
 
 
 
 
 
Chapter III 
Dynamics of transthyretin 
oligomer internalization 
  
  
  
 
 
 
 
DYNAMICS OF TRANSTHYRETIN OLIGOMER INTERNALIZATION 
 
 
Ana Rita Batista a,b, Joana Magalhães a,b, Paula Sampaio c, Miguel Sena-Esteves d, 
Maria João Saraiva a,b 
 
a Molecular Neurobiology, IBMC – Instituto de Biologia Molecular e Celular, Porto, Portugal  
b ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal 
c Advanced Light Microscopy Unit, IBMC, Porto, Portugal 
d Department of Neurology, Gene Therapy Center, University of Massachusetts Medical School, 
Worcester, MA, USA 
  
  
 
CHAPTER III⏐Dynamics of transthyretin oligomer internalization 
85 
ABSTRACT 
Mutated transthyretin (TTR), particularly TTR-V30M, can aggregate, form fibrils, and 
deposit extracellularly mainly in the peripheral nervous system causing familial amyloidotic 
polyneuropathy (FAP). Prior to fibril deposition, the presence of non-fibrillar aggregates 
can trigger cytotoxicity and apoptosis, although the mechanisms underlying these events 
are still unclear. Currently the prevalent hypothesis is that TTR oligomer toxicity is 
mediated via cell surface receptors and changes in intracellular signaling. Here we 
hypothesize that in FAP, communication between TTR aggregates and cells takes place 
both by signal transduction and internalization events, as it has been observed in 
Alzheimer’s disease (AD). Using a novel system where mammalian cells produce and 
secrete TTR labeled with a tetracysteine tag (TTR-V30M-TC), we investigated whether 
TTR aggregates are internalized by a neuroblastoma cell line and their intracellular fate. 
We observed that (i) TTR-V30M-TC aggregates are internalized by an endocytic process 
involving both clathrin- and cholesterol-dependent mechanisms; (ii) upon internalization, 
aggregates are rapidly translocated to lysosomal compartments for degradation. These 
observations pave the way to possible approaches to modulate uptake of TTR aggregates 
to accelerate clearance from the extracellular milieu in order to prevent extracellular TTR 
deposition. 
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INTRODUCTION 
Transthyretin (TTR) is a circulating protein synthesized mainly by liver hepatocytes, brain 
choroid plexus epithelium, and retinal epithelium (Soprano et al., 1985). It is a 
homotetrameric protein consisting of 4 identical subunits of 14kDa and 127 amino acids 
each (Kanda et al., 1974). Mutations in the TTR gene are associated with familial 
amyloidotic polyneuropathy (FAP), a neurodegenerative disease affecting mainly the 
peripheral nervous system (PNS). The pathological hallmark of FAP is the extracellular 
deposition of TTR amyloid fibrils in the nerve (Andrade, 1952; Saraiva et al., 1984). To 
date more than 100 point mutations have been described in the TTR gene (Saraiva, 
2001). The most common FAP-associated TTR mutation is the substitution of valine by 
methionine at position 30 of the mature protein (V30M). 
The mechanism of TTR amyloid fibril formation is not yet completely understood. The 
most accepted model state that the process is triggered by tetramer dissociation to a 
compact non-native monomer with low stability, resulting in partially unfolded monomeric 
species with a high tendency for aggregation into amyloid fibrils (Quintas et al., 2001; 
Sousa and Saraiva, 2003). In vivo studies using FAP patient nerves from different stages 
of disease progression have shown the presence of non-fibrillar TTR aggregates in early 
disease, and not amyloid, and co-existence of non-fibrillar and fibrillar aggregates at later 
stages of disease (Sousa et al., 2001a). The presence of non-fibrillar aggregates is the 
cause of cellular toxicity in human FAP nerves at early stages of disease, and in 
transgenic mice expressing TTR V30M or L55P (Sousa et al., 2001a; Sousa et al., 2002). 
The mechanism by which non-fibrillar aggregates induce intracellular events is still not 
completely understood. Sousa and colleagues showed that TTR aggregates bind to the 
receptor for advanced glycation end products (RAGE) triggering inflammation and 
apoptosis through NF-κB activation (Sousa et al., 2001b; Sousa et al., 2000c); this 
receptor was also implicated in the activation of the MEK-ERK MAPK signaling pathway 
(Monteiro et al., 2006b). Also the interaction of TTR aggregates with the plasma 
membrane causes a change in membrane fluidity followed by cytotoxicity, has been 
described (Hou et al., 2005). These data suggests that TTR toxicity is a process that 
occurs via cell surface interactions. However, other mechanisms may also be involved, 
particularly, internalization of small intermediate aggregates. 
Currently there is no evidence of intracellular TTR aggregates. However, a number of 
membrane receptors have been implicated in the internalization of soluble TTR. Recent 
studies report that internalization of soluble TTR in neurons is a clathrin-dependent 
process (Dekki et al., 2011), mediated by megalin a member of the low-density lipoprotein 
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(LDL) receptor family (Fleming et al., 2009). Megalin also mediates TTR uptake in kidney 
(Sousa et al., 2000b); and in liver another unidentified receptor-associated protein (RAP)-
sensitive lipoprotein receptor appears to be involved as well (Sousa and Saraiva, 2001). 
Presently it is unclear whether any of these receptors may also be involved in the uptake 
of TTR aggregates, and warrants further investigation. 
In other amyloidogenic diseases, such as Alzheimer’s disease (AD), the pathological 
hallmark is the accumulation of extracellular plaques. Nonetheless, it is now widely 
accepted that intracellular amyloid β peptide (Aβ) also plays an important role in disease. 
Neurons accumulate intracellular Aβ originated by cleavage of APP but also from 
internalization of extracellular Aβ peptides, both in soluble and oligomeric forms (Chafekar 
et al., 2008; Lai and Mclaurin, 2010; Mohamed and Posse De Chaves, 2011). The exact 
mechanism of Aβ uptake remains to be defined; soluble and oligomeric Aβ have been 
shown to interact with several membrane receptors including LRP1, RAGE, NMDA or 
insulin receptor; as well as lipid rafts and heparan sulfate proteoglycans (Carro et al., 
2002; Lai and Mclaurin, 2010; Mohamed and Posse De Chaves, 2011; Sandwall et al., 
2010).  
In the present work we investigate the possible internalization of TTR aggregates and 
their intracellular localization using confocal microscopy and a novel system where TTR is 
fluorescently labeled with a tetracysteine tag. In addition, we test the different 
mechanisms by which TTR aggregates could be internalized and degraded. 
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MATERIALS AND METHODS 
Cell culture 
HEK293 cells (human embryonic kidney, European Collection of Cell Cultures) stably 
expressing TTR-WT-TC and TTR-V30M-TC (Batista et al., 2013) were cultured in EMEM 
(Eagle’s minimum essential media, Lonza), supplemented with 10% (w/v) FBS, 2mM L-
Glutamine, 100U/mL penicillin/streptomycin (all from Gibco) and 1% (w/v) non-essential 
amino acids (Sigma-Aldrich). SH-SY5Y cell line (human neuroblastoma, European 
Collection of Cell Cultures) was cultured in EMEM:Ham’s F-12 (1:1, Lonza), 
supplemented with 10% (w/v) FBS, 2mM L-Glutamine, 100U/mL penicillin/streptomycin 
(all from Gibco) and 1% (w/v) non-essential amino acids (Sigma-Aldrich). All cell lines 
were routinely propagated in T-25 flasks in monolayer at 37°C, in 5% CO2 humidified 
atmospheres. 
 
Conditioned media preparation 
HEK293 cells were plated in 24-well multiplates (0.2x106 cells/well). Twenty-four hours 
after plating, FlAsH staining was performed as described (Hoffmann et al., 2010). Briefly, 
cells were incubated for 30min at 37°C with 5mM sodium 2-mercaptoethane sulfonate and 
0.5mM Tris(2-carboxyethyl) phosphine hydrochloride solution (both from Sigma-Aldrich) in 
OptiMEM (Gibco). Cells were then washed and incubated with 1µM FlAsH-EDT solution 
(Molecular Probes, Invitrogen) in HBSS for 1h at 37°C, followed by washes with 250µM 
1,2-ethanedithiol (EDT, Sigma-Aldrich) in HBSS. After staining, cells were washed 3 times 
with HBSS and incubated with DMEM (Dulbecco’s modified Eagle’s medium, Gibco) 
without phenol red supplemented with 5% (w/v) FBS, 2mM L-Glutamine and 100U/mL 
penicillin/streptomycin (all from Gibco). Cells were allowed to produce and secrete labeled 
TTR-TC for 18–20h, medium was then collected and TTR concentration was measured by 
ELISA, as previously described (Cardoso et al., 2007). 
 
TTR-TC species characterization: aggregation detection and cellular toxicity 
Conditioned medium from HEK293 expressing TTR-V30M-TC was subjected to a slot-blot 
filter assay, using conditioned medium with TTR-WT-TC as control. Briefly, medium 
containing 600ng of either TTR-WT-TC or TTR-V30M-TC was applied to a 0.2µm pore 
cellulose acetate membrane filter (Whatman) using a manifold system and subjected to 
vacuum to separate aggregates from solution. The membrane was then immunoblotted 
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using rabbit polyclonal anti-hTTR (Dako, 1:500) as a primary antibody. The enhanced 
chemiluminescense method (ECL, GE Healthcare Bioscience) was used for detection of 
TTR filter-retained aggregates. 
For cell toxicity assays, SH-SY5Y cells were grown on Lab-Tek slides (Nunc) and 
incubated for 24h with conditioned media containing the above mentioned concentrations 
of both TTR-WT-TC and TTR-V30M-TC. Cell viability was measured using the Live/Dead 
assay (Molecular Probes, Invitrogen) according to the manufacturer’s instructions. Briefly, 
cells were washed with PBS and incubated for 30min at 37°C with the a mixture of 
ethidium homodimer-1:calcein (0.25µM and 1.25µM, respectively) and visualized under a 
Zeiss Axiovert 200M microscope (Carl Zeiss Microscopy, Germany)  using filters for GFP 
(green fluorescence protein) and Texas-Red. Percentage of dead cells was calculated as 
the ratio between red-stained cells (EthD-1) and the total number of cells (sum of red and 
green stained cells). 
 
Time lapse fluorescence imaging 
Time-lapse analysis of TTR-V30M-TC uptake was performed on SH-SY5Y cells plated at 
5x103 cells/well on 8-well µ-Slide (Ibidi, Germany) using conditioned medium containing 
250–300ng of TTR-V30M-TC. Time-lapse images were collected every 15 sec with 1µm 
z-steps, at 37°C, with a Spinning Disk Confocal System Andor Revolution XD (Andor 
Technology, UK) exciting with 488 nm laser. Imaging started at the time when conditioned 
medium was added to the cells and lasted for different times, as indicated in the results 
section. Experiments were also conducted adding 100µM of TUDCA to the conditioned 
medium of TTR-V30M-TC. 
For time-lapse fluorescence analysis of lysosomal protein degradation, SH-SY5Y cells 
plated at 5x103 cells/well on 8-well µ-Slide (Ibidi, Germany) were subjected to lysosomal 
staining using 75nM of LysoTracker Red DND-99 (Molecular Probes, Invitrogen) for 2h, 
according to manufacturer’s instructions. After labeling, cells were live-imaged under a 
Laser Scanning Confocal Microscope Leica TCS SP5 II (Leica Microsystems, Germany) 
with controlled temperature at 37°C. Time-lapse images were acquired by sequential line 
excitation using laser lines 514nm and 561nm, and were collected every 30sec with 
0.5µm z-steps, starting at the time when conditioned medium was added to the cells and 
lasting for different times, as indicated in the results section. 
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Effect of uptake inhibitors  
Cells were grown on glass coverslips coated with poly-D-lysine (Sigma-Aldrich). Twenty-
four hours later, cells were pre-incubated for 30min at 37°C with different possible uptake 
inhibitors: 80µM dynasore (Sigma), 300µg/mL recombinant RAP (receptor associated 
protein, produced as previously described in (Sousa et al., 2000b)), 10µg/mL recombinant 
soluble RAGE (produced as described in (Monteiro et al., 2006a)), 100µg/mL pig heparin 
with 14kDa (a kind gift from Jin-Ping Li, Uppsala University), 500nM nocodazole (Sigma-
Aldrich), 5mM methyl-β-cyclodextrin (Sigma-Aldrich) and 2.5µM filipin (Sigma-Aldrich). 
Recombinant RAP and sRAGE were detoxified using Endotoxin Removing Gel (Pierce) 
and protein concentration was determined by the Bio-Rad assay kit (Bio-Rad) using serial 
dilutions of bovine serum albumin as protein standard. After pre-incubation, cells were 
washed with HBSS and incubated with conditioned medium containing 250–300ng of 
TTR-V30M-TC for 3h and then fixed with ice-cold acetone for 10min at –20°C. In parallel, 
experiments incubating cells with conditioned medium at 4°C were carried out. Coverslips 
were mounted in Vectashield with 4’,6-diamidino-2-phenylindole (DAPI, Vector Labs) and 
visualized under a Laser Scanning Confocal Microscope Leica TCS SP5 II (Leica 
Microsystems, Germany) using laser lines 405nm, 514nm and 561nm. 
 
Interaction with lipid rafts 
SH-SY5Y cells were plated on glass coverslips coated with poly-D-lysine (Sigma-Aldrich). 
Twenty-four hours after plating, cells were incubated with conditioned medium containing 
250–300ng of TTR-V30M-TC for 3h. Cells were washed with HBSS at room temperature 
and a second wash with ice-cold HBSS. Cells were then incubated with 10µg/mL cholera 
toxin subunit B (CTxB, List Biological Laboratories) in ice-cold DMEM for 10min at 4°C, 
washed with ice-cold HBSS and then incubated with goat anti-CTxB antibody for 15min at 
4°C. Coverslips were fixed with ice-cold acetone for 10min at –20°C. For detection of 
primary antibody, AlexaFluor-647 anti-goat IgG (Molecular Probes, Invitrogen) was used 
(1:1,000, 30min, RT). Coverslips were mounted in Vectashield with DAPI (Vector Labs) 
and visualized under a Laser Scanning Confocal Microscope Leica TCS SP5 II using laser 
lines 405nm, 514nm and 633nm. 
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Western blot 
SH-SY5Y cells were plated in 6-wells multiplates (Orange Scientific). Twenty-four hours 
later, conditioned medium containing 1µg TTR-V30M-TC was added to cells and 
incubated for different time points. Cells were then lysed in RIPA lysis buffer (50mM Tris-
HCl, 150mM NaCl, 1mg/mL sodium deoxycholate, 1% NP-40) containing 1x protease 
inhibitors mixture (GE Healthcare Bioscience). Total protein concentration in cell lysates 
was determined by the Bio-Rad assay kit (Bio-Rad) as above described; 40µg of total 
protein were separated in a 15% polyacrylamide SDS-PAGE gel and then transferred onto 
a 0.2µm pore nitrocellulose membrane (Whatman) using a wet transfer system. Primary 
antibodies were rabbit polyclonal anti-LC-3 A/B (Cell Signaling, 1:1,000) and mouse 
monoclonal anti-α-tubulin (Sigma-Aldrich, 1:10,000) for normalization. The enhanced 
chemiluminescense method (ECL, GE Healthcare Bioscience) was used to develop blots. 
Quantitive analysis of western blot images was performed using the ImageJ software 
(NIH). 
 
Image processing 
Time-lapse images were deconvolved by Classic Maximum Likehood Extimation algorithm 
of Huygens Professional software suite (SVI, Netherlands). Processing of all images and 
video assembly, as well as co-localization analysis with plug-in Dynamic ROI Profiler, 
were performed using Fiji software (Schindelin et al., 2012), 
 
Statistical Analysis 
Experimental results shown are the average of at least 3 independent experiments and 
are presented as mean ± SEM. Statistical significances were evaluated by one-way 
ANOVA with Bonferroni post test. Differences were considered significant for p<0.05 or as 
designated. Statistical analysis was performed using GraphPad Prism 5.0 for Mac OS X. 
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RESULTS 
Establishment of a new system to investigate uptake of TTR aggregates 
Previous studies have shown that production of oligomers with AlexaFluor488-labeled 
TTR results in species with atypical size and appearance that cannot be internalized by 
cells (Magalhães, 2011). Here we used a different approach to study uptake of TTR 
aggregates using TTR variants fused to a small C-terminal tetracysteine (TC) tag stably 
expressed from lentivirus vector-transduced HEK293 cells (Batista et al., 2013); cells 
produced and secreted TTR-WT-TC or TTR-V30M-TC to the conditioned medium at an 
average of 1µg/mL, as measured by ELISA. When analyzed by a filter assay in cellulose 
acetate that retains particles higher than 0.2µm in size and subsequently blotted with an 
antibody against TTR, we observe that, for the same TTR concentration, TTR-V30M-TC 
susceptibility to form aggregates in the conditioned media is higher than TTR-WT-TC 
(Figure III.1A). Also, TTR-V30M-TC medium was significantly more toxic to SH-SY5Y cells 
than TTR-WT-TC medium (Figure III.1B), similar to what is verified when in vitro prepared 
oligomers are added to the cells (Macedo et al., 2010). 
 
Figure III.1. TTR aggregates presence in conditioned medium. (A) Slot immunoblot filter assay of 
the different conditioned media with TTR WT-TC and TTR V30M-TC. (B) Cellular toxicity induced 
in SH-SY5Y cells by the different conditioned media, as measured by a Live/Dead viability assay. 
Error bars represent SEM. *p<0.05. 
 
Moreover, when conditioned media was analyzed by total internal reflection fluorescence 
(TIRF) microscopy (data not shown), it was possible to observe that the WT medium 
contains particles that are, on average, less intense and narrower than the ones in TTR 
V30M containing medium, indicating that V30M medium contains particles with an 
increased aggregation number or larger oligomers. Also, assays measuring the Thioflavin 
T fluorescence (data not shown), a method that specifically reports the presence of β-
sheet structures arranged in a cross-β conformation characteristic of amyloid (Cardoso et 
A B
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al., 2000), showed that V30M TTR in conditioned medium has a higher amyloidogenic 
character as compared to WT media samples. 
 
Time dependent internalization of TTR aggregates and their fate inside the cell 
Previous studies have shown uptake of wild type TTR is a fast process that reaches its 
maximum after 60min (Dekki et al., 2011; Kuchler-Bopp et al., 2000). Internalization of 
TTR aggregates by SH-SY5Y cells was monitored by live cell imaging after addition of 
conditioned medium containing 300ng of TTR-V30M-TC or TTR-WT-TC. Our studies with 
TTR-V30M-TC show a similar behavior for aggregates uptake, with a rapid initial uptake of 
the protein achieving a maximum internalization rate after approximately 40min (Figure 
III.2A, Movie III.1 in Supplemental Material) as suggested by the fact that signal intensity 
remained stable beyond this time and up to 70min, suggesting saturation of the system 
(Figure III.2B). In contrast, no signal was detectable for TTR-WT-TC, most likely because 
this system only allows us to detect large molecular aggregates, as the signal intensity 
generated from soluble protein may be too weak to detect with the imaging system used 
in these experiments (described in chapter II). These uptake events were not chance 
events, as they were observed in virtually all cells in the culture dishes. 
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Figure III.2. TTR V30M-TC uptake kinetics. (A) Selected still images from time-lapse videos. SH-
SY5Y cells were imaged in bright field, TTR-TC is green. Scale bar represents 10µm. (for time 
lapse video, see Supplemental Material, Movie III.1) (B) Quantification of the mean pixel intensity 
for TTR-V30M-TC in different frames over time. 
 
We wanted to further investigate the subcellular destination of TTR aggregates after 
uptake. Studies involving other amyloidogenic proteins such as Aβ or Tau, target these 
proteins to the lysosomal compartment where they are degraded (Chafekar et al., 2008; 
Omtri et al., 2012; Wu et al., 2013). Therefore we investigated whether this was also the 
case for aggregated TTR-V30M-TC. Using Lysotracker Red, we stained lysosomes of SH-
SY5Y cells, then we added conditioned medium with TTR-V30M-TC and we evaluated the 
route of aggregates in the cell using confocal live cell imaging. Approximately 30min after 
adding the medium to the cells we observed partial localization of TTR-V30M-TC in 
lysosomes (Figure III.3C, Movie III.2 in Supplemental Material). After approximately 
90min, co-localization was still evident (Figure III.3E), but with further incubation time the 
lysosomal signal started to fade, most likely due to photobleaching, not allowing us to 
conclude if the aggregates can escape the lysosomal degradation pathway. However, not 
all the aggregates appear to localize in the lysosomal degradation pathway, indicating that 
either the degradation ability is limited, allowing the aggregates to accumulate in the 
cytoplasm and induce cytotoxicity, or that aggregates can be trapped in other vesicles 
such as endosomes (early, sorting, recycling or late endosomes). 
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Figure III.3. Co-localization of TTR-TC and lysosomes. Selected still frames from time-lapse 
analysis (A-E). TTR-TC is green, lysosomes are red. Scale bars represent 10µm. White 
arrowheads point out co-localization of TTR-TC and lysosomes in yellow in the different frames. 
(for time lapse video, see Supplemental Material, Movie III.2) 
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Aggregates uptake mechanism 
Clathrin dependent mechanisms have been shown to operate in soluble TTR 
internalization, both in sensory neurons (Fleming et al., 2009) and in pancreatic β-cells 
(Dekki et al., 2011). To investigate whether clathrin-dependent mechanisms could be 
involved in TTR aggregates internalization, we pre-incubated SH-SY5Y cells for 30min 
with different inhibitors for various pathways before adding the conditioned medium 
containing TTR-V30M-TC aggregates and cells were fixed after 3h (the longest time 
course we observed in cell live imaging) and then analyzed by confocal microscopy.  
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Figure III.4. Analysis of TTR aggregate internalization pathways. (A-H) Direct fluorescence 
analysis of TTR-V30M-TC in SH-SY5Y cells under different conditions inhibitory of various 
pathways. TTR-TC is green, nuclei are stained with DAPI (blue). Scale bars: 10µm. Plots represent 
quantification of the mean pixel intensity of TTR-TC signal of the different conditions. Error bars 
stand for SEM. ***p<0.001. 
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When cells were incubated at 4°C (Figure III.4A) only traces of fluorescence was 
observed, meaning that TTR aggregates internalization does not occur by passive 
diffusion, thus an energy dependent endocytosis process operates, indicating the possible 
involvement of the same mechanisms that have been described for soluble TTR. 
To investigate whether TTR aggregates are internalized by a clathrin-mediated process 
we treated cells with 80µM dynasore. Dynasore is a cell-permeable small molecule that 
inhibits the GTPase activity of dynamin, essential for clathrin-dependent coated-vesicle 
formation (Kirchhausen et al., 2008). Upon incubation with conditioned medium we 
observed a significant decrease in protein uptake as measured by fluorescence intensity 
(Figure III.4B). However, because the conditioned medium system we use is not 
exclusively composed of TTR aggregates but instead it is a mixture of TTR-V30M-TC in 
its soluble and aggregated forms, we cannot conclude that aggregates are internalized via 
clathrin, because the use of dynasore may be inhibiting only the uptake of the soluble 
form. Also, the use of dynasore is specifically inhibiting dynamin activity, affecting the 
formation of clathrin-coated vesicles in an indirect manner; other endocytic pathways are 
also dependent on dynamin, namely IL2Rβ, flotilin-dependent, circular dorsal ruffles, 
phagocytosis or even caveolae-mediated (Doherty and Mcmahon, 2009; Ferguson and 
De Camilli, 2012). Therefore we investigated other uptake mechanisms. 
We next pursued to clarify the involvement of megalin, since it is responsible for TTR 
uptake in kidney (Sousa et al., 2000b) and hepatoma cells (Sousa and Saraiva, 2001). 
RAP is a chaperone especially designed to assist in the biosynthesis and intracellular 
transport of endocytic receptors (Willnow, 1998) that binds to all members of the LDL 
receptor family and therefore can be used to saturate the receptor megalin and thus 
investigate its role in the uptake of TTR-V30M-TC aggregates (Sousa and Saraiva, 2001). 
Incubation of SH-SY5Y cells with 300µg/mL of recombinant RAP had no effect on TTR-
V30M-TC uptake compared to control (Figure III.4C). So, we can conclude that in our 
system megalin does not play a significant role in the uptake of TTR-V30M-TC 
aggregates. 
RAGE is another receptor that could be involved in TTR uptake as it has been shown to 
bind soluble TTR on the cell surface (Sousa et al., 2000c). Apparently RAGE also 
mediates soluble Aβ uptake into cortical neurons (Lai and Mclaurin, 2010). Soluble RAGE 
(sRAGE) has been used as a decoy receptor to trap ligands and prevent RAGE signaling 
(Monteiro et al., 2006a). Incubation of cells with 10µg/mL recombinant sRAGE had no 
effect on TTR-V30M-TC uptake (Figure III.4D), indicating that despite the fact that 
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association of TTR with RAGE can trigger signaling pathways leading to cytotoxicity 
(Monteiro et al., 2006a; Sousa et al., 2001b), it is not due to internalization. 
Several cell surface receptors have been involved in Aβ uptake, like heparan sulfate 
proteoglycans (Sandwall et al., 2010). It has been described that proteoglycans mediate 
the cellular uptake of Aβ42 associated with RAP (Kanekiyo and Bu, 2009); also heparin 
suppresses Aβ42 binding and internalization in neuronal cell lines and mouse primary 
neurons (Kanekiyo et al., 2011). Hence, we investigated a possible role for heparan 
sulfate in the uptake of TTR aggregates. Heparin has the ability to bind several 
extracellular proteins, showing high affinity to heparan sulfate and can be used to hinder 
proteoglycan binding sites. In our system, pre-incubation of cells with 100µg/mL heparin 
had no effect on TTR-V30M-TC uptake (Figure III.4E). Therefore heparan sulfate 
proteoglycans do not appear to be involved in uptake of TTR-V30M-TC aggregates. 
Endocytosis involves several mechanisms, one of which is macropinocytosis. 
Macropinocytosis is characterized by the formation of membrane ruffles, a process that is 
dependent on both actin and tubulin (Mandrekar et al., 2009). To exclude if TTR-V30M-TC 
aggregates are internalized via macropinocytosis, we incubated cells with 500nM of 
nocodazole, an inhibitor of microtubule polymerization, which has an essential role in 
membrane ruffles closure and consequent formation of vesicle capable of entering the 
endocytic pathway (Mandrekar et al., 2009). Our data suggests that macropinocytosis is 
not the main mechanism for TTR-V30M-TC aggregates uptake, as treatment with 
nocodazole does not affect internalization when compared to control cells (Figure III.4F), 
however actin participation should also be discarded using for example cytochalasin D to 
inhibit actin polymerization. 
Another endocytic mechanism is micropinocytosis, which involves actin-independent 
formation of small vesicles that can be be caveolin-coated and usually occur within 
cholesterol-rich lipid domains (Mandrekar et al., 2009). TTR interactions with the lipids in 
the plasma membrane have already been described (Hou et al., 2005). Later, Hou and 
colleagues identified cholesterol as the main membrane lipid to interact with TTR and 
raised the hypothesis that TTR could bind preferentially to lipid rafts (Hou et al., 2008). 
Different compounds are used to extract cholesterol from the plasma membrane. Methyl-
β-cyclodextrin (MβCD) is a membrane impermeable oligosaccharide that selectively and 
rapidly extracts cholesterol from the plasma membrane (Awasthi-Kalia et al., 2001). When 
cells were pretreated with 5mM MβCD no differences were observed in TTR uptake 
(Figure III.4G). However, when we pre-incubated cells with 2.5µM filipin, a polyene 
antibiotic that binds to both cholesterol and GM1 ganglioside and forms complexes in the 
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plasma membrane sequestering cholesterol and inducing structural disorder (Arthur et al., 
2011; Awasthi-Kalia et al., 2001), a significant decrease in uptake is observed (Figure 
III.4H). Despite the fact that both compounds inhibit cholesterol action in plasma 
membrane, we observed very different results. A possible explanation may be that both 
compounds use different mechanisms to sequester cholesterol, MβCD is more associated 
with caveolin suppression (Ivanov, 2008) and SH-SY5Y cells do not express caveolin-1; 
on the other hand, filipin is described to disrupt lipid rafts (Mandrekar et al., 2009) and 
bind to GM1 ganglioside (Arthur et al., 2011), whereas MbCD appears to only bind 
gangliosides GM2 and GM3 (Davidson et al., 2009). Therefore we can conclude that 
GM1-rich lipid rafts play an important role in the uptake of TTR-V30M-TC aggregates. 
To further explore the hypothesis that TTR-V30M-TC aggregates are internalized via lipid 
rafts, we indirectly stained lipid rafts with CTxB and used confocal microscopy to search 
for co-localization with aggregates. Lipid rafts are membrane microdomaisn enriched in 
GM1 ganglioside, therefore CTxB can be used to label lipid rafts since it binds with high 
efficiency to GM1 (Harder et al., 1998). A certain degree of co-localization between TTR-
V30M-TC and CTxB was observed (Figure III.5), indicating that GM1-rich lipid rafts play a 
role in the internalization of TTR aggregates. 
 
Figure III.5. Analysis of TTR-V30M-TC interaction with lipid rafts in SH-SY5Y cells. Lipid rafts are 
seen in red by staining of GM1 ganglioside with CTxB. White arrowheads point out the co-
localization between TTR-TC and lipid rafts (yellow). Nuclei are stained with DAPI (blue). Scale bar 
represents 10µm. 
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Intracellular uptake of TTR aggregates – a role in disease and possible modulation 
We also proposed to investigate the role of TTR aggregates internalization in disease. 
Recently, our group showed that tauroursodeoxycholic acid (TUDCA) significantly reduces 
deposition of toxic TTR aggregates in a mouse model of FAP, as well apoptotic, oxidative 
and extracellular matrix markers of the disease (Cardoso et al., 2010; Macedo et al., 
2008). Because TUDCA is a hydrophilic bile acid used in some forms of cholestatic 
syndromes and capable of emulsifying lipids and degrade cholesterol (Amaral et al., 
2009), we hypothesize that TUDCA could interact with plasma membrane cholesterol and 
thus play a role in internalization of TTR aggregates by facilitating uptake and 
degradation. Incubation of SH-SY5Y cells with 100µM TUDCA had no effect on uptake of 
TTR-V30M-TC aggregates (Figure III.6A-B, Movie III.3 in Supplemental Material). Also in 
the activation of degradation pathways no major differences were observed, as analyzed 
by western blot measure of LC3-II levels (Figure III.6C), a protein activated during the 
formation of autophagolysosomes involved in degradation pathways. 
 
Figure III.6. The effect of the modulator TUDCA in TTR V30M-TC uptake kinetics. (A) Selected still 
images from time-lapse videos. SH-SY5Y cells were imaged in brightfield, TTR-V30M-TC is green. 
Scale bar represents 10µm. (for time lapse video, see Supplemental Material, Movie III.3) (B) Plot 
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represents quantification of the mean pixel intensity for TTR-V30M-TC in different frames over time 
and compared to the values of protein incubated without TUDCA. (C) Plot represents the 
quantification of LC3-II relative to α-tubulin at different time points in SH-SY5Y cells measured by 
western blot. Error bars stand for SEM. 
 
Therefore, we conclude that TUDCA has no impact on uptake of TTR aggregates and its 
effect in decreasing TTR deposition in tissues is most likely related to its anti-apoptotic 
and anti-oxidative characteristics (Amaral et al., 2009; Macedo et al., 2008), rather than 
contributing to the clearance of aggregates from the extracellular milieu by promoting their 
internalization and consequent degradation. 
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DISCUSSION 
A key aspect for the treatment of amyloidogenic disorders is to understand how amyloid or 
amyloid-like extracellular protein aggregation can trigger intracellular events that 
sometimes lead to cell death. Several authors have previously described that interaction 
of TTR aggregates with membrane lipids (Hou et al., 2005) and RAGE (Monteiro et al., 
2006a; Sousa et al., 2001b) can trigger cytotoxicity, inflammatory and apoptotic pathways. 
But how an extracellular aggregate can trigger intracellular responses in these cases is 
still unknown.  
Over the years several studies have examined TTR uptake by different cells types such 
as human hepatoma cells (Divino and Schussler, 1990), rat yolk sac cells (Sousa et al., 
2000b), ependymoma cells (Kuchler-Bopp et al., 2000), hepatocytes and fibroblasts 
(Sousa and Saraiva, 2001), sensory neurons (Fleming et al., 2009) or pancreatic β-cells 
(Dekki et al., 2011). The majority of these studies have used purified recombinant TTR-
WT labeled either with [125I] or AlexaFluor 488 for fluorescent detection. Our study aims at 
studying internalization of oligomeric TTR-V30M and not the soluble protein. 
Our work establishes a new approach to study uptake of TTR aggregates in cell culture. 
For these studies we have used conditioned medium from eukaryotic cells stably 
expressing TTR variants fused to a C-terminus TC tag (Batista et al., 2013). In this system 
TTR is produced and secreted by eukaryotic cells, with protein aggregation occurring 
naturally in conditioned media without mechanical factors that could influence 
aggregation; more importantly, the small TC tag used to label TTR is unlikely to interfere 
with the protein proper folding and aggregation; importantly TTR-V30M-TC produced in 
this manner induced cytotoxicity compared to TTR-WT-TC (Figure III.1B). 
Monteiro and colleagues described that upon stimulation with TTR aggregates, it takes 
about 15min to activate the ERK1/2 MAPK cascade (Monteiro et al., 2006b), suggesting 
that a short period of exposure to TTR aggregates is sufficient to trigger cellular 
responses. Soluble TTR uptake is also described to be a rapid event, taking place in 
15min (Dekki et al., 2011). Here we observed that internalization of TTR aggregates is 
also a rapid event, occurring in an energy-dependent manner in a time frame of 15min 
and saturating after 40min (Figure III.2). This suggests that the previously described 
signaling pathways may be activated not only by interaction of TTR aggregates with 
membrane receptors (Monteiro et al., 2006b; Sousa et al., 2001b) but also by 
internalization of aggregates. 
CHAPTER III⏐Dynamics of transthyretin oligomer internalization 
105 
Internalized proteins may follow different routes inside the cell: delivery to lysosomes for 
degradation (via late endosomes), recycling to cell membrane (via early endosomes) or 
secretory pathway entry after retrieval from late endosomes and transport to the Golgi 
apparatus and/or the ER. In our system we observed that TTR aggregates were being 
delivered to lysosomes most likely to be degraded, in a similar way to what has been 
observed with other amyloidogenic proteins, such as Aβ1-42 (Omtri et al., 2012) or tau (Wu 
et al., 2013). Nonetheless further experiments should be performed to verify if TTR 
aggregates could undergo retrograde transport and if, in a similar way to Shiga toxins, 
could be transferred from early and recycling endosomes to the trans-Golgi network 
(TGN) and from there to the endoplasmic reticulum (ER) and subjected to ER-associated 
degradation (ERAD) (Johannes and Popoff, 2008; Johannes and Romer, 2010). 
Moreover, in continuous uptake experiments, it has been reported that the amount of 
internalized Aβ1-42 may exceed lysosomal degradation capacity leading to accumulation 
inside the cell (Fuentealba et al., 2010), therefore this aspect should also be addressed in 
TTR aggregates internalization. Also, long-term experiments should be conducted to 
assess if TTR aggregates could be internalized and escape degradation, similar to serum 
amyloid A (SAA) when processed by macrophages, that forms intracellular amyloid upon 
internalization and is then secreted (Kluve-Beckerman et al., 2002); however, intracellular 
TTR amyloid deposits have not been observed in cell culture (Santos et al., 2007), hence 
this should be a very remote hypothesis. 
To clarify these yet unclear questions, experiments involving co-staining with antibodies to 
protein specific for difference sub-cellular compartments (such as markers for ER, Golgi, 
early or late endosomes) should be performed in the future. 
There are several possible internalization pathways. Soluble TTR appears to be 
internalized through receptor-mediated endocytosis in a clathrin-dependent manner 
(Fleming et al., 2009). However, there may be differences in internalization pathways of 
soluble protein and aggregates, mainly due to the size of particles – smaller particles 
enter the cells via clathrin while bigger particles use clathrin-independent pathways, often 
associated with caveolin or cholesterol (Rejman et al., 2004). We have shown here that 
internalization of TTR-V30M-TC is sensitive both to dynamin inhibition as well as to 
cholesterol sequestration. TTR-V30M-TC uptake was decreased by the use of dynasore 
that inhibits dynamin, essential for the formation of clathrin-coated vesicles (Kirchhausen 
et al., 2008; Macia et al., 2006); however several endocytic pathways are dependent on 
dynamin and thus direct involvement of clathrin needs further investigation, by direct 
interference with clathrin itself or AP2 (adaptor protein 2) (Doherty and Mcmahon, 2009), 
using for instance siRNA. TTR-V30M-TC uptake was also decreased upon sequestration 
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of membrane cholesterol and GM1 using the antibiotic filipin; however the opposite result 
was observed when we depleted cholesterol with the oligosaccharide MβCD, which can 
be explained because MβCD and filipin use different mechanisms to sequester 
cholesterol, and thus may exert different effects depending on the type of cells being 
investigated (Ivanov, 2008). Altogether our data suggests that TTR-V30M-TC is 
internalized both by clathrin-dependent and cholesterol/GM1-dependent mechanisms. 
The involvement of different internalization pathways may be explained by the complex 
mixture of the conditioned medium used in our system, because it should be composed 
not only by pure aggregates but rather by a combination of soluble and aggregated TTR-
V30M-TC.  
Therefore we strongly believe that involvement of cholesterol allows TTR aggregates to 
enter the cell via membrane microdomains called planar lipid rafts (also known as non-
caveolar rafts) (Allen et al., 2007). This supposition is consistent with our results 
concerning experiments with filipin and CTxB. 
Surprisingly, we did not observe any correlation between uptake of TTR-V30M-TC 
aggregates and either RAGE or RAP, the membrane receptors more commonly 
associated with TTR. 
Uptake of TTR aggregates from circulation can contribute to their clearance and may also 
prevent deposition. Considering the hypothesis that TTR-V30M-TC aggregates are 
internalized via lipid rafts in a cholesterol-dependent mechanism, we tested the bile acid 
TUDCA used to emulsify lipids and degrade cholesterol (Amaral et al., 2009); TUDCA has 
been related with reduction of TTR deposition in mouse models of FAP (Cardoso et al., 
2010; Macedo et al., 2008) and it is now in clinical trials for patients with TTR amyloidosis 
(Obici et al., 2012). However TUDCA showed no effect on TTR-V30M-TC aggregate 
uptake or degradation in our system (Figure III.6), suggesting that its ability to decrease 
TTR deposition may be related mostly to its anti-apoptotic effect. 
The model now developed contributed to better understanding the mechanisms by which 
TTR aggregates are internalized, their intracellular traffic and how degradation occurs. 
Thanks to this we should be able to further investigate the receptors involved in the 
process of triggering cytotoxicity and perhaps modulate this process, leading to a more 
effective cellular disposal of extracellular aggregates, promoting their clearance from the 
extracellular milieu and preventing their deposition, particularly in neuronal tissues. We 
now strongly believe that, if interaction of TTR aggregates with RAGE triggers 
inflammation (Sousa et al., 2001b), it is the aggregates interaction with lipid rafts that is 
contributing to ER stress and apoptosis. Interaction of TTR aggregates with lipid rafts 
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causes disruption of membrane fluidity and triggers calcium release (Hou et al., 2005), 
which can lead to apoptosis; also, the death receptor Fas, which can localize in lipid rafts 
(for review see Gajate and Mollinedo, 2011; George and Wu, 2012) has been implicated 
in FAP (Macedo et al., 2007). 
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ABSTRACT 
Familial amyloidotic polyneuropathy is a neurodegenerative disorder characterized by the 
extracellular deposition of amyloid fibrils composed by mutated transthyretin (TTR) mainly 
in the peripheral nervous system (PNS). At present, liver transplantation is the only 
available treatment to halt the progression of clinical symptoms in FAP. Here we propose 
to establish a new gene therapy approach using AAV vectors to efficiently deliver the 
trans-suppressor TTR T119M variant to the liver of transgenic V30M mice. Analysis of the 
GI tract of injected animals revealed a significant reduction in the deposition of TTR non-
fibrillar aggregates in as much as 34% in stomach and 30% in colon, as well as to 
decreased levels of biomarkers associated with TTR deposition, namely the ER stress 
marker BiP and the ECM protein MMP-9. However, these results were only observed in 
animals injected at younger ages, with no therapeutic effect observed when TTR 
deposition is already installed. Altogether our data suggest the possibility to use this gene 
therapy approach in a prophylactic manner to prevent FAP pathology.  
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INTRODUCTION 
Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant hereditary disease 
characterized by the extracellular deposition of amyloid fibrils predominantly in the 
peripheral nervous system (PNS) (Andrade, 1952). Amyloid fibrils are commonly 
composed of mutant TTR V30M (Saraiva et al., 1984), a protein mainly synthesized in the 
liver and the choroid plexus epithelium in the brain, and responsible for the transport of 
thyroxine (T4) in plasma and cerebrospinal fluid (CSF), respectively (Raz and Goodman, 
1969). TTR circulates as a tetrameric protein; the presence of mutations results in 
reduced thermodynamic stability (Sekijima et al., 2005), therefore tetrameric TTR can 
dissociate into a compact non-native monomer with low conformational stability that can 
lead to amyloid fibril formation (Quintas et al., 2001). 
The only effective treatment for FAP is orthotopic liver transplantation. If performed in 
early stage of disease, liver transplantation has been reported to halt the progression of 
clinical manifestations. However this therapy encompasses several problems: (i) it is 
extremely expensive; (ii) patients with liver transplantation must continue lifelong 
administration of immunosuppressants; (iii) both carriers of TTR mutations who do not 
show clinical symptoms and patients in advanced stage of FAP cannot undergo liver 
transplantation; (iv) limited organ availability (Ando, 2005). Therefore new strategies for 
therapy are needed. 
The proposed strategies for FAP are based on the same therapeutic principles 
investigated for other amyloidosis, such as inhibiting aggregation and/or disrupting TTR 
amyloid by selective molecules (Ando and Ueda, 2012). Genetic and biochemical studies 
gave insights on prospective therapies encompassing inhibition of TTR aggregation by 
stabilization of the mutant TTR (Alves et al., 1997a); self-assembly properties of TTR 
T119M, a non-amyloidogenic variant commonly found in Portugal, have been intensely 
investigated because of milder disease in compound V30M/T119M heterozygote 
individuals (Coelho et al., 1996). Comparative studies of TTR variants V30M and T119M 
by semi-denaturing isoelectric focusing (IEF) revealed that the presence of the non-
amyloidogenic variant increases the resistance to dissociation, thus stabilizing TTR and 
exerting its anti-amyloidogenic effects by counteracting the weaker subunit interactions of 
V30M tetramers (Alves et al., 1997b; Sebastiao et al., 2001). More recently, 
Hammarström and colleagues showed that incorporation of one subunit of TTR T119M 
into a predominantly V30M tetramer strongly stabilized the mixed tetramer against 
dissociation (Hammarström et al., 2001; Hammarström et al., 2003b). These studies 
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suggest that a gene therapy approach for the synthesis of TTR T119M in the liver is likely 
to inhibit TTR fibril formation. 
In recent years, adeno-associated virus (AAV) vectors have emerged as the most 
promising vectors for in vivo gene delivery. The lack of pathogenicity, the persistent gene 
expression, and its ability to efficiently transduce dividing and non-dividing cells have 
increased the potential of AAV vectors as a delivery vehicle for in vivo gene therapy 
applications (Daya and Berns, 2008). In an effort to increase the efficiency of AAV-
mediated in vivo gene delivery, new capsids have been generated; AAV8 vectors have 
proven to be exceptionally efficient in liver transduction after intravenous delivery (Nakai 
et al., 2005) and induce immune tolerance to the expressed transgene (Mingozzi et al., 
2003). 
Here we assessed the effectiveness of liver-directed AAV-mediated gene delivery of TTR 
T119M to reverse and/or preventing pathology in a TTR V30M transgenic mouse model. 
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MATERIALS AND METHODS 
AAV vector design and preparation 
The AAV vector used in this study was modified from pAAV-CBA-mβgal-W (Broekman et 
al., 2007) by removing the mβgal cDNA and replacing the CBA promoter with a liver 
specific enhancer-promoter combination composed of the human apolipoprotein hepatic 
control region (HCR) and human alpha-1-antitrypsin gene promoter followed by the hAAT 
5’ untranslated region and a modified SV40 intron as previously described (Nathwani et 
al., 2006). This enhancer-promoter was synthesized by PCR amplification and matches 
the sequence published by Nathwani and colleagues (Nathwani et al., 2006). The vector 
was further modified into a self-complementary design by deletion of the terminal 
resolution site (as described in Mccarty et al., 2003) in the AAV2 inverted terminal repeat  
(ITR) near the AHA promoter to generate plasmid scAAV-AHA-W. T119M TTR cDNA was 
cloned into this plasmid by PCR amplification followed by sequencing. Vector stocks 
made with AAV8 capsid were produced by transient transfection of 293T cells and 
purification by iodixanol gradient centrifugation followed by anion-exchange 
chromatography using HiTrapQ columns (GE Healthcare), as described (Broekman et al., 
2006), or cesium chloride gradient centrifugation. Transgene-empty vector was also 
produced as described. 
Titers of vector stocks were determined by real-time quantitative PCR using primers and 
probe specific for the bovine growth hormone (BGH) polyadenylation signal (pA) present 
in these vectors, and represented as viral genomes (vg)/mL.  
 
Animal procedures 
Mice were handled according to National rules and to the European Community Council 
Directive (86/609/EC) for the care and handling of laboratory animals. All animals were 
maintained at 22 ± 2°C, humidity 45%–65%, under a 12 h light/dark cycle and fed regular 
chow and tap water ad libitum. 
Six weeks old female 129/SvJ animals obtained from The Jackson Laboratory (Bar 
Harbor, Maine, USA) were injected in the tail vein with 1x109vg, 1x1010vg, 1x1011vg or 
3x1011vg (n=4 animals per group) of scAAV8-TTR T119M. One month after injection, 
submandibular bleeding was performed (Golde et al., 2005) for analysis of human TTR 
concentration in serum. 
TTR KO mice (Episkopou et al., 1993) and TTR KO animals crossed to heterozygous 
Hsf1 null mice (Santos et al., 2010a), both in the 129/Sv background, were injected in the 
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tail vein with 3x1011vg of scAAV8-TTR T119M at the age of 3 months (n=5 per group). 
One month after injection animals were euthanized after anesthesia with a mixture of 
ketamine/medetomidine and blood was collected, as well as liver that was snap-frozen in 
dry ice and store at -70°C. Transgenic animals carrying human TTR V30M in a TTR null 
background (hereafter referred to as hTTR V30M animals; Kohno et al., 1997) of the 
same age were used as controls in this experiment. 
In another experiment, 12-months-old hTTR V30M animals were injected in the tail vein 
with 3x1011vg of scAAV8-TTR T119M (n=10) or with the same amount of empty vector 
(n=7). A second experiment was conducted using the same transgenic model at the age 
of 3 months (n=9 for scAAV8-TTR T119M and n=10 for empty vector). Three months after 
injections the animals were euthanized after deeply anesthetized with a mixture of 
ketamine/medetomidine; all tissues, including stomach, colon, liver and dorsal root ganglia 
(DRG), were immediately excised and transected; a portion was frozen at -70°C while the 
other was fixed in 4% neutral buffered formalin and embedded for paraffin processing. 
Blood was also collected from the inferior vena cava and serum was separated by 
centrifugation. 
 
Serum TTR quantification 
Serum TTR was quantified by quantitative ELISA as previously described (Cardoso et al., 
2007). Briefly, 96-well plates (Maxisorp, Nunc) were coated overnight at 4°C with a 
polyclonal rabbit anti-human TTR antibody in carbonate/bicarbonate coating buffer, and 
blocked with 5% (w/v) skim milk in PBS; diluted serum was applied to the wells for 1h at 
room temperature; a second anti-human TTR antibody peroxidase-conjugated was then 
used. Development was performed with 5mM 2,2′-azinobis (3-ethybenzthiazoline-6-
sulfonic acid) (ABTS, Sigma) and measured at 405nm. TTR concentration was calculated 
from a standard curve ranging from 5 to 340ng/mL. 
 
Viral genome copies quantification 
Briefly, genomic DNA was extracted from the different organs using the automated 
Maxwell 16 System (Promega). The Maxwell 16 System uses paramagnetic-particle 
technology for fast automation of DNA extraction resulting in reproducible yields and 
purity. The number of viral genome copies was quantified by qPCR of the BGH polyA 
sequence. 
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Primer sequences: 
Forward: 5’ – TgCgATgCAATTTCCTCAT – 3’ 
Reverse: 5’ – CCTCgACTgTgCCTTCTAg – 3’ 
Probe: 6FAM – TgCCAgCCATCTgTTgTTTgCC – BBQ 
 
TTR mass spectrometry 
TTR variants identification by MALDI (matrix-assisted laser-desorption ionization) mass 
spectrometry analysis was performed after immunoprecipitation with anti-human TTR 
antibody. Briefly, 25µL of serum were incubated with a rabbit anti-human TTR antibody 
(1:20 dilution; Dako) and kept overnight at 4°C with stirring. Next, protein A Sepharose 
beads were added and allowed to mix for 1h at room temperature with agitation. The 
beads were washed and the complex eluted with SDS-loading buffer. Finally, samples 
were fractioned on a 15% acrylamide SDS-PAGE gel under denaturing conditions and the 
gel was stained following Coomassie blue colloidal protocol. The TTR band was excised 
from the gel and in-gel digestions were performed by adding modified porcine trypsin 
(Promega). Peptide mass spectra were acquired by Applied Biosystems 4800 Plus MALDI 
TOF-TOF Analyzer apparatus. The resulting peak lists were identified using 
UniprotKB/Swiss-Prot database. 
 
Quantitative real-time PCR (qPCR) 
For gene expression quantification, total RNA from mice liver was isolated using PureLink 
RNA Mini Kit (Ambion) following the manufacturer’s instructions. cDNA synthesis was 
performed using random hexamers with Superscript II following manufacturer’s 
instructions (Invitrogen). cDNA was then quantified in an iQ5 Bio-Rad real time PCR 
machine with iQ™ Sybr® Green Supermix (Biorad). Ribosomal gene 18S was used for 
normalization. The ΔΔCT method was used for quantification calculations (Bustin et al., 
2009). 
Primer sequences:  
hTTR Fwd: ATGGCTTCTCATCGTCTGCT 
hTTR Rev: GACCATCAGAGGACACTTGGA 
mouse 18S Fwd: AAATCAGTTATGGTTCCTTTGGTC 
mouse 18S Rev: GCTCTAGAATTACCACAGTTATCCAA 
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High Resolution Melting Analysis (HRM) 
The quantity of each one of TTR variants present in mice liver was measured by HRM 
using the synthesized cDNA. To generate standard curves, linearity tests were performed 
by HRM using two primer sets for TTR V30M and TTR T119M respectively. Serial 
dilutions of plasmids encoding either V30M or T119M TTR cDNA were used as standards 
to create reconstituted samples with a constant V30M DNA quantity (100ng) but 
containing 100%, 90%, 80%, 70%, 60%, 40%, 30%, 20%, 10% and 0% of T119M plasmid 
DNA. Each dilution was then amplified with the two primer sets and submitted to HRM. 
HRM was carried out on a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad). 
PCR was performed in 15µL volume containing 1x SsoFast™ EvaGreen® Supermix, 
200nM of each primer and 2µL of cDNA template. The amplification protocol was 3min at 
95°C, then 40 cycles of 10sec at 95°C and 10sec at 60°C. HRM was performed at 95°C 
for 1min, 55°C for 3min and with a ramping from 65°C to 95°C rising by 0.2°C for 10sec. 
Melting curves were normalized using the Precision Melt Analysis™ software before and 
after the major fluorescence decrease. A differential profile was then evaluated for each 
sample by comparing fluorescence at the melting point against the value of fluorescence 
of the negative control (TTR V30M DNA). All experiments were performed in triplicate. 
Since reproducibility is an important issue in any quantitative determination, we tested the 
intra- and inter-assay variability of HRM using two primers sets (V30M and T119M) in 10 
liver samples carrying variable T119M transductions. To evaluate intra-assay 
reproducibility, 5 replicates of the same V30M/T119M cDNAs were measured in a single 
HRM experiment. In addition, using the same samples and primers, we repeated the 
measurement in 5 consecutive experiments to determine inter-assay variability. 
All PCR products were sequenced to confirm the presence of the point mutation. 
Primer sequences:  
V30M Fwd: GGTGAATCCAAGTGTCCTC 
V30M Rev: AGGTGTCATCAGCAGCCTTT 
T119M Fwd: GCATGCAGAGGTGGTATTCA 
T119M Rev: GTCCCTCATTCCTTGGGATT 
 
Thyroxine binding assays 
Qualitative studies of binding of T4 to serum TTR were carried out by incubation of 5µL of 
mice serum with [125I]-T4 (specific activity: 1250µCi/µg; concentration 320µCi/mL; Perkin 
Elmer) followed by separation of the T4 binding proteins in serum by PAGE in a 
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glycine/acetate buffer system, as previously described (Almeida et al., 2004). The gel was 
dried under vacuum and T4 binding proteins were visualized by phosphor imaging 
(Thyphoon 8600, Amersham Biosciences). 
 
TTR tetrameric stability assays by Isoelectric Focusing (IEF) under semi-denaturing 
conditions 
To perform this assay, 25µL of serum was separated in native PAGE and the gel band 
corresponding to TTR was excised and applied to an IEF gel. IEF was carried out in a 
polyacrylamide gel containing 5% ampholytes (pH range 4–6.5) and in the presence of 
4M urea, at 1200V for 6h, essentially as described (Altland et al., 1981; Alves et al., 
1997a). These semi-denaturing conditions allow the visualization of bands corresponding 
to TTR monomers, an oxidized form of monomer and tetramers. Proteins were fixed in 
20% (v/v) trichloroacetic acid and stained with Coomassie blue; the dried gel was scanned 
with Molecular Imager GS800 calibrated densitometer (Bio-Rad); semi-quantification of 
images was performed using the ImageJ software (NIH) and is presented as the ratio 
between tetramers and monomers compared to control. TTR KO animals injected with 
scAAV8-TTR T119M were used as controls. 
 
Congo red staining 
The presence of amyloid in tissue sections was investigated after staining with Congo red 
(CR) and observation under polarized light (Puchtler and Sweat, 1965). Briefly, 5µm-thick 
sections were deparaffinated in Histoclear (National Diagnostics), hydrated in a 
descendent alcohol series and then incubated in 80% ethanol saturated with NaCl for 
20min. Sections were then incubated in a solution of 0.5% Congo red (Sigma-Aldrich) in 
80% ethanol saturated with NaCl, counterstained with hematoxylin, dehydrated in an 
ascendant alcohol series and coverslipped under Entellan (Merck). Sections were 
analyzed under polarized light with an Olympus BX50 light microscope equipped with 
Olympus DP71 digital camera. Amyloid was identified by the characteristic yellow-green 
birefringence. 
 
Immunohistochemistry (IHC) 
Three-µm-thick sections were deparaffinated in Histoclear (National Diagnostics) and 
hydrated in a descendent alcohol series. Endogenous peroxidase activity was quenched 
with 3% hydrogen peroxide in PBS for 30min. Tissue slides were incubated with blocking 
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buffer containing 4% FBS and 1% BSA in PBS for 1h at room temperature and then 
incubated overnight at 4°C with primary antibodies diluted in blocking buffer. Primary 
antibodies used were: rabbit polyclonal antibody against human TTR (1:300, Dako), goat 
polyclonal anti-BiP (Grp78, 1:50, Santa Cruz) and rabbit polyclonal anti-MMP-9 (1:1,000, 
Abcam). Antigen visualization was performed using Vectastain® Elite ABC Reagent 
(Vector Labs), according to the manufacturer’s instructions, and diaminobenzidine 
(Sigma-Aldrich) used as substrate for color development. Sections were counterstained 
with hematoxylin, dehydrated in an ascendant alcohol series and coverslipped under 
Entellan (Merck). On parallel control sections, incubation with primary antibody was 
replaced by blocking buffer; staining was absent under these conditions. 
Sections were examined with an Olympus BX50 light microscope equipped with an 
Olympus DP71 digital camera for image acquisition. Semi-quantitative 
immunohistochemistry analysis was performed using Image-Pro Plus software (Media 
Cybernetics), by measuring the ratio between the area occupied by pixels corresponding 
to the immunohistochemical substrate’s color and the total area. Each slide was analyzed 
in 5 different representative areas. The observer was blind to samples identification. 
 
Western blot 
Stomach and colon samples were homogenized in lysis buffer containing 20mM MOPS, 
2mM EGTA, 5mM EDTA, 30mM NaF, 40mM β-glycerophosphate, 20mM sodium 
pyrophosphate, 1mM sodium orthovanadate, 1mM phenylmethylsulfonyl, 0.5% NP-40 (all 
from Sigma-Aldrich) and 1x protease inhibitors mixture (GE Healthcare Bioscience). Total 
protein concentration in cell lysates was determined by the Bio-Rad assay kit (Bio-Rad) 
using serial dilutions of bovine serum albumin as protein standard; 50µg of total protein 
were separated in a 12% polyacrylamide SDS-PAGE gel and then transferred onto a 
0.2µm pore nitrocellulose membrane (Whatman) using a wet transfer system. Primary 
antibodies were rabbit polyclonal anti-BiP (Grp78, 1:1,000, Abcam) and mouse 
monoclonal anti-α-tubulin (Sigma-Aldrich, 1:10,000) for normalization. The enhanced 
chemiluminescense method (ECL, GE Healthcare Bioscience) was used to develop the 
blots. Quantitative analysis of western blot images was performed using the ImageJ 
software (NIH). 
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Two-dimensional differential gel electrophoresis (2D-DIGE) 
Proteins were extracted from DRG in lysis buffer containing MOPS, EGTA, EDTA, Triton 
x-100 by Potter homogenization. After centrifugation, the supernatant was precipitated 
with 2D Clean-up kit (GE Healthcare), according to the manufacturer’s protocol. Dried 
pellets were dissolved in IEF DIGE lysis buffer for 2D gel electrophoresis. A last 
centrifugation was performed to remove any insoluble material. Protein concentration was 
determined with 2D Quant Kit (GE Healthcare) following manufacturer’s instructions. An 
internal standard was made by mixing each of the samples used in the study. The 
samples and the internal standard were labeled with CyDye DIGE Fluor minimal dyes in 
accordance with the regular protocol. 
Each set of two samples was labeled with different Cy dyes and loaded on a previously 
rehydrated IPG strip (Immobiline Dry Strips, 24cm, pH 4–7, GE Healthcare). IEF was 
carried out on an IPGphor III system (GE Healthcare). After IEF the proteins were reduced 
and alkylated by soaking the strip in a reducing solution with alkylating agent. Separation 
of the second dimension was performed on 1.0mm thick gels under low fluorescence 
glass plates (GE Healthcare). IPG strips were loaded on SDS-PAGE 12.5% acrylamide 
gels. For the second dimension an Ettan DALTsix electrophoresis unit (GE Healthcare) 
was used. 
The DIGE images were created with a laser-based scanner FLA-5100 (FujiFilm) under 
Image Reader FLA 5000 version 1.0 (FujiFilm). The gel images were then analyzed using 
Progenesis SameSpots analysis software version 3.3.1 (NonLinear Dynamics). Each spot 
with an ANOVA p-value > 0.05 or with an absolute abundance variation of less than 1.3 
fold was excluded from further consideration. Similarly, PCA analysis was also carried out 
and any spots with a power value below 0.7 were also excluded.  
Excised gel spots and bands were washed to remove stain traces. In-gel digestions were 
performed by adding modified porcine trypsin (Promega). The obtained supernatant was 
recovered, peptides were desalted and concentrated using homemade micro-columns 
(GELoader tip, Eppendorf) with POROS 20R2 resin (Applied Biosystems). The tryptic 
peptides were eluted with matrix solution (α-cyano-4-hydrocynnamic acid) directly onto 
MALDI target. Peptide mass spectra were acquired by Applied Biosystems 4800 Plus 
MALDI TOF-TOF Analyzer apparatus. Data were acquired in positive MS reflector. 
Processing and interpretation of the MS spectra was performed with 4000 Series 
Explorer™ Software (Applied Biosystems). The resulting peak lists were used to search 
for matches in an in-house compiled database of UniprotKB/Swiss-Prot database release 
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2013_03 (539616 sequence entries) using Mascot search program. Significance (p<0.05) 
of results was calculated by the MASCOT program for each database.  
 
Microarrays and data processing 
Total RNA from DRG and colon was isolated using PureLink RNA Mini Kit (Ambion) 
according to manufacturer’s instructions. RNA quantity and quality were assessed using 
the Nanodrop ND-1000 (Thermo Scientific) and Experion RNA StdSens Analysis Kit (Bio-
Rad) systems, and only samples with RNA quality indicator (RQI) above 7.5 were 
considered for further study. Preparation and labeling of RNA was performed using the 
One-Color Microarray-Based Gene Expression Analysis Low Input Quick Amp Labeling kit 
(Agilent Technologies). Briefly, 300ng of total RNA from DRG injected with scAAV8-TTR 
T119M or empty vector were used as input together with spike-in controls to generate 
Cy3-labeled cRNA. Amplified cRNA samples were purified with RNeasy Mini kit (Qiagen) 
and hybridized to Mouse Whole Gene expression 4 × 44K v2 Microarray slides (Agilent 
Technologies) at 65°C for 17h. After washing procedures, hybridizations’ images were 
acquired using a G2505B Microarray Scanner (Agilent Technologies). 
The Feature Extraction software was used for spot identification, background subtraction 
and quantification of the fluorescent signal. Raw expression data were processed using 
BRB-ArrayTools v3.8.1 software (Simon et al., 2007); arrays were median normalized to 
adjust the scale of intensities across samples and arrays. Differentially expressed 
transcripts between the two conditions were filtered using the Class Comparison tool, by 
performing a t-test assuming equal variances with a p<0.05, using TM4 Microarray 
Software Suite (MeV) version 4.3 (Saeed et al., 2003). Genes with fold changes over 1.5 
and below 0.5 were considered to be up- or down-regulated. The NCBI web-based 
functional annotation tool DAVID (Database for Annotation, Visualization, and Integrated 
Discovery) (Huang da et al., 2009a, b) was used to investigate functional associations of 
genes. 
 
Statistical analysis 
Experimental results shown are presented as mean ± SEM. Statistical significance was 
evaluated by Student’s t-test, unless otherwise stated. Differences were considered 
significant for p<0.05 or as designated. Statistical analysis was performed using 
GraphPad Prism 5.0 for Mac OS X. 
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RESULTS 
Generation of a new somatic transgenic mouse model expressing TTR T119M 
In the present study, we aimed to establish a new approach for the treatment of FAP 
using liver-directed AAV gene transfer of TTR T119M in transgenic mice carrying TTR 
V30M, hypothesizing that it would affect TTR deposition, particularly in the GI tract. We 
used systemic delivery of an AAV8 vector encoding T119M TTR under the control of a 
strong liver-specific promoter (Figure IV.1A). 
Six-week-old female mice from the same genetic background of the animals to be used 
later in our experimental gene therapy trial were injected in the tail vein with 4 different 
doses of scAAV8-TTR T119M viral genomes, varying from 1x109 to 3x1011vg. The 
animals were euthanized 1 month later and TTR serum levels measured by ELISA. A 
dose-dependent increase of hTTR serum concentration was observed (Figure IV.1B). 
Since no adverse events were observed in any of the groups, we decided to use 
3x1011vg/animal in subsequent studies. 
We have been working with two animal models for FAP. One is a mouse model 
expressing human TTR V30M in a TTR null background that presents TTR deposition in 
the gastrointestinal tract (Kohno et al., 1997). More recently our lab developed a new 
mouse model where human TTR V30M is expressed in a heat shock transcription factor 1 
(Hsf1) null background, resulting for the first time in TTR deposition in the peripheral 
nervous system (Santos et al., 2010a). Prior to initiating larger studies we conducted a 
pilot study to determine the efficiency of TTR expression after systemic delivery of AAV8-
TTR T119M vector (3x1011vg/mouse) in the two mouse strains: TTR null mice (Episkopou 
et al., 1993); and TTR KO in the Hsf1 null background (HSF(+/-) / TTR KO) (Santos et al., 
2010a). At 1 month post-infusion the TTR serum concentration in Hsf1 null animals was 
considerably lower than before, whereas TTR null mice TTR levels were similar to those 
observed in hTTR V30M transgenic animals (Figure IV.1C). The vector genome content in 
the liver was significantly lower in HSF(+/-) / TTR KO mice compared to TTR null mice 
(Figure IV.1D). Therefore subsequent studies were carried out in the mouse model that 
expresses hTTR V30M in a TTR null background (Kohno et al., 1997). 
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Figure IV.1. In vivo TTR-T119M expression in mice. (A) Schematic representation of the scAAV-
TTR-T119M vector genome. Abbreviations: ITR, AAV2 inverted terminal repeat; AHA, liver specific 
promoter; WPRE, woodchuck hepatitis post-transcriptional regulatory element; pA, polyadenylation 
signal. (B) TTR levels in serum as measured by ELISA in a dose escalation test in animals injected 
with increasing doses of scAAV8-TTR T119M vector genomes. (C) TTR levels in serum as 
measured by ELISA in animals of different genetic backgrounds injected with 3x1011vg/mL of 
scAAV8-TTR T119M. Transgenic hTTR V30M animals available in the lab served as control. (D) 
AAV vector genome copy number in liver. Plot represents the ratio of AAV vector genome copies 
per diploid mouse liver genome measured in animals of different genetic backgrounds. 
 
 
TTR T119M expression in transgenic animals carrying the V30M TTR mutation 
The possibility of a therapeutic effect resulting from the administration of AAV vectors 
encoding TTR T119M was investigated by injecting 3- and 12-months old animals 
expressing the TTR variant V30M in a TTR null background. Upon tail vein injection of 
3x1011vg of scAAV8-TTR T119M, as well as of scAAV8-empty vector as a control, 
animals were euthanized 3 months later and TTR T119M expression was characterized. 
First we evaluated the expression of TTR T119M in transgenic mice. When we quantified 
TTR plasma levels by ELISA, a significant increase was observed in TTR serum levels in 
pAWPRETTR  -­  T119MAHA
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T119M-injected animals of both ages, when compared to empty vector injected animals 
(Figure IV.2A and Table IV.1) as expected, since animals were infused with a vector that 
provides the cells with additional copies of a TTR expression cassette. 
Table IV.1. TTR plasma levels in animals injected with empty vector and with scAAV8-TTR T119M 
at different ages. Results shown as shown as mean ± SEM in mg/dL. 
TTR plasma concentration (mg/dL) 
 Empty vector TTR T119M 
Old animals 41 ± 4.2 89 ± 6.9 
Young animals 39 ± 2.1 55 ± 2.1 
 
Interestingly, this increase is more substantial in older animals, despite the fact that no 
significant differences were found in gene expression across ages; we can hypothesize 
that this fact is related to a diminished ability in protein clearance in older animals, as 
generally TTR concentration in serum decreases with age (Ingenbleek and De Visscher, 
1979). 
In scAAV8-TTR T119M-injected animals, TTR mRNA in liver increased by 58% compared 
to that in mice injected with transgene-empty vector (Figure IV.2B). To confirm if this 
increase in total TTR mRNA was due to AAV-mediated TTR T119M expression, qPCR-
HRM was used to quantify the relative levels of TTR V30M and T119M transcripts; HRM 
is a simple solution for genotyping and mutation scanning based on the analysis of the 
melting profile of a PCR product, since sequence differences result in the formation of 
heteroduplexes changing the shape of the melting curve (Reed et al., 2007; Reed and 
Wittwer, 2004). We used primers specific for each one of the mutations and calculated the 
height of the melting curves generated, using serial dilutions of plasmids encoding TTR 
V30M or TTR T119M as standards curves, based on the method described for the 
quantification of DNA methylation (Malentacchi et al., 2009). Later, we sequenced the 
PCR fragments produced by this approach and confirmed the presence of each mutation 
amplified by the 2 different pairs of primers. This analysis showed TTR T119M mRNA to 
be ~ 50% of transgenic TTR V30M mRNA (Figure IV.2C). 
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Figure IV.2. TTR T119M expression in mice. (A) hTTR concentration in sera of injected mice 
measured by ELISA. Error bars represent SEM. ** p<0.01; *** p<0.001. (B) TTR gene expression 
as measured by RT-qPCR in mice liver. Error bars represent SEM. (C) Gene expression of the two 
TTR variants, measured by qPCR-HRM in liver of injected animals. Error bars represent SEM. *** 
p<0.001. 
 
We further evaluated the identity of TTR variants in the serum of injected animals by 
immunoprecipitation of the protein followed by MS analysis. The results are displayed in 
Figure IV.3, which highlights the peaks corresponding to TTR peptides (Figure IV.3B), 
according to the expected peptide masses predicted in the UniProtKB/Swiss-Prot 
database, for the amino acid replacement in mutations. In all samples, peptides with a 
mass of 1398, corresponding to TTR V30M, were found in all samples (left panels), 
whereas peptides with masses corresponding to the mutated form T119M of TTR (2390; 
right panels) were only found in the serum of animals injected with scAAV8-TTR T119M. 
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Figure IV.3. Identification of TTR variants present in serum of injected animals. (A) 
Immunoprecipitation analysis of serum from mice injected with empty vector and scAAV8-TTR 
T119M. The band corresponding to TTR is identified by an arrow and was excised from the gel and 
analyzed by MS. (B) MS analysis of immunoprecipitated TTR reveals specific peptides for TTR 
V30M (left panels) and TTR T119M (right panels). 
 
AAV8 vectors display a wide tissue tropism after systemic infusion (Nakai et al., 2005; 
Wang et al., 2005b). Therefore we next assessed the presence of AAV vector genomes in 
organs targeted for TTR deposition to exclude the possibility that tissue TTR aggregates 
were related to local TTR synthesis rather than the physiological mechanism of its 
secretion by the liver. AAV vector genome copies were quantified in stomach and in DRG 
by qPCR, and were only detectable in liver (Figure IV.4). 
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Figure IV.4. Quantification of scAAV8-TTR T119M vector genomes in mouse liver, stomach and 
DRG represented as the ratio of AAV vector genome copies per diploid mouse liver genome. Error 
bars represent SEM. 
 
 
T4 binding assays 
Previously Alves and colleagues have described normal thyroid hormone concentration in 
serum, but increased T4 binding to TTR in carriers of TTR T119M (Alves et al., 1993). 
Later, it was shown that TTR T119M has increased affinity for T4 binding both in vitro and 
in vivo (Almeida et al., 1997). Using a serum [125I]-T4 binding assay, increased binding of 
T4 to TTR was observed in scAAV8-TTR T119M injected animals compared to control 
animals injected with transgene empty vector (Figure IV.5). Since no major differences 
were observed in the binding of TBG or albumin, the 2 other major T4 binding proteins in 
serum, we hypothesize that increased in T4 binding could be related to a higher TTR 
concentration in these samples, leading us to next investigate TTR stability in scAAV8-
TTR T119M injected transgenic mice of different ages. 
 
Figure IV.5. T4 binding assays of mouse serum incubated with [125I]-T4. The migration of different 
T4 binding plasma proteins is indicated.  
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TTR T119M acts as a stabilizer in the serum of transgenic animals carrying TTR V30M of 
different ages 
Previous studies have described the stabilization effect of TTR T119M in serum of FAP 
patients, preventing tetramer dissociation and thus contributing to a more benign form of 
the disease (Alves et al., 1997b; Hammarström et al., 2001). The stabilization effect of 
TTR T119M in our study was investigated by IEF in a semi-denaturing polyacrylamide gel 
in the presence of 4M urea. Plasma samples from animals injected with scAAV8-TTR 
T119M or transgene-empty vector from the 2 different ages groups (3 and 15 months of 
age) were compared for band patterns and tetramer/monomer ratios. Under the conditions 
used, TTR presents a characteristic pattern of two main bands, representing monomers 
(normal and oxidized form), and several bands of lower isoelectric point (pl), representing 
different forms of tetramers (Altland et al., 1981; Alves et al., 1997b). When analyzed in 
this system, the empty vector injected increased intensity at the monomer position and 
diminished intensity at the tetramer position; in contrast, TTR T119M injected animals 
present a higher amount of tetramer in relation to monomer. The groups of animals in our 
study were compared with the serum of animals expressing TTR T119M in a TTR null 
background, where the absence of TTR monomers was observed. The tetramer/monomer 
ratio is higher in transgenic mice expressing TTR T119M as compared to empty vector 
transgenic animals (Figure IV.6), indicating that in these animals TTR has higher stability 
and higher resistance to tetramer dissociation; also the relative percentage of 
tetramer/monomer is not significantly changed in young animals compared to old animals. 
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Figure IV.6. Analysis of TTR stabilization in mice serum by IEF in the presence of 4M urea. Upper 
panel: TTR from injected mice was separated by PAGE and the isolated protein was analysed by 
IEF. The different molecular species visualized in the IEF gel after Coomassie Blue staining are 
indicated. This gel is representative of other gels run in parallel. Lower panel: plot represents 
quantification of the ratio tetramer/monomer relative to the control samples of mice carrying TTR 
T119M only. Error bars represent SEM. 
 
 
Induced expression of TTR T119M decreases TTR deposition in the GI tract of TTR V30M 
transgenic animals at early age 
To assess the therapeutic effect of TTR T119M overexpression in FAP progression, we 
used 12-months-old hTTR V30M transgenic animals, an age when extensive TTR 
deposition is evident. In parallel, we also performed a study to assess the prophylactic 
effect of this new therapy in younger animals at 3 months of age, before TTR deposition in 
the GI tract. 
We analyzed the effect of scAAV8-TTR T119M on TTR deposition in both age groups by 
performing Congo red (CR) amyloid staining and IHC for TTR in different organs. 
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Extracellular TTR deposition can be detected both in fibrillar and non-fibrillar form 
depending on age and stage of disease (Kohno et al., 1997; Sousa et al., 2001a). In the 
12-months old group, the presence of CR-positive material (the hallmark of amyloid 
deposition) was observed in the stomach of 2 out of 7 analyzed animals in the empty 
vector experimental group and not observed in any other of remaining groups (Figure 
IV.7A), indicative of a possible preventive effect of TTR T119M in the formation of fibrillar 
deposition. In the group of young animals amyloid presence was not expected since they 
were euthanized at age 6 months and amyloid is only present in older animals (starting at 
11 months; Kohno et al., 1997). 
We also analyzed the GI tract for the total amount of TTR deposition, both fibrillar and 
non-fibrillar, by IHC. Using a specific antibody against hTTR, no differences were 
observed concerning TTR deposition in stomach or in colon of old animals (Figure IV.7B). 
However, when we analyzed animals at younger ages, the presence of TTR T119M 
caused a significant decrease of TTR deposition both in stomach and colon (Figure 
IV.7C). We believe this effect is due to the stabilization effect exerted in TTR 
heterotetramers by the presence of TTR T119M, not allowing tetramer dissociation (Alves 
et al., 1997b; Hammarström et al., 2001; Hammarström et al., 2003b). 
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Figure IV.7. TTR deposition assessment in the GI tract of AAV-treated transgenic mice. (A) CR 
positive amorphous deposits in stomach (left panel), which emit birefringence under polarized light 
(right panel). Scale bars, 50µm. Table shows the number of identified CR positive cases. (B) 
Representative IHC for hTTR in stomach and colon of the old animals experimental group. Scale 
bars, 100µm. Plot corresponds to the semi-quantification of TTR staining represented as the ratio 
of the occupied area in the whole tissue. Error bars represent SEM. (C) Representative IHC for 
hTTR in stomach and colon of the young animals experimental group. Scale bars, 100µm. Plot 
corresponds to the semi-quantification of TTR staining represented as the ratio of the occupied 
area in the whole tissue. Error bars represent SEM. ** p<0.01; *** p<0.001. 
 
 
Expression of TTR T119M decreases FAP disease biomarkers in TTR V30M transgenic 
animals at early age 
Next we analyze the status of the ER chaperone BiP (Grp78) and the extracellular matrix 
(ECM) protein MMP-9 as these molecules have been shown to be up-regulated in FAP 
(Cardoso et al., 2008; Macedo et al., 2007; Sousa et al., 2005; Teixeira et al., 2006), and 
thus can be used as disease biomarkers. 
Using semi-quantitative IHC we evaluated BiP levels in the GI tract organs where TTR 
deposition occurs. In the experimental group of old animals no differences were observed 
either in stomach or colon (Figure IV.8A). In the younger group of animals, the expression 
of TTR T119M led to a significant decrease in BiP levels both in stomach and colon, 
however no differences were found in older animals (Figure IV.8B). To further confirm 
these results, we performed western blot analysis of these organs. As expected, no 
differences were found in the old animals group (Figure IV.8C). In the young animals 
group, BiP was significantly decreased only in colon (Figure IV.8D). This fact may be 
caused by the dilution factor introduced in the western blot analysis by organ 
homogenization. Interestingly, we observed a slight difference only in colon (p<0.05), the 
same organ where we found the greatest difference by IHC (p<0.01). 
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Figure IV.8. ER stress evaluation in the GI tract of transgenic mice in AAV-treated animals. (A) 
Representative IHC for BiP in stomach and colon of the old animals experimental group. Scale 
bars, 100µm. Plot corresponds to the semi-quantification of BiP staining represented as the ratio of 
the occupied area in the whole tissue. Error bars represent SEM. (B) Representative IHC for BiP in 
stomach and colon of the young animals experimental group. Scale bars, 100µm. Plot corresponds 
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to the semi-quantification of BiP staining represented as the ratio of the occupied area in the whole 
tissue. Error bars represent SEM. * p<0.05; ** p<0.05. (C) Representative western blot of BiP and 
α-tubulin in stomach and colon of old animals. Plot: density quantification of the ratio BiP / α-tubulin 
represented by mean ± SEM. (D) Representative western blot of BiP and α-tubulin in stomach and 
colon of young animals. Plot: density quantification of the ratio BiP / α-tubulin represented by mean 
± SEM. * p<0.05. 
 
Levels of MMP-9 were also assessed by semi-quantitative IHC. Since MMP-9 is up-
regulated only when fibrillar deposition is present (Cardoso et al., 2008; Sousa et al., 
2005), we would expect to observe differences in the stomach of old animals, the only 
group where we found CR positive amyloid deposits; however it was not observed. 
Surprisingly, we only found a very slight difference in MMP-9 levels in colon of the young 
animals group (Figure IV.9A-B). This is the organ where the major differences in disease 
biomarkers were found, perhaps indicating that this could be the most affect organ in the 
progression of the disease. 
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Figure IV.9. MMP-9 evaluation in the GI tract of AAV-injected transgenic mice. (A) Representative 
IHC for MMP-9 in stomach and colon of the old animals experimental group. Scale bars, 100µm. 
Plot corresponds to the semi-quantification of MMP-9 staining represented as the ratio of the 
occupied area in the whole tissue. Error bars represent SEM. (B) Representative IHC for MMP-9 in 
stomach and colon of the young animals experimental group. Scale bars, 100µm. Plot corresponds 
to the semi-quantification of MMP-9 staining represented as the ratio of the occupied area in the 
whole tissue. Error bars represent SEM. * p<0.05. 
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Search for new pathways involved in the protection induced by the T119M stabilizing 
variant: an approach using both proteomics and transcriptomics 
The PNS is the key target tissue for development of therapies for FAP. Although TTR 
deposition in DRG is not apparent in hTTR V30M transgenic mice, different signaling 
pathways seem to be altered in DRG nonetheless (Monteiro et al., 2006b). Therefore we 
evaluated novel pathways that might be changed by the presence of a stabilizing TTR 
variant. We used two different approaches: a proteomics study involving 2D-DIGE 
analysis and gene expression analysis using microarrays. 
The DRG proteome of old animals experimental group was compared in animals injected 
with empty vector or scAAV8-TTR T119M; 7 protein spots with a statistically significant 
change in abundance (p<0.05) in treated mice were detected (Figure IV.10). These spots 
were picked from the gels and identified by MALDI-TOF MS. 
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Figure IV.10. 2D-DIGE differential protein expression analysis. Representative image of a 2D-
DIGE gel labeled with Cy3 and Cy5; indicated spots showed a statistically significant variation of 
spot volume with 95% confidence level (p<0.05). Lower panel: table depicting the code assignment 
between spots and differentially expressed proteins identified by MALDI-TOF-TOF MS. 
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Spot 613 was not identified as a protein, thus we concluded it corresponds to a 
contamination. Out of the remaining 6 protein spots, 5 were identified as TTR species; 
based on molecular weight and isolelectric point it was suggested that spots 788, 1633 
and 1663 corresponded to tetrameric TTR, spot 1679 corresponded to monomeric TTR 
and spot 1607 represented a higher molecular form of TTR, suggestive of a modified form 
of TTR, perhaps with post-translational modifications. Interestingly, the increased quantity 
of tetrameric TTR in DRG of animals injected with scAAV8-TTR T119M and decreased 
monomeric TTR is in accordance to the higher ratio tetramer / monomer that we found in 
the serum of these animals.  
The 7th protein spot statistically different corresponds to the cytoplasmic malate 
dehydrogenase (MDH). This enzyme catalyzes the final step of tricarboxylic acid (TCA) 
cycle, the NAD+/NADH-dependent interconversion of malate and oxaloacetate, and it is 
essential for maintaining a favorable NAD+/NADH ratio for the oxidative metabolism of 
glucose in neurons (McKenna et al., 2006). Our analysis confirms a decrease in MDH 
protein levels in animals injected with AAV8-TTR T119M. Previous studies have shown 
that MDH activity is up-regulated in the brain of AD patients (Bubber et al., 2005). In the 
absence of further testing, we believe that lower levels of this enzyme ultimately might 
indicate a decrease in oxidative stress on DRG scAAV8-TTR T119M injected animals. 
We also analyzed the transcriptome of DRG and colon from AAV-treated young animals, 
by performing whole genome microarrays and gene expression comparisons between 
animals injected with scAAV8-TTR T119M or transgene-empty vector. The result was a 
list of genes with differences in expression levels, either increased or decreased by the 
expression of TTR T119M in transgenic animals carrying TTR V30M. Functional 
classification shows that most genes are involved in the immune system and in the 
activation of signaling pathways (GPCR signaling); we also found several genes involved 
in cell-cell interaction, ion channel activity, ECM or lipid metabolism (Figure IV.11). 
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Figure IV.11. Functional classification of genes differentially expressed in animals injected with 
scAAV8-TTR T119M. Up- (≥1.5) and down- (≤0.5) regulated genes in (A) DRG and (B) colon. ND: 
not determined. 
 
The list of genes generated in this microarray requires further investigation to select 
potential interesting genes and needs to be validated by qPCR, western blotting and/or 
immunohistochemistry, depending on antibody availability. 
A complete list of the genes found to be up- and down-regulated is presented in Appendix 
II. 
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DISCUSSION 
Currently a definitive treatment for FAP is still unavailable. The best possible treatment of 
the disease is, so far, liver transplantation. However, there are several problems with this 
therapy, including organ availability, immunological issues or eligibility for transplantation; 
therefore new therapeutic strategies are needed. The strategies put forward so far as 
potentially therapeutic for FAP follow for most aspects what has been done for other 
amyloidoses, such as inhibiting aggregation and/or disrupting TTR amyloid by selective 
molecules (Ando, 2005).  
With the present work we proposed to establish the basis for what could in the future 
become a new treatment for FAP. Gene therapy approaches have arisen as new gene 
replacement and/or correction technologies have emerged. Nakamura and colleagues 
reported the conversion of mutated V30M TTR to WT TTR in the liver of a transgenic 
mouse using single-stranded oligonucleotides (SSOs) (Nakamura et al., 2004). More 
recently, reduction of a specific mutated TTR gene expression was achieved using 
antisense nucleotides (ASOs) both in liver (Benson et al., 2006) and in the choroid plexus 
albeit to lower extent (Benson et al., 2010). Currently, clinical trials to evaluate safety and 
tolerability of systemically delivered small interfering RNA (siRNA) (phase 2 trial; 
www.alnylam.com; clinicaltrials.gov; identifiers NCT01617967) or an antisense drug 
(phase 2/3 trial; www.isispharm.com; clinicaltrials.gov; identifiers NCT01737398) are 
ongoing, both aiming to reduce the amount of mutant and normal TTR made by the liver. 
Here we investigated a different gene therapy approach based on the knowledge that 
compound heterozygotes V30M/T119M show little clinical manifestations of FAP, due to 
increased protein stability (Alves et al., 1997a; Coelho et al., 1996). Previous studies have 
shown that lentiviral vectors encoding TTR T119M can transduce hepatocytes and lead to 
the formation of more stable heterotetramers with amyloidogenic variants (Kamata et al., 
2009). 
AAV vectors have emerged as a promising in vivo gene delivery platform to liver mainly 
due to highly efficient transduction after systemic delivery and ability to mediate long-term 
transgene expression with no apparent toxicity (Warrington and Herzog, 2006; Xiao et al., 
1998). To enhance liver transduction after systemic administration, we used self-
complementary vector (for a faster gene expression due to bypassing of second-strand 
DNA synthesis required upon infection by single-stranded AAV vectors to become 
transcriptionally active), encoding a strong liver specific promoter and pseudotyped with 
highly liver-tropic AAV8 capsid. scAAV8 vectors have demonstrated higher transduction 
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efficiency of murine livers, and are currently being tested in clinical trials for factor IX 
deficiency (Davidoff et al., 2005; Mccarty et al., 2003; Nathwani et al., 2009). 
Our lab currently has 2 FAP mouse models: one mouse model expressing human TTR 
V30M in a TTR null background (Kohno et al., 1997) and another model that carries 
human TTR V30M in a TTR null background and Hsf1 null background (Santos et al., 
2008). Only the latter model presents TTR deposition in the PNS, while both show 
extensive deposition in the GI tract. Because of the importance of TTR in the PNS we 
decided to use the model in the Hsf1 background. However, preliminary studies showed 
limited transduction of liver after systemic administration of scAAV8 vector in these mice. 
Because vector genome copies in hepatocytes were very low (Figure IV.1D) we 
hypothesize that absence of Hsf1 may alter liver receptors for AAV8; however, to our 
knowledge, there is no evidence of Hsf1 playing any role in AAV biology.  
Presently there is no technique to distinguish endogenous TTR V30M from vector 
encoded TTR T119M proteins in serum. Therefore we analyzed mRNA levels of each 
variant in liver by HRM, which is a technique used to identify genetic mutations and 
polymorphisms and recently adapted to quantify DNA methylation (Malentacchi et al., 
2009). Despite being able to quantify TTR T119M mRNA as approximately 50% of TTR 
V30M mRNA, we still have no information on the ratio of V30M:T119M in heterotetramers 
that hypothetically are being formed in liver. However it appears that TTR tetramers in 
serum after gene transfer of TTR T119M were more stable than TTR V30M-only 
tetramers, as assessed by IEF (Figure IV.6). Hammarström and colleagues have shown 
that as little as one T119M monomer in the heterotetramer is enough to increase 
resistance to dissociation (Hammarström et al., 2001; Hammarström et al., 2003b) and 
thus preventing formation of aggregates (Quintas et al., 2001). 
This stabilization effect on the tetramer and resistance to dissociation resulting from AAV-
mediated expression of TTR T119M in liver was sufficient to prevent TTR deposition in the 
GI tract of hTTR V30M transgenic mice if treatment was initiated at a young age. However 
this gene therapy approach had no effect on older animals, indicating that the presence of 
a protective TTR variant has no influence on the already deposited protein. Nonetheless 
we observed decreased number of CR-positive cases, with the number of cases 
decreasing in the animals injected with scAAV8-TTR T119M; this observation may not be 
totally related to the treatment, but instead stochastic events, as amyloid penetrance at 
the age of the study is not 100% (Kohno et al., 1997). Therefore, injection of a larger 
number of animals will be necessary to further investigate this possibility. Together with 
the decrease in TTR deposition also the disease biomarker BiP, an ER stress chaperone, 
showed reduced levels in scAAV8-TTR T119M mice injected at young age. We also 
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analyzed MMP-9, an ECM protein described to be up-regulated in the presence of 
amyloid fibrils (Cardoso et al., 2008; Sousa et al., 2005). Interestingly, differences were 
observed in the colon of young animals, an experimental group where amyloid deposits 
has not been documented; although Sousa and colleagues did not observe MMP-9 up-
regulation in the presence of non-fibrillar deposition (Sousa et al., 2005), later Cardoso 
and colleagues verified that oligomeric TTR in cell culture up-regulates MMP-9 expression 
(Cardoso et al., 2008). Therefore we can hypothesize that differences in MMP-9 
expression can be dependent on disease stage, and in fact the organ where differences 
on MMP-9 levels were documented in this study is the same organ where we observed 
the best improvements after scAAV8-TTR T119M injection, with higher decrease both in 
TTR deposition and BiP levels. 
Another goal of this study was to uncover new events and/or pathways that might be 
involved in FAP, making them possible future targets for modulation. We used 2 different 
approaches: proteomic and transcriptomic analysis. Using 2D-DIGE analysis of DRG our 
major findings were decreased levels of a modified form of TTR in animals injected with 
scAAV8-TTR T119M, as well as the reduction in MDH levels. Increased MDH activity 
results in higher the NAD+/NADH ratio and consequently alters the redox state of the cell, 
leading to increased oxidative stress (Mali and Zisapels, 2008; Shi et al., 2008). This is 
important as increased oxidative stress appears to be a disease feature in FAP (Macedo 
et al., 2007). Recently, our lab described the existence of N-glycosylated TTR in the 
serum of V30M carriers, however this form is not suppressed by the presence of TTR 
T119M in compound heterozygous (Teixeira and Saraiva, 2013). We have no indications 
if the modified form of TTR found in our animals corresponds to N-glycosylation; however 
we think interesting to investigate if this form is present in aggregates and/or protein 
deposits and whether the presence of TTR T119M can affect its concentration in tissue, 
although it is not affected in serum. Altogether the significance in disease of modified TTR 
forms has yet to be addressed. 
In the transcriptomics approach, we found several genes differentially expressed, either 
up- or down-regulated, both in DRG and colon. The vast majority of altered genes are 
involved in the immune system; previously, inflammation has already been described as 
having an important role in FAP (Sousa et al., 2001b), so we believe that the role that TTR 
T119M is having in modulating the immune system is worth to be further investigated. 
Interestingly, the DRG transcriptome revealed that the two most down-regulated genes 
are Stefin A2-like 1 (Stfa2l1) and Stefin A2 (Stfa2); both genes are part of the stefin gene 
cluster which codifies for a subgroup of the cystatin superfamily that act as cytoplasmic 
inhibitors of cysteine proteases such as cathepsins (Bilodeau et al., 2009). Stefin A was 
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found in neuritic plaques in brains of AD patients (Bernstein et al., 1994) and it is a known 
inhibitor of cathepsin B, a protease in lysosomes (Renko et al., 2010); therefore we 
believe that if stefin A is decreased, the activity of cathepsin B in lysosomes should be 
increased, thus contributing to the possible degradation of TTR aggregates. For that 
reason, we consider that this particular group of genes and/or proteins should be studied 
in future investigations. 
In summary, we proved that is possible to use a gene therapy approach to express a 
protective TTR variant in liver, able to stabilize TTR V30M and to decrease the non-fibrillar 
deposition and disease biomarkers in the GI tract of a transgenic mouse model. However, 
this approach should be used as prophylaxis rather than as a treatment. Taken together, 
our work paves the way in the study of treatments for FAP, as it opens new approaches 
that may be used to modulate/alter disease progression. 
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Transthyretin (TTR) amyloidoses are caused by aggregation and deposition of TTR 
variants in different organs. Familial amyloidotic polyneuropathy (FAP) related with the 
V30M TTR variant is probably the best characterized of the plethora of TTR-related 
disorders, with extracellular amyloid fibril deposition mainly in the peripheral nervous 
system (PNS). However, an effective therapy is still needed, as liver transplantation, the 
only efficient therapy available on halting disease progression (by abolishing TTR variant 
synthesis by liver) presents too many disadvantages. Additionally, TTR amyloidoses with 
involvement of other TTR variants need further investigation on their mechanisms and 
possible therapeutics, in particular the aggressive forms of leptomeningeal amyloidosis 
involving highly destabilized TTR variants. 
Work presented in chapter II of this thesis was designed to study the metabolism of TTR-
L12P, as this variant causes leptomeningeal and liver amyloidosis (Brett et al., 1999), 
features not observed simultaneously for most other FAP-associated TTR variants. 
Previous reports have shown that TTR variants associated with leptomeningeal 
amyloidosis are highly destabilized both thermodynamically and kinetically and therefore 
are retained by the cell quality control in the ER and degraded (Sato et al., 2007; Sekijima 
et al., 2005). However, we observed not only a different secretion pattern of this variant 
between hepatocyte-like and choroid plexus (CP)-derived cells, with decreased secretion 
in hepatocyte-like cells but WT-comparable efficiency secretion in CP cells; also, we found 
that in hepatocytes TTR L12P is not degraded by the endoplasmic reticulum (ER) 
machinery, it rather accumulates in lysosomes (Figure V.1A). We also showed for the first 
time that TTR L12P is secreted by hepatocytes both in vitro and in vivo in a N-
glycosylated form. It would be interesting to address whether this post-translational 
modification represents an escape to ER-associated degradation (ERAD). Moreover, we 
generated a new mouse model of TTR L12P amyloidosis by adeno-associated virus 
(AAV)-mediated gene transfer to the liver of TTR null mice presenting low levels of protein 
in serum as well as TTR aggregates in the liver, as described in human patients. 
However, we did not observe TTR deposition in other organs, most likely due to the very 
low levels of circulating protein, which might be overcome with a heterozygous approach 
with simultaneous expression of wild type (WT) and variant TTR. The major challenge 
remaining to this somatic transgenic approach is to replicate the leptomeningeal 
amyloidosis associated with TTR L12P, since TTR produced in the liver does not affect 
the central nervous system (CNS). Therefore, we suggest the use of AAV-mediated gene 
transfer targeting CP cells in the brain to assess the effects and mechanisms underlying 
leptomeningeal amyloidosis and investigate possible therapies. 
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In chapter III of the presented work, we assessed the mechanism by which extracellular 
TTR aggregates are targeted to lysosomes for degradation. We show that extracellular 
TTR V30M aggregates are internalized by a neuroblastoma cell line in a dynamin- and 
lipid rafts-dependent mechanism and delivered to lysosomes for degradation (Figure 
V.1B). Despite representing a major breakthrough in understanding the mechanism of 
TTR internalization and how TTR aggregates communicate with cells, a few questions 
remain unclear, namely: (i) what is the intracellular traffic that aggregates follow? (ii) how 
are they delivered to lysosomal compartment? (iii) are aggregates recycled to cell 
surface? These topics should be answered in the future using markers for different 
subcellular compartments combined with live-cell imaging, to uncover the intracellular 
processing steps of TTR aggregates. Identification of all molecular entities involved in 
TTR aggregate uptake is of special interest as it can be a potential target for intervention 
to modulate clearance. An increase in clearance from the extracellular milieu would be 
expected to diminish the rate of fibril formation and potentially stop further deposition in 
the extracellular matrix. 
In the final chapter (chapter IV), we explore a new therapy approach to FAP using AAV-
mediated gene transfer to deliver TTR T119M gene to the liver of an FAP transgenic 
mouse model of TTR V30M presenting TTR deposits in the gastrointestinal (GI) system 
(Figure V.1C). TTR T119M is described as a protective variant in FAP (Alves et al., 
1997a; Coelho et al., 1996). We observed a significant decrease in TTR deposition in the 
GI tract (both stomach and colon) of transgenic mice injected with scAAV8-TTR T119M at 
a young age, when compared to control (empty vector-injected animals), as well as 
concomitant decrease of disease biomarkers in tissues. Our study paves the way for the 
establishment of a gene therapy protocol where de novo expression of TTR T119M in liver 
of TTR V30M carriers at an early stage could prevent FAP pathology. The stabilizing 
effect of T119M variant on TTR hetero-tetramers is well described (Alves et al., 1997b; 
Hammarström et al., 2001; Hammarström et al., 2003b). Although this is thought to be the 
mechanism by which the T119M exerts its modulatory effect, we investigated if other 
mechanisms could be involved in preventing disease progression by comparing the 
transcriptomic profile of colon and DRG of animals injected with scAAV8-TTR T119M and 
controls. A list containing several genes with altered expression, both up- and down-
regulated, was obtained and needs to be validated by RT-qPCR, western blotting and/or 
immunohistochemistry.  
Interestingly, several genes related to extracellular matrix (ECM) remodeling were found 
with altered expression in our arrays, as well as genes associated with lysosomal activity 
and autophagy. The relation between up-regulation of ECM proteins and TTR aggregates 
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and fibrils in FAP has been known for some time (Cardoso et al., 2008; Sousa et al., 
2005) and our recent findings described in chapters II and III shed light on a possible role 
for lysosomal degradation in TTR amyloidosis. Lysosomal activity, ECM proteins and 
molecules involved in aggregate uptake should therefore be considered as potential 
pharmacological targets to alleviate pathological cascades in FAP (Figure V.1D). 
Altogether, our data suggests that destabilized TTR variants produced by hepatocytes are 
retained inside the cells to a certain extent to be degraded in lysosomes. In contrast CP-
derived cells secrete those variants at nearly the same efficiency as WT protein; this 
degradation pathway is also followed by aggregates internalized via lipid rafts, and this is 
likely to be the pathway triggering the previously described events of ER stress and 
apoptosis. AAV-mediated gene transfer proves to be a valid approach to generate new 
somatic transgenic mouse models to study the mechanisms of TTR amyloidosis as well 
as gene therapy approach to FAP. 
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Figure V.1. Schematic representation of the crosstalk mechanisms involved in FAP studied in this 
thesis. (A) TTR destabilized variants, as L12P, are targeted for lysosomal degradation in 
hepatocytes, with only a small fraction being secreted. (B) Extracellular TTR aggregates can be 
internalized by cells in dynamin- and lipid rafts-dependent mechanisms and delivered to lysosomes 
for degradation. However, there are still questions on the exact intracellular traffic they follow to 
reach lysosomes, as well as on other routes they might follow, including retrograde transport to 
Golgi and ER for proteasomal degradation or recycling to cell surface. (C) AAV-mediated gene 
delivery of a protective TTR variant may prevent disease progression by stabilizing TTR tetramer 
and blocking aggregates formation. These approach may also contribute to ECM remodeling (D) 
which may contribute to amyloid deposits degradation. 
 
  
  
  
 
 
 
 
 
 
 
 
 
Chapter VI 
References 
CHAPTER VI⏐References 
156 
Aleshire, S.L., Bradley, C.A., Richardson, L.D., and Parl, F.F. (1983). Localization of 
human prealbumin in choroid plexus epithelium. J Histochem Cytochem 31, 608-612. 
Allen, J.A., Halverson-Tamboli, R.A., and Rasenick, M.M. (2007). Lipid raft microdomains 
and neurotransmitter signalling. Nat Rev Neurosci 8, 128-140. 
Almeida, M.R., Damas, A.M., Lans, M.C., Brouwer, A., and Saraiva, M.J. (1997). 
Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic 
carriers and structural analysis. Endocrine 6, 309-315. 
Almeida, M.R., Macedo, B., Cardoso, I., Alves, I., Valencia, G., Arsequell, G., Planas, A., 
and Saraiva, M.J. (2004). Selective binding to transthyretin and tetramer stabilization in 
serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal 
derivative. Biochem J 381, 351-356. 
Altland, K., Benson, M.D., Costello, C.E., Ferlini, A., Hazenberg, B.P.C., Hund, E., Kristen, 
A.V., Linke, R.P., Merlini, G., Salvi, F., et al. (2007). Genetic microheterogeneity of human 
transthyretin detected by IEF. Electrophoresis 28, 2053-2064. 
Altland, K., Rauh, S., and Hackler, R. (1981). Demonstation of human prealbumin by 
double one-dimensional slab gel electrophoresis. Electrophoresis 2, 148-155. 
Altland, K., and Winter, P. (1999). Potential treatment of transthyretin-type amyloidoses by 
sulfite. Neurogenetics 2, 183-188. 
Alvarez, R., Borland, T., Chen, Q., Milstein, S., Nguyen, T., Hinkle, G., Kuchimanchi, S., 
Costigan, J., Ristoiu, V., Wang, G., et al. (2010). ALN-TTR, an RNAi therapeutic for the 
treatment of transthyretin-mediated amyloidosis. Amyloid-J Protein Fold Disord 17, 51-52. 
Alves, I.L., Altland, K., Almeida, M.R., Winter, P., and Saraiva, M.J. (1997a). Screening 
and biochemical characterization of transthyretin variants in the Portuguese population. 
Hum Mutat 9, 226-233. 
Alves, I.L., Divino, C.M., Schussler, G.C., Altland, K., Almeida, M.R., Palha, J.A., Coelho, 
T., Costa, P.P., and Saraiva, M.J. (1993). Thyroxine binding in a TTR Met 119 kindred. J 
Clin Endocrinol Metab 77, 484-488. 
Alves, I.L., Hays, M.T., and Saraiva, M.J. (1997b). Comparative stability and clearance of 
[Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 249, 662-668. 
Alvsaker, J.O., Haugli, F.B., and Laland, S.G. (1967). The presence of vitamin A in human 
tryptophan-rich prealbumin. Biochem J 102, 362-366. 
Amaral, J.D., Viana, R.J., Ramalho, R.M., Steer, C.J., and Rodrigues, C.M. (2009). Bile 
acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 50, 1721-1734. 
Andersson, K., Olofsson, A., Nielsen, E.H., Svehag, S.E., and Lundgren, E. (2002). Only 
amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res 
Commun 294, 309-314. 
Andersson, K., Pokrzywa, M., Dacklin, I., and Lundgren, E. (2013). Inhibition of TTR 
aggregation-induced cell death--a new role for serum amyloid P component. PLoS ONE 8, 
e55766. 
CHAPTER VI⏐References 
157 
Ando, Y. (2005). Liver transplantation and new therapeutic approaches for familial 
amyloidotic polyneuropathy (FAP). Med Mol Morphol 38, 142-154. 
Ando, Y., Nyhlin, N., Suhr, O., Holmgren, G., Uchida, K., el Sahly, M., Yamashita, T., 
Terasaki, H., Nakamura, M., Uchino, M., et al. (1997). Oxidative stress is found in amyloid 
deposits in systemic amyloidosis. Biochem Biophys Res Commun 232, 497-502. 
Ando, Y., Suhr, O., and el-Salhy, M. (1998). Oxidative stress and amyloidosis. Histol 
Histopathol 13, 845-850. 
Ando, Y., and Ueda, M. (2012). Diagnosis and therapeutic approaches to transthyretin 
amyloidosis. Curr Med Chem 19, 2312-2323. 
Andrade, C. (1952). A peculiar form of peripheral neuropathy; familiar atypical generalized 
amyloidosis with special involvement of the peripheral nerves. Brain 75, 408-427. 
Anelli, T., and Sitia, R. (2008). Protein quality control in the early secretory pathway. 
EMBO J 27, 315-327. 
Arthur, J.R., Heinecke, K.A., and Seyfried, T.N. (2011). Filipin recognizes both GM1 and 
cholesterol in GM1 gangliosidosis mouse brain. J Lipid Res 52, 1345-1351. 
Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at 
the clinical crossroads. Mol Ther 20, 699-708. 
Awasthi-Kalia, M., Schnetkamp, P.P., and Deans, J.P. (2001). Differential effects of filipin 
and methyl-beta-cyclodextrin on B cell receptor signaling. Biochem Biophys Res Commun 
287, 77-82. 
Bartalena, L., and Robbins, J. (1993). Thyroid hormone transport proteins. Clin Lab Med 
13, 583-598. 
Batista, A.R., Sena-Esteves, M., and Saraiva, M.J. (2013). Hepatic production of 
transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic 
mouse model. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832, 
1183-1193. 
Baures, P.W., Oza, V.B., Peterson, S.A., and Kelly, J.W. (1999). Synthesis and evaluation 
of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-
inflammatory drug, flufenamic acid. Bioorg Med Chem 7, 1339-1347. 
Benson, M.D. (1996). Leptomeningeal amyloid and variant transthyretins. Am J Pathol 
148, 351-354. 
Benson, M.D., and Kincaid, J.C. (2007). The molecular biology and clinical features of 
amyloid neuropathy. Muscle Nerve 36, 411-423. 
Benson, M.D., Kluve-Beckerman, B., Zeldenrust, S.R., Siesky, A.M., Bodenmiller, D.M., 
Showalter, A.D., and Sloop, K.W. (2006). Targeted suppression of an amyloidogenic 
transthyretin with antisense oligonucleotides. Muscle Nerve 33, 609-618. 
Benson, M.D., Smith, R.A., Hung, G., Kluve-Beckerman, B., Showalter, A.D., Sloop, K.W., 
and Monia, B.P. (2010). Suppression of choroid plexus transthyretin levels by antisense 
oligonucleotide treatment. Amyloid 17, 43-49. 
CHAPTER VI⏐References 
158 
Berg, I., Thor, S., and Hammarstrom, P. (2009). Modeling familial amyloidotic 
polyneuropathy (Transthyretin V30M) in Drosophila melanogaster. Neurodegener Dis 6, 
127-138. 
Berk, J.L., Suhr, O.B., Sekijima, Y., Yamashita, T., Heneghan, M., Zeldenrust, S.R., Ando, 
Y., Ikeda, S., Gorevic, P., Merlini, G., et al. (2012). The Diflunisal Trial: study accrual and 
drug tolerance. Amyloid 19 Suppl 1, 37-38. 
Bernstein, H.G., Rinne, R., Kirschke, H., Järvinen, M., Knöfel, B., and Rinne, A. (1994). 
Cystatin A-like immunoreactivity is widely distributed in human brain and accumulates in 
neuritic plaques of Alzheimer disease subjects. Brain Res Bull 33, 477-481. 
Bilodeau, M., MacRae, T., Gaboury, L., Laverdure, J.P., Hardy, M.P., Mayotte, N., 
Paradis, V., Harton, S., Perreault, C., and Sauvageau, G. (2009). Analysis of blood stem 
cell activity and cystatin gene expression in a mouse model presenting a chromosomal 
deletion encompassing Csta and Stfa2l1. PLoS ONE 4, e7500. 
Biochemistry, N.C.o.t.I.U.o. (1981). Nomenclature Committee of IUB (NC-IUB) IUB-IUPAC 
Joint Commission on Biochemical Nomenclature (JCBN). Newsletter 1981. J Biol Chem 
256, 12-14. 
Biroccio, A., Del Boccio, P., Panella, M., Bernardini, S., Di Ilio, C., Gambi, D., Stanzione, 
P., Sacchetta, P., Bernardi, G., Martorana, A., et al. (2006). Differential post-translational 
modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. 
Proteomics 6, 2305-2313. 
Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B., and Rerat, C. (1978). Structure of 
prealbumin: secondary, tertiary and quaternary interactions determined by Fourier 
refinement at 1.8 A. J Mol Biol 121, 339-356. 
Blake, C.C., Geisow, M.J., Swan, I.D., Rerat, C., and Rerat, B. (1974). Structure of human 
plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain 
conformation, quaternary structure and thyroxine binding. J Mol Biol 88, 1-12. 
Blott, E.J., and Griffiths, G.M. (2002). Secretory Lysosomes. Nat Rev Mol Cell Biol 3, 122-
131. 
Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., 
Hutchinson, W.L., Mangione, P.P., Gallimore, J.R., Millar, D.J., et al. (2010). Antibodies to 
human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 93-
97. 
Brett, M., Persey, M.R., Reilly, M.M., Revesz, T., Booth, D.R., Booth, S.E., Hawkins, P.N., 
Pepys, M.B., and Morgan-Hughes, J.A. (1999). Transthyretin Leu12Pro is associated with 
systemic, neuropathic and leptomeningeal amyloidosis. Brain 122 ( Pt 2), 183-190. 
Brockstedt, D.G., Podsakoff, G.M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., and 
Engleman, E.G. (1999). Induction of immunity to antigens expressed by recombinant 
adeno-associated virus depends on the route of administration. Clin Immunol 92, 67-75. 
Broekman, M.L., Baek, R.C., Comer, L.A., Fernandez, J.L., Seyfried, T.N., and Sena-
Esteves, M. (2007). Complete correction of enzymatic deficiency and neurochemistry in 
the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene 
delivery. Mol Ther 15, 30-37. 
CHAPTER VI⏐References 
159 
Broekman, M.L., Comer, L.A., Hyman, B.T., and Sena-Esteves, M. (2006). Adeno-
associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 
serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138, 
501-510. 
Bubber, P., Haroutunian, V., Fisch, G., Blass, J.P., and Gibson, G.E. (2005). 
Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57, 
695-703. 
Bulawa, C.E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J.A., Packman, J., 
Powers, E.T., Wiseman, R.L., Foss, T.R., et al. (2012). Tafamidis, a potent and selective 
transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 
109, 9629-9634. 
Bunkenborg, J., Pilch, B.J., Podtelejnikov, A.V., and Wisniewski, J.R. (2004). Screening 
for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 4, 
454-465. 
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., 
Nolan, T., Pfaffl, M.W., Shipley, G.L., et al. (2009). The MIQE guidelines: minimum 
information for publication of quantitative real-time PCR experiments. Clinical Chemistry 
55, 611-622. 
Buxbaum, J.N., Ye, Z., Reixach, N., Friske, L., Levy, C., Das, P., Golde, T., Masliah, E., 
Roberts, A.R., and Bartfai, T. (2008). Transthyretin protects Alzheimer's mice from the 
behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 105, 2681-
2686. 
Cardelli, J.A., Richardson, J., and Miears, D. (1989). Role of acidic intracellular 
compartments in the biosynthesis of Dictyostelium lysosomal enzymes. The weak bases 
ammonium chloride and chloroquine differentially affect proteolytic processing and sorting. 
Journal of Biological Chemistry 264, 3454-3463. 
Cardoso, I., Almeida, M.R., Ferreira, N., Arsequell, G., Valencia, G., and Saraiva, M.J. 
(2007). Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin 
aggregation: relevance in drug design. Biochem J 408, 131-138. 
Cardoso, I., Brito, M., and Saraiva, M.J. (2008). Extracellular matrix markers for disease 
progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-
related. Dis Markers 25, 37-47. 
Cardoso, I., Goldsbury, C.S., Muller, S.A., Olivieri, V., Wirtz, S., Damas, A.M., Aebi, U., 
and Saraiva, M.J. (2002). Transthyretin fibrillogenesis entails the assembly of monomers: 
a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317, 
683-695. 
Cardoso, I., Martins, D., Ribeiro, T., Merlini, G., and Saraiva, M.J. (2010). Synergy of 
combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and 
associated biomarkers: studies in FAP mouse models. J Transl Med 8, 74. 
Cardoso, I., Merlini, G., and Saraiva, M.J. (2003). 4'-iodo-4'-deoxydoxorubicin and 
tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: 
screening for TTR fibril disrupters. FASEB J 17, 803-809. 
CHAPTER VI⏐References 
160 
Cardoso, I., Pereira, P.J., Damas, A.M., and Saraiva, M.J. (2000). Aprotinin binding to 
amyloid fibrils. Eur J Biochem 267, 2307-2311. 
Cardoso, I., and Saraiva, M.J. (2006). Doxycycline disrupts transthyretin amyloid: 
evidence from studies in a FAP transgenic mice model. FASEB J 20, 234-239. 
Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., and Torres-Aleman, I. (2002). Serum 
insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397. 
Cavallaro, T., Martone, R.L., Dwork, A.J., Schon, E.A., and Herbert, J. (1990). The retinal 
pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest 
Ophthalmol Vis Sci 31, 497-501. 
Chafekar, S.M., Baas, F., and Scheper, W. (2008). Oligomer-specific Abeta toxicity in cell 
models is mediated by selective uptake. Biochim Biophys Acta 1782, 523-531. 
Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R., and Wilson, J. (1999). Immune 
responses to adenovirus and adeno-associated virus in humans. Gene Ther 6, 1574-
1583. 
Chirmule, N., Xiao, W., Truneh, A., Schnell, M.A., Hughes, J.V., Zoltick, P., and Wilson, 
J.M. (2000). Humoral immunity to adeno-associated virus type 2 vectors following 
administration to murine and nonhuman primate muscle. J Virol 74, 2420-2425. 
Choi, S.H., Leight, S.N., Lee, V.M.-Y., Li, T., Wong, P.C., Johnson, J.A., Saraiva, M.J., 
and Sisodia, S.S. (2007). Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with 
hemizygous deletions of TTR (transthyretin). J Neurosci 27, 7006-7010. 
Coelho, T., Chorão, R., Sousa, A., Alves, I., Torres, M.F., and Saraiva, M.J.M. (1996). 
Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected 
from the devastating effects of familial amyloid polyneuropathy. Neuromuscular disorders : 
NMD 6, S20. 
Coelho, T., Maia, L.F., Martins da Silva, A., Waddington Cruz, M., Plante-Bordeneuve, V., 
Lozeron, P., Suhr, O.B., Campistol, J.M., Conceicao, I.M., Schmidt, H.H., et al. (2012). 
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. 
Neurology 79, 785-792. 
Coimbra, A., and Andrade, C. (1971a). Familial amyloid polyneuropathy: an electron 
microscope study of the peripheral nerve in five cases. I. Interstitial changes. Brain 94, 
199-206. 
Coimbra, A., and Andrade, C. (1971b). Familial amyloid polyneuropathy: an electron 
microscope study of the peripheral nerve in five cases. II. Nerve fibre changes. Brain 94, 
207-212. 
Colosimo, A., Goncz, K.K., Holmes, A.R., Kunzelmann, K., Novelli, G., Malone, R.W., 
Bennett, M.J., and Gruenert, D.C. (2000). Transfer and expression of foreign genes in 
mammalian cells. Biotechniques 29, 314-318, 320-312, 324 passim. 
Conner, S.D., and Schmid, S.L. (2003). Regulated portals of entry into the cell. Nature 
422, 37-44. 
CHAPTER VI⏐References 
161 
Contestabile, A. (2001). Oxidative stress in neurodegeneration: mechanisms and 
therapeutic perspectives. Curr Top Med Chem 1, 553-568. 
Costa, P.P., Figueira, A.S., and Bravo, F.R. (1978). Amyloid fibril protein related to 
prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 75, 4499-
4503. 
Costa, R., Ferreira-da-Silva, F., Saraiva, M.J., and Cardoso, I. (2008a). Transthyretin 
protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a 
mechanism sensitive to the Kunitz protease inhibitor. PLoS ONE 3, e2899. 
Costa, R., Goncalves, A., Saraiva, M.J., and Cardoso, I. (2008b). Transthyretin binding to 
A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582, 936-942. 
Coutinho, P., Martins Da Silva, A., Kopes Lima, J., and Resende Barbosa, A. (1980). 
Forty years of experience with type I amyloid neuropathy. Review of 483 cases. Amyloid 
and Amyloidosis, 88-98. 
Couto, L.B., and High, K.A. (2010). Viral vector-mediated RNA interference. Curr Opin 
Pharmacol 10, 534-542. 
Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. (2004). 
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. 
Science 305, 1292-1295. 
Damas, A.M., Ribeiro, S., Lamzin, V.S., Palha, J.A., and Saraiva, M.J. (1996). Structure of 
the Val122Ile variant transthyretin - a cardiomyopathic mutant. Acta Crystallogr D Biol 
Crystallogr 52, 966-972. 
Damas, A.M., and Saraiva, M.J. (2000). Review: TTR amyloidosis-structural features 
leading to protein aggregation and their implications on therapeutic strategies. J Struct 
Biol 130, 290-299. 
Davidoff, A.M., Gray, J.T., Ng, C.Y., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., and 
Nathwani, A.C. (2005). Comparison of the ability of adeno-associated viral vectors 
pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of 
the liver in murine and nonhuman primate models. Mol Ther 11, 875-888. 
Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, 
D.S., Vanier, M.T., and Walkley, S.U. (2009). Chronic cyclodextrin treatment of murine 
Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage 
and disease progression. PLoS ONE 4, e6951. 
Daya, S., and Berns, K.I. (2008). Gene Therapy Using Adeno-Associated Virus Vectors. 
Clinical Microbiology Reviews 21, 583-593. 
Dekki, N., Refai, E., Holmberg, R., Köhler, M., Jörnvall, H., Berggren, P.-O., and Juntti-
Berggren, L. (2011). Transthyretin binds to glucose-regulated proteins and is subjected to 
endocytosis by the pancreatic β-cell. Cell Mol Life Sci. 
Dember, L.M. (2005). Emerging treatment approaches for the systemic amyloidoses. 
Kidney Int 68, 1377-1390. 
CHAPTER VI⏐References 
162 
Dickson, P.W., Aldred, A.R., Marley, P.D., Bannister, D., and Schreiber, G. (1986). Rat 
choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). 
Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. J 
Biol Chem 261, 3475-3478. 
Dickson, P.W., Aldred, A.R., Menting, J.G., Marley, P.D., Sawyer, W.H., and Schreiber, G. 
(1987). Thyroxine transport in choroid plexus. J Biol Chem 262, 13907-13915. 
Dickson, P.W., Howlett, G.J., and Schreiber, G. (1985). Rat transthyretin (prealbumin). 
Molecular cloning, nucleotide sequence, and gene expression in liver and brain. J Biol 
Chem 260, 8214-8219. 
Ding, W., Zhang, L., Yan, Z., and Engelhardt, J.F. (2005). Intracellular trafficking of adeno-
associated viral vectors. Gene Ther 12, 873-880. 
Divino, C.M., and Schussler, G.C. (1990). Receptor-mediated uptake and internalization 
of transthyretin. J Biol Chem 265, 1425-1429. 
Dobrzynski, E., and Herzog, R.W. (2005). Tolerance induction by viral in vivo gene 
transfer. Clinical medicine & research 3, 234-240. 
Dobrzynski, E., Mingozzi, F., Liu, Y.L., Bendo, E., Cao, O., Wang, L., and Herzog, R.W. 
(2004). Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene 
transfer. Blood 104, 969-977. 
Dobson, C.M. (2003). Protein folding and misfolding. Nature 426, 884-890. 
Doherty, G.J., and Mcmahon, H.T. (2009). Mechanisms of endocytosis. Annu Rev 
Biochem 78, 857-902. 
Eneqvist, T., Lundberg, E., Nilsson, L., Abagyan, R., and Sauer-Eriksson, A.E. (2003). 
The transthyretin-related protein family. Eur J Biochem 270, 518-532. 
Episkopou, V., Maeda, S., Nishiguchi, S., Shimada, K., Gaitanaris, G.A., Gottesman, 
M.E., and Robertson, E.J. (1993). Disruption of the transthyretin gene results in mice with 
depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci U S A 90, 
2375-2379. 
Felding, P., and Fex, G. (1982). Cellular origin of prealbumin in the rat. Biochim Biophys 
Acta 716, 446-449. 
Ferguson, S.M., and De Camilli, P. (2012). Dynamin, a membrane-remodelling GTPase. 
Nat Rev Mol Cell Biol 13, 75-88. 
Ferrari, F.K., Samulski, T., Shenk, T., and Samulski, R.J. (1996). Second-strand synthesis 
is a rate-limiting step for efficient transduction by recombinant adeno-associated virus 
vectors. J Virol 70, 3227-3234. 
Ferreira, N., Cardoso, I., Domingues, M.R., Vitorino, R., Bastos, M., Bai, G., Saraiva, M.J., 
and Almeida, M.R. (2009). Binding of epigallocatechin-3-gallate to transthyretin modulates 
its amyloidogenicity. FEBS Letters 583, 3569-3576. 
Ferreira, N., Saraiva, M.J., and Almeida, M.R. (2011). Natural polyphenols inhibit different 
steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters 585, 
2424-2430. 
CHAPTER VI⏐References 
163 
Ferreira, N., Saraiva, M.J., and Almeida, M.R. (2012). Epigallocatechin-3-Gallate as a 
Potential Therapeutic Drug for TTR-Related Amyloidosis: "In Vivo" Evidence from FAP 
Mice Models. PLoS ONE 7, e29933. 
Fleming, C.E., Mar, F.M., Franquinho, F., Saraiva, M.J., and Sousa, M.M. (2009). 
Transthyretin internalization by sensory neurons is megalin mediated and necessary for 
its neuritogenic activity. J Neurosci 29, 3220-3232. 
Fleming, C.E., Saraiva, M.J., and Sousa, M.M. (2007). Transthyretin enhances nerve 
regeneration. Journal of Neurochemistry 103, 831-839. 
Flotte, T.R. (2004). Gene therapy progress and prospects: recombinant adeno-associated 
virus (rAAV) vectors. Gene Ther 11, 805-810. 
Fuentealba, R.A., Liu, Q., Zhang, J., Kanekiyo, T., Hu, X., Lee, J.-M., LaDu, M.J., and Bu, 
G. (2010). Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal 
Abeta42 uptake and lysosomal trafficking. PLoS ONE 5, e11884. 
Gajate, C., and Mollinedo, F. (2011). Lipid rafts and Fas/CD95 signaling in cancer 
chemotherapy. Recent Pat Anticancer Drug Discov 6, 274-283. 
George, K.S., and Wu, S. (2012). Lipid raft: A floating island of death or survival. Toxicol 
Appl Pharmacol 259, 311-319. 
Ghosh, P., Dahms, N.M., and Kornfeld, S. (2003). Mannose 6-phosphate receptors: new 
twists in the tale. Nat Rev Mol Cell Biol 4, 202-212. 
Golde, W.T., Gollobin, P., and Rodriguez, L.L. (2005). A rapid, simple, and humane 
method for submandibular bleeding of mice using a lancet. Lab Anim (NY) 34, 39-43. 
Goldsmith, B.M., and Munson, S. (1987). Rate nephelometry and radial immunodiffusion 
compared for measuring serum prealbumin. Clin Chem 33, 161-163. 
Griffin, B.A., Adams, S.R., Jones, J., and Tsien, R.Y. (2000). Fluorescent labeling of 
recombinant proteins in living cells with FlAsH. Meth Enzymol 327, 565-578. 
Griffin, B.A., Adams, S.R., and Tsien, R.Y. (1998). Specific covalent labeling of 
recombinant protein molecules inside live cells. Science 281, 269-272. 
Grimm, D., and Kay, M.A. (2003). From virus evolution to vector revolution: use of 
naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human 
gene therapy. Curr Gene Ther 3, 281-304. 
Haass, C., and Selkoe, D.J. (2007). Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112. 
Hagen, G.A., and Elliott, W.J. (1973). Transport of thyroid hormones in serum and 
cerebrospinal fluid. J Clin Endocrinol Metab 37, 415-422. 
Hamilton, J.A., Steinrauf, L.K., Braden, B.C., Liepnieks, J., Benson, M.D., Holmgren, G., 
Sandgren, O., and Steen, L. (1993). The x-ray crystal structure refinements of normal 
human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. J Biol 
Chem 268, 2416-2424. 
CHAPTER VI⏐References 
164 
Hammarstrom, P., Jiang, X., Hurshman, A.R., Powers, E.T., and Kelly, J.W. (2002). 
Sequence-dependent denaturation energetics: A major determinant in amyloid disease 
diversity. Proc Natl Acad Sci U S A 99 Suppl 4, 16427-16432. 
Hammarström, P., Schneider, F., and Kelly, J.W. (2001). Trans-suppression of misfolding 
in an amyloid disease. Science 293, 2459-2462. 
Hammarström, P., Sekijima, Y., White, J.T., Wiseman, R.L., Lim, A., Costello, C.E., 
Altland, K., Garzuly, F., Budka, H., and Kelly, J.W. (2003a). D18G transthyretin is 
monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a 
prescription for central nervous system amyloidosis? Biochemistry 42, 6656-6663. 
Hammarström, P., Wiseman, R.L., Powers, E.T., and Kelly, J.W. (2003b). Prevention of 
transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 
713-716. 
Harder, T., Scheiffele, P., Verkade, P., and Simons, K. (1998). Lipid domain structure of 
the plasma membrane revealed by patching of membrane components. J Cell Biol 141, 
929-942. 
Hennebry, S.C., Wright, H.M., Likic, V.A., and Richardson, S.J. (2006). Structural and 
functional evolution of transthyretin and transthyretin-like proteins. Proteins 64, 1024-
1045. 
Hille-Rehfeld, A. (1995). Mannose 6-phosphate receptors in sorting and transport of 
lysosomal enzymes. Biochim Biophys Acta 1241, 177-194. 
Hoffmann, C., Gaietta, G., Zürn, A., Adams, S.R., Terrillon, S., Ellisman, M.H., Tsien, 
R.Y., and Lohse, M.J. (2010). Fluorescent labeling of tetracysteine-tagged proteins in 
intact cells. Nat Protoc 5, 1666-1677. 
Hoggan, M.D., Blacklow, N.R., and Rowe, W.P. (1966). Studies of small DNA viruses 
found in various adenovirus preparations: physical, biological, and immunological 
characteristics. Proc Natl Acad Sci U S A 55, 1467-1474. 
Hollander, C.S., Odak, V.V., Prout, T.E., and Asper, S.P., Jr. (1962). An evaluation of the 
role of prealbumin in the binding of thyroxine. J Clin Endocrinol Metab 22, 617-622. 
Holmgren, G., Ericzon, B.G., Groth, C.G., Steen, L., Suhr, O., Andersen, O., Wallin, B.G., 
Seymour, A., Richardson, S., Hawkins, P.N., et al. (1993). Clinical improvement and 
amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. 
Lancet 341, 1113-1116. 
Hornberg, A., Eneqvist, T., Olofsson, A., Lundgren, E., and Sauer-Eriksson, A.E. (2000). 
A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol 
Biol 302, 649-669. 
Hou, X., Aguilar, M.-I., and Small, D.H. (2007). Transthyretin and familial amyloidotic 
polyneuropathy. Recent progress in understanding the molecular mechanism of 
neurodegeneration. FEBS J 274, 1637-1650. 
Hou, X., Mechler, A., Martin, L.L., Aguilar, M.-I., and Small, D.H. (2008). Cholesterol and 
anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid 
membranes. Biochim Biophys Acta 1778, 198-205. 
CHAPTER VI⏐References 
165 
Hou, X., Richardson, S.J., Aguilar, M.-I., and Small, D.H. (2005). Binding of amyloidogenic 
transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. 
Biochemistry 44, 11618-11627. 
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic 
Acids Res 37, 1-13. 
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57. 
Ingenbleek, Y., and Bernstein, L. (1999). The stressful condition as a nutritionally 
dependent adaptive dichotomy. Nutrition 15, 305-320. 
Ingenbleek, Y., and De Visscher, M. (1979). Hormonal and nutritional status: critical 
conditions for endemic goiter epidemiology? Metabolism 28, 9-19. 
Inoue, S., Kuroiwa, M., Saraiva, M.J., Guimaraes, A., and Kisilevsky, R. (1998). 
Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-
resolution electron microscopy. J Struct Biol 124, 1-12. 
Ivanov, A.I. (2008). Pharmacological inhibition of endocytic pathways: is it specific enough 
to be useful? Methods Mol Biol 440, 15-33. 
Jacobson, D.R., Alves, I.L., Saraiva, M.J., Thibodeau, S.N., and Buxbaum, J.N. (1995). 
Transthyretin Ser 6 gene frequency in individuals without amyloidosis. Hum Genet 95, 
308-312. 
Jacobson, D.R., McFarlin, D.E., Kane, I., and Buxbaum, J.N. (1992). Transthyretin Pro55, 
a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and 
neurologic involvement. Hum Genet 89, 353-356. 
Jacobson, D.R., Pastore, R.D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F.S., and 
Buxbaum, J.N. (1997). Variant-sequence transthyretin (isoleucine 122) in late-onset 
cardiac amyloidosis in black Americans. N Engl J Med 336, 466-473. 
Jacobsson, B. (1989). Localization of transthyretin-mRNA and of immunoreactive 
transthyretin in the human fetus. Virchows Arch A Pathol Anat Histopathol 415, 259-263. 
Johannes, L., and Popoff, V. (2008). Tracing the retrograde route in protein trafficking. 
Cell 135, 1175-1187. 
Johannes, L., and Romer, W. (2010). Shiga toxins--from cell biology to biomedical 
applications. Nat Rev Microbiol 8, 105-116. 
Kabat, E.A., Moore, D.H., and Landow, H. (1942). An Electrophoretic Study of the Protein 
Components in Cerebrospinal Fluid and Their Relationship to the Serum Proteins. J Clin 
Invest 21, 571-577. 
Kamata, M., Susanto, M.T., and Chen, I.S.Y. (2009). Enhanced transthyretin tetramer 
stability following expression of an amyloid disease transsuppressor variant in mammalian 
cells. J Gene Med 11, 103-111. 
Kanai, M., Raz, A., and Goodman, D.S. (1968). Retinol-binding protein: the transport 
protein for vitamin A in human plasma. J Clin Invest 47, 2025-2044. 
CHAPTER VI⏐References 
166 
Kanda, Y., Goodman, D.S., Canfield, R.E., and Morgan, F.J. (1974). The amino acid 
sequence of human plasma prealbumin. J Biol Chem 249, 6796-6805. 
Kanekiyo, T., and Bu, G. (2009). Receptor-associated protein interacts with amyloid-beta 
peptide and promotes its cellular uptake. J Biol Chem 284, 33352-33359. 
Kanekiyo, T., Zhang, J., Liu, Q., Liu, C.-C., Zhang, L., and Bu, G. (2011). Heparan 
sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute 
major pathways for neuronal amyloid-beta uptake. J Neurosci 31, 1644-1651. 
Kaspar, B.K., Vissel, B., Bengoechea, T., Crone, S., Randolph-Moore, L., Muller, R., 
Brandon, E.P., Schaffer, D., Verma, I.M., Lee, K.F., et al. (2002). Adeno-associated virus 
effectively mediates conditional gene modification in the brain. Proc Natl Acad Sci U S A 
99, 2320-2325. 
Kay, M.A. (2011). State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 
12, 316-328. 
Kirchhausen, T., Macia, E., and Pelish, H.E. (2008). Use of dynasore, the small molecule 
inhibitor of dynamin, in the regulation of endocytosis. Meth Enzymol 438, 77-93. 
Kirik, D., and Björklund, A. (2003). Modeling CNS neurodegeneration by overexpression 
of disease-causing proteins using viral vectors. Trends Neurosci 26, 386-392. 
Kisilevsky, R. (2000). Review: amyloidogenesis-unquestioned answers and unanswered 
questions. J Struct Biol 130, 99-108. 
Klein, R.L., Dayton, R.D., Lin, W.L., and Dickson, D.W. (2005). Tau gene transfer, but not 
alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational 
behavior in the rat. Neurobiol Dis 20, 64-73. 
Kluve-Beckerman, B., Manaloor, J.J., and Liepnieks, J.J. (2002). A pulse-chase study 
tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular 
amyloid. Arthritis Rheum 46, 1905-1913. 
Kohno, K., Palha, J.A., Miyakawa, K., Saraiva, M.J., Ito, S., Mabuchi, T., Blaner, W.S., 
Iijima, H., Tsukahara, S., Episkopou, V., et al. (1997). Analysis of amyloid deposition in a 
transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 
150, 1497-1508. 
Kubota, H. (2009). Quality control against misfolded proteins in the cytosol: a network for 
cell survival. J Biochem 146, 609-616. 
Kuchler-Bopp, S., Dietrich, J.B., Zaepfel, M., and Delaunoy, J.P. (2000). Receptor-
mediated endocytosis of transthyretin by ependymoma cells. Brain Res 870, 185-194. 
LaFerla, F.M., Green, K.N., and Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer's 
disease. Nat Rev Neurosci 8, 499-509. 
Lai, A.Y., and Mclaurin, J. (2010). Mechanisms of amyloid-Beta Peptide uptake by 
neurons: the role of lipid rafts and lipid raft-associated proteins. International Journal of 
Alzheimer's Disease vol 2011 Article ID 548380. 
Lentz, T.B., Gray, S.J., and Samulski, R.J. (2012). Viral vectors for gene delivery to the 
central nervous system. Neurobiol Dis 48, 179-188. 
CHAPTER VI⏐References 
167 
Li, H., Murphy, S.L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M.O., High, 
K.A., and Ertl, H.C. (2007). Pre-existing AAV capsid-specific CD8+ T cells are unable to 
eliminate AAV-transduced hepatocytes. Mol Ther 15, 792-800. 
Linden, R.M., and Berns, K.I. (2000). Molecular biology of adeno-associated viruses. 
Contrib Microbiol 4, 68-84. 
Liz, M.A., Faro, C.J., Saraiva, M.J., and Sousa, M.M. (2004). Transthyretin, a new cryptic 
protease. J Biol Chem 279, 21431-21438. 
Liz, M.A., Fleming, C.E., Nunes, A.F., Almeida, M.R., Mar, F.M., Choe, Y., Craik, C.S., 
Powers, J.C., Bogyo, M., and Sousa, M.M. (2009). Substrate specificity of transthyretin: 
identification of natural substrates in the nervous system. Biochem J 419, 467-474. 
Liz, M.A., Gomes, C.M., Saraiva, M.J., and Sousa, M.M. (2007). ApoA-I cleaved by 
transthyretin has reduced ability to promote cholesterol efflux and increased 
amyloidogenicity. J Lipid Res 48, 2385-2395. 
Liz, M.A., Leite, S.C., Juliano, L., Saraiva, M.J., Damas, A.M., Bur, D., and Sousa, M.M. 
(2012). Transthyretin is a metallopeptidase with an inducible active site. Biochem J 443, 
769-778. 
Lux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., 
Kofler, D.M., Finke, S., Hallek, M., et al. (2005). Green fluorescent protein-tagged adeno-
associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 79, 
11776-11787. 
Määttänen, P., Gehring, K., Bergeron, J.J.M., and Thomas, D.Y. (2010). Protein quality 
control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol 21, 500-511. 
Macedo, B., Batista, A.R., do Amaral, J.B., and Saraiva, M.J. (2007). Biomarkers in the 
assessment of therapies for familial amyloidotic polyneuropathy. Mol Med 13, 584-591. 
Macedo, B., Batista, A.R., Ferreira, N., Almeida, M.R., and Saraiva, M.J. (2008). Anti-
apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of 
Familial Amyloidotic Polyneuropathy. Biochimica et Biophysica Acta (BBA) - Molecular 
Basis of Disease 1782, 517-522. 
Macedo, B., Magalhães, J., Batista, A.R., and Saraiva, M.J. (2010). Carvedilol treatment 
reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. 
Pharmacol Res 62, 514-522. 
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., and Kirchhausen, T. (2006). 
Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10, 839-850. 
Magalhães, J. (2011). Counteracting toxicity in misfolding disorders: the case of Familial 
Amyloidotic Polyneuropathy. PhD Thesis (Universidade do Porto). 
Magnus, J.H., Stenstad, T., Kolset, S.O., and Husby, G. (1991). Glycosaminoglycans in 
extracts of cardiac amyloid fibrils from familial amyloid cardiomyopathy of Danish origin 
related to variant transthyretin Met 111. Scand J Immunol 34, 63-69. 
CHAPTER VI⏐References 
168 
Makover, A., Moriwaki, H., Ramakrishnan, R., Saraiva, M.J., Blaner, W.S., and Goodman, 
D.S. (1988). Plasma transthyretin. Tissue sites of degradation and turnover in the rat. J 
Biol Chem 263, 8598-8603. 
Malentacchi, F., Forni, G., Vinci, S., and Orlando, C. (2009). Quantitative evaluation of 
DNA methylation by optimization of a differential-high resolution melt analysis protocol. 
Nucleic Acids Res 37, e86. 
Mali, Y., and Zisapels, N. (2008). Gain of interaction of ALS-linked G93A superoxide 
dismutase with cytosolic malate dehydrogenase. Neurobiol Dis 32, 133-141. 
Mandrekar, S., Jiang, Q., Lee, C.Y.D., Koenigsknecht-Talboo, J., Holtzman, D.M., and 
Landreth, G.E. (2009). Microglia mediate the clearance of soluble Abeta through fluid 
phase macropinocytosis. J Neurosci 29, 4252-4262. 
Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Rasko, J., 
Ozelo, M.C., Hoots, K., Blatt, P., et al. (2006). Successful transduction of liver in 
hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat 
Med 12, 342-347. 
Martone, R.L., Herbert, J., Dwork, A., and Schon, E.A. (1988). Transthyretin is 
synthesized in the mammalian eye. Biochem Biophys Res Commun 151, 905-912. 
Mccarty, D.M., Fu, H., Monahan, P.E., Toulson, C.E., Naik, P., and Samulski, R.J. (2003). 
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary 
vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10, 2112-
2118. 
McCarty, D.M., Monahan, P.E., and Samulski, R.J. (2001). Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 
independently of DNA synthesis. Gene Ther 8, 1248-1254. 
McCarty, D.M., Young, S.M., Jr., and Samulski, R.J. (2004). Integration of adeno-
associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38, 819-845. 
McIntosh, J., Lenting, P.J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., 
Tuddenham, E.G., Christophe, O.D., McVey, J.H., et al. (2013). Therapeutic levels of FVIII 
following a single peripheral vein administration of rAAV vector encoding a novel human 
factor VIII variant. Blood 121, 3335-3344. 
McKenna, M.C., Waagepetersen, H.S., Schousboe, A., and Sonnewald, U. (2006). 
Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of 
reducing equivalents: current evidence and pharmacological tools. Biochem Pharmacol 
71, 399-407. 
McKinnon, B., Li, H., Richard, K., and Mortimer, R. (2005). Synthesis of thyroid hormone 
binding proteins transthyretin and albumin by human trophoblast. J Clin Endocrinol Metab 
90, 6714-6720. 
Merlini, G., Ascari, E., Amboldi, N., Bellotti, V., Arbustini, E., Perfetti, V., Ferrari, M., 
Zorzoli, I., Marinone, M.G., Garini, P., et al. (1995). Interaction of the anthracycline 4'-
iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl 
Acad Sci U S A 92, 2959-2963. 
CHAPTER VI⏐References 
169 
Mingozzi, F., and High, K.A. (2007). Immune responses to AAV in clinical trials. Current 
gene therapy 7, 316-324. 
Mingozzi, F., and High, K.A. (2011). Therapeutic in vivo gene transfer for genetic disease 
using AAV: progress and challenges. Nat Rev Genet 12, 341-355. 
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., 
High, K.A., and Herzog, R.W. (2003). Induction of immune tolerance to coagulation factor 
IX antigen by in vivo hepatic gene transfer. J Clin Invest 111, 1347-1356. 
Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E.J., Ragni, 
M.V., Manno, C.S., Sommer, J., Jiang, H., et al. (2007). CD8(+) T-cell responses to 
adeno-associated virus capsid in humans. Nat Med 13, 419-422. 
Miroy, G.J., Lai, Z., Lashuel, H.A., Peterson, S.A., Strang, C., and Kelly, J.W. (1996). 
Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci 
U S A 93, 15051-15056. 
Mitsuhashi, S., Yazaki, M., Tokuda, T., Sekijima, Y., Washimi, Y., Shimizu, Y., Ando, Y., 
Benson, M.D., and Ikeda, S.-I. (2005). Biochemical characteristics of variant transthyretins 
causing hereditary leptomeningeal amyloidosis. Amyloid 12, 216-225. 
Mohamed, A., and Posse De Chaves, E. (2011). Aβ internalization by neurons and glia. 
International Journal of Alzheimer's Disease vol 2011 Article ID 127984. 
Monaco, H.L. (2000). The transthyretin-retinol-binding protein complex. Biochim Biophys 
Acta 1482, 65-72. 
Monaco, H.L., Rizzi, M., and Coda, A. (1995). Structure of a complex of two plasma 
proteins: transthyretin and retinol-binding protein. Science 268, 1039-1041. 
Monteiro, F.A., Cardoso, I., Sousa, M.M., and Saraiva, M.J. (2006a). In vitro inhibition of 
transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the 
soluble receptor for advanced glycation end products (RAGE). FEBS Letters 580, 3451-
3456. 
Monteiro, F.A., Sousa, M.M., Cardoso, I., do Amaral, J.B., Guimarães, A., and Saraiva, 
M.J. (2006b). Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. 
Journal of Neurochemistry 97, 151-161. 
Murakami, T., Ohsawa, Y., and Sunada, Y. (2008). The transthyretin gene is expressed in 
human and rodent dorsal root ganglia. Neurosci Lett 436, 335-339. 
Murakami, T., Ohsawa, Y., Zhenghua, L., Yamamura, K., and Sunada, Y. (2010). The 
transthyretin gene is expressed in Schwann cells of peripheral nerves. Brain Res 1348, 
222-225. 
Murakami, T., Yasuda, Y., Mita, S., Maeda, S., Shimada, K., Fujimoto, T., and Araki, S. 
(1987). Prealbumin gene expression during mouse development studied by in situ 
hybridization. Cell Differ 22, 1-9. 
Myron Johnson, A., Merlini, G., Sheldon, J., and Ichihara, K. (2007). Clinical indications 
for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. 
Clin Chem Lab Med 45, 419-426. 
CHAPTER VI⏐References 
170 
Nagata, Y., Tashiro, F., Yi, S., Murakami, T., Maeda, S., Takahashi, K., Shimada, K., 
Okamura, H., and Yamamura, K. (1995). A 6-kb upstream region of the human 
transthyretin gene can direct developmental, tissue-specific, and quantitatively normal 
expression in transgenic mouse. J Biochem 117, 169-175. 
Naiki, H., and Gejyo, F. (1999). Kinetic analysis of amyloid fibril formation. Methods 
Enzymol 309, 305-318. 
Nakai, H., Fuess, S., Storm, T.A., Muramatsu, S., Nara, Y., and Kay, M.A. (2005). 
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in 
mice. J Virol 79, 214-224. 
Nakamura, M., Ando, Y., Nagahara, S., Sano, A., Ochiya, T., Maeda, S., Kawaji, T., 
Ogawa, M., Hirata, A., Terazaki, H., et al. (2004). Targeted conversion of the transthyretin 
gene in vitro and in vivo. Gene Ther 11, 838-846. 
Nakamura, Y., Yutani, C., Nakazato, M., Date, Y., Baba, T., and Goto, Y. (1999). A case 
of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less 
polyneuropathy, and the presence of giant cells. Pathol Int 49, 898-902. 
Nascimento-Ferreira, I., Santos-Ferreira, T., Sousa-Ferreira, L., Auregan, G., Onofre, I., 
Alves, S., Dufour, N., Colomer Gould, V.F., Koeppen, A., Deglon, N., et al. (2011). 
Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates 
Machado-Joseph disease. Brain 134, 1400-1415. 
Nathwani, A.C., Cochrane, M., McIntosh, J., Ng, C.Y., Zhou, J., Gray, J.T., and Davidoff, 
A.M. (2009). Enhancing transduction of the liver by adeno-associated viral vectors. Gene 
Ther 16, 60-69. 
Nathwani, A.C., Gray, J.T., Ng, C.Y., Zhou, J., Spence, Y., Waddington, S.N., 
Tuddenham, E.G., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006). Self-
complementary adeno-associated virus vectors containing a novel liver-specific human 
factor IX expression cassette enable highly efficient transduction of murine and nonhuman 
primate liver. Blood 107, 2653-2661. 
Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., 
Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. (2011). Adenovirus-associated 
virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365, 2357-2365. 
Nayak, S., and Herzog, R.W. (2010). Progress and prospects: immune responses to viral 
vectors. Gene Ther 17, 295-304. 
Nilsson, S.F., Rask, L., and Peterson, P.A. (1975). Studies on thyroid hormone-binding 
proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to 
prealbumin and effects of thyroxine on prealbumin subunit self association. J Biol Chem 
250, 8554-8563. 
Nonnenmacher, M., and Weber, T. (2011). Adeno-associated virus 2 infection requires 
endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10, 563-576. 
Nonnenmacher, M., and Weber, T. (2012). Intracellular transport of recombinant adeno-
associated virus vectors. Gene Ther 19, 649-658. 
CHAPTER VI⏐References 
171 
Nordlie, M., Sletten, K., Husby, G., and Ranlov, P.J. (1988). A new prealbumin variant in 
familial amyloid cardiomyopathy of Danish origin. Scand J Immunol 27, 119-122. 
Nunes, A.F., Saraiva, M.J., and Sousa, M.M. (2006). Transthyretin knockouts are a new 
mouse model for increased neuropeptide Y. FASEB J 20, 166-168. 
Obici, L., Cortese, A., Lozza, A., Lucchetti, J., Gobbi, M., Palladini, G., Perlini, S., Saraiva, 
M.J., and Merlini, G. (2012). Doxycycline plus tauroursodeoxycholic acid for transthyretin 
amyloidosis: a phase II study. Amyloid 19 Suppl 1, 34-36. 
Oliveira, S.M., Cardoso, I., and Saraiva, M.J. (2012). Transthyretin: roles in the nervous 
system beyond thyroxine and retinol transport. Expert Review of Endocrinology & 
Metabolism 7, 181-189. 
Oliveira, S.M., Ribeiro, C.A., Cardoso, I., and Saraiva, M.J. (2011). Gender-dependent 
transthyretin modulation of brain amyloid-β levels: evidence from a mouse model of 
Alzheimer's disease. Journal of Alzheimer's disease : JAD 27, 429-439. 
Omtri, R.S., Davidson, M.W., Arumugam, B., Poduslo, J.F., and Kandimalla, K.K. (2012). 
Differences in the Cellular Uptake and Intracellular Itineraries of Amyloid Beta Proteins 40 
and 42: Ramifications for the Alzheimer's Drug Discovery. Mol Pharmaceutics. 
Palha, J.A. (2002). Transthyretin as a thyroid hormone carrier: function revisited. Clin 
Chem Lab Med 40, 1292-1300. 
Palha, J.A., Episkopou, V., Maeda, S., Shimada, K., Gottesman, M.E., and Saraiva, M.J. 
(1994). Thyroid hormone metabolism in a transthyretin-null mouse strain. J Biol Chem 
269, 33135-33139. 
Palha, J.A., Fernandes, R., de Escobar, G.M., Episkopou, V., Gottesman, M., and 
Saraiva, M.J. (2000). Transthyretin regulates thyroid hormone levels in the choroid plexus, 
but not in the brain parenchyma: study in a transthyretin-null mouse model. Endocrinology 
141, 3267-3272. 
Palha, J.A., Hays, M.T., Morreale de Escobar, G., Episkopou, V., Gottesman, M.E., and 
Saraiva, M.J. (1997). Transthyretin is not essential for thyroxine to reach the brain and 
other tissues in transthyretin-null mice. Am J Physiol 272, E485-493. 
Parekh, R.B., Dwek, R.A., Thomas, J.R., Opdenakker, G., Rademacher, T.W., Wittwer, 
A.J., Howard, S.C., Nelson, R., Siegel, N.R., Jennings, M., et al. (1989). Cell-type-specific 
and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. 
Biochemistry 28, 7644-7662. 
Parekh, R.B., Tse, A.G., Dwek, R.A., Williams, A.F., and Rademacher, T.W. (1987). 
Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin 
recognition of rat Thy-1. EMBO J 6, 1233-1244. 
Pepys, M.B. (2001). Pathogenesis, diagnosis and treatment of systemic amyloidosis. 
Philos Trans R Soc Lond B Biol Sci 356, 203-210; discussion 210-201. 
Peterson, P.A., Nilsson, S.F., Ostberg, L., Rask, L., and Vahlquist, A. (1974). Aspects of 
the metabolism of retinol-binding protein and retinol. Vitam Horm 32, 181-214. 
CHAPTER VI⏐References 
172 
Pinton, P., Giorgi, C., Siviero, R., Zecchini, E., and Rizzuto, R. (2008). Calcium and 
apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 27, 
6407-6418. 
Planté-Bordeneuve, V., and Said, G. (2011). Familial amyloid polyneuropathy. Lancet 
Neurol 10, 1086-1097. 
Pokrzywa, M., Dacklin, I., Hultmark, D., and Lundgren, E. (2007). Misfolded transthyretin 
causes behavioral changes in a Drosophila model for transthyretin-associated 
amyloidosis. Eur J Neurosci 26, 913-924. 
Power, D.M., Elias, N.P., Richardson, S.J., Mendes, J., Soares, C.M., and Santos, C.R. 
(2000). Evolution of the thyroid hormone-binding protein, transthyretin. Gen Comp 
Endocrinol 119, 241-255. 
Puchtler, H., and Sweat, F. (1965). Congo red as a stain for fluorescence microscopy of 
amyloid. J Histochem Cytochem 13, 693-694. 
Quintas, A., Vaz, D.C., Cardoso, I., Saraiva, M.J., and Brito, R.M. (2001). Tetramer 
dissociation and monomer partial unfolding precedes protofibril formation in 
amyloidogenic transthyretin variants. J Biol Chem 276, 27207-27213. 
Raz, A., and Goodman, D.S. (1969). The interaction of thyroxine with human plasma 
prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 244, 
3230-3237. 
Redondo, C., Damas, A.M., and Saraiva, M.J. (2000). Designing transthyretin mutants 
affecting tetrameric structure: implications in amyloidogenicity. Biochem J 348 Pt 1, 167-
172. 
Reed, G.H., Kent, J.O., and Wittwer, C.T. (2007). High-resolution DNA melting analysis 
for simple and efficient molecular diagnostics. Pharmacogenomics 8, 597-608. 
Reed, G.H., and Wittwer, C.T. (2004). Sensitivity and specificity of single-nucleotide 
polymorphism scanning by high-resolution melting analysis. Clin Chem 50, 1748-1754. 
Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W., and Buxbaum, J.N. (2004). Tissue 
damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the 
major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101, 2817-2822. 
Rejman, J., Oberle, V., Zuhorn, I.S., and Hoekstra, D. (2004). Size-dependent 
internalization of particles via the pathways of clathrin- and caveolae-mediated 
endocytosis. Biochem J 377, 159-169. 
Renko, M., Požgan, U., Majera, D., and Turk, D. (2010). Stefin A displaces the occluding 
loop of cathepsin B only by as much as required to bind to the active site cleft. FEBS J 
277, 4338-4345. 
Ribeiro, C.A., Santana, I., Oliveira, C., Baldeiras, I., Moreira, J., Saraiva, M.J., and 
Cardoso, I. (2012). Transthyretin decrease in plasma of MCI and AD patients: 
investigation of mechanisms for disease modulation. Curr Alzheimer Res 9, 881-889. 
Rodriguez-Boulan, E., and Musch, A. (2005). Protein sorting in the Golgi complex: shifting 
paradigms. Biochim Biophys Acta 1744, 455-464. 
CHAPTER VI⏐References 
173 
Rogers, J. (1995). Inflammation as a pathogenic mechanism in Alzheimer's disease. 
Arzneimittelforschung 45, 439-442. 
Rüggeberg, S., Horn, P., Li, X., Vajkoczy, P., and Franz, T. (2008). Detection of a gamma-
carboxy-glutamate as novel post-translational modification of human transthyretin. Protein 
Pept Lett 15, 43-46. 
Ruiz-Canada, C., Kelleher, D.J., and Gilmore, R. (2009). Cotranslational and 
posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. 
Cell 136, 272-283. 
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., 
Currier, T., Thiagarajan, M., et al. (2003). TM4: a free, open-source system for microarray 
data management and analysis. BioTechniques 34, 374-378. 
Said, G., Grippon, S., and Kirkpatrick, P. (2012). Tafamidis. Nat Rev Drug Discov 11, 185-
186. 
Samulski, R.J., Berns, K.I., Tan, M., and Muzyczka, N. (1982). Cloning of adeno-
associated virus into pBR322: rescue of intact virus from the recombinant plasmid in 
human cells. Proc Natl Acad Sci U S A 79, 2077-2081. 
Samulski, R.J., Chang, L.S., and Shenk, T. (1989). Helper-free stocks of recombinant 
adeno-associated viruses: normal integration does not require viral gene expression. J 
Virol 63, 3822-3828. 
Sandwall, E., O'Callaghan, P., Zhang, X., Lindahl, U., Lannfelt, L., and Li, J.P. (2010). 
Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology 20, 
533-541. 
Santos, S.D., Cardoso, I., Magalhães, J., and Saraiva, M.J. (2007). Impairment of the 
ubiquitin-proteasome system associated with extracellular transthyretin aggregates in 
familial amyloidotic polyneuropathy. J Pathol 213, 200-209. 
Santos, S.D., Fernandes, R., and Saraiva, M.J. (2010a). The heat shock response 
modulates transthyretin deposition in the peripheral and autonomic nervous systems. 
Neurobiol Aging 31, 280-289. 
Santos, S.D., Lambertsen, K.L., Clausen, B.H., Akinc, A., Alvarez, R., Finsen, B., and 
Saraiva, M.J. (2010b). CSF transthyretin neuroprotection in a mouse model of brain 
ischemia. Journal of Neurochemistry 115, 1434-1444. 
Santos, S.D., Magalhães, J., and Saraiva, M.J. (2008). Activation of the heat shock 
response in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 67, 449-455. 
Saraiva, M.J. (2001). Transthyretin mutations in hyperthyroxinemia and amyloid diseases. 
Hum Mutat 17, 493-503. 
Saraiva, M.J. (2002). Hereditary transthyretin amyloidosis: molecular basis and 
therapeutical strategies. Expert Rev Mol Med 4, 1-11. 
Saraiva, M.J., Birken, S., Costa, P.P., and Goodman, D.S. (1984). Amyloid fibril protein in 
familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality 
in transthyretin (prealbumin). J Clin Invest 74, 104-119. 
CHAPTER VI⏐References 
174 
Saraiva, M.J., Costa, P.P., and Goodman, D.S. (1985). Biochemical marker in familial 
amyloidotic polyneuropathy, Portuguese type. Family studies on the transthyretin 
(prealbumin)-methionine-30 variant. J Clin Invest 76, 2171-2177. 
Saraiva, M.J., Magalhaes, J., Ferreira, N., and Almeida, M.R. (2012). Transthyretin 
deposition in familial amyloidotic polyneuropathy. Curr Med Chem 19, 2304-2311. 
Sasaki, H., Nakazato, M., Saraiva, M.J., Matsuo, H., and Sakaki, Y. (1989). Activity of a 
metallothionein-transthyretin fusion gene in transgenic mice. Possible effect of plasmid 
sequences on tissue-specific expression. Mol Biol Med 6, 345-353. 
Sasaki, H., Sakaki, Y., Matsuo, H., Goto, I., Kuroiwa, Y., Sahashi, I., Takahashi, A., 
Shinoda, T., Isobe, T., and Takagi, Y. (1984). Diagnosis of familial amyloidotic 
polyneuropathy by recombinant DNA techniques. Biochem Biophys Res Commun 125, 
636-642. 
Sasaki, H., Tone, S., Nakazato, M., Yoshioka, K., Matsuo, H., Kato, Y., and Sakaki, Y. 
(1986). Generation of transgenic mice producing a human transthyretin variant: a possible 
mouse model for familial amyloidotic polyneuropathy. Biochem Biophys Res Commun 
139, 794-799. 
Sasaki, H., Yoshioka, N., Takagi, Y., and Sakaki, Y. (1985). Structure of the chromosomal 
gene for human serum prealbumin. Gene 37, 191-197. 
Sato, T., Ando, Y., Susuki, S., Mikami, F., Ikemizu, S., Nakamura, M., Suhr, O., Anraku, 
M., Kai, T., Suico, M.A., et al. (2006). Chromium(III) ion and thyroxine cooperate to 
stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS 
Lett 580, 491-496. 
Sato, T., Sako, Y., Sho, M., Momohara, M., Suico, M.A., Shuto, T., Nishitoh, H., 
Okiyoneda, T., Kokame, K., Kaneko, M., et al. (2012). STT3B-Dependent 
Posttranslational N-Glycosylation as a Surveillance System for Secretory Protein. 
Molecular Cell 47, 99-110. 
Sato, T., Susuki, S., Suico, M.A., Miyata, M., Ando, Y., Mizuguchi, M., Takeuchi, M., 
Dobashi, M., Shuto, T., and Kai, H. (2007). Endoplasmic reticulum quality control 
regulates the fate of transthyretin variants in the cell. EMBO J 26, 2501-2512. 
Schaffer, D.V., Koerber, J.T., and Lim, K.-i. (2008). Molecular engineering of viral gene 
delivery vehicles. Annu Rev Biomed Eng 10, 169-194. 
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., 
Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source 
platform for biological-image analysis. Nat Methods 9, 676-682. 
Schreiber, G., and Richardson, S.J. (1997). The evolution of gene expression, structure 
and function of transthyretin. Comp Biochem Physiol B Biochem Mol Biol 116, 137-160. 
Schwarzman, A.L., Gregori, L., Vitek, M.P., Lyubski, S., Strittmatter, W.J., Enghilde, J.J., 
Bhasin, R., Silverman, J., Weisgraber, K.H., Coyle, P.K., et al. (1994). Transthyretin 
sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S 
A 91, 8368-8372. 
CHAPTER VI⏐References 
175 
Sebastiao, M.P., Lamzin, V., Saraiva, M.J., and Damas, A.M. (2001). Transthyretin 
stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol 
306, 733-744. 
Sebastiao, M.P., Merlini, G., Saraiva, M.J., and Damas, A.M. (2000). The molecular 
interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' 
oligomer leading to disaggregation. Biochem J 351, 273-279. 
Sebastiao, M.P., Saraiva, M.J., and Damas, A.M. (1998). The crystal structure of 
amyloidogenic Leu55 --> Pro transthyretin variant reveals a possible pathway for 
transthyretin polymerization into amyloid fibrils. J Biol Chem 273, 24715-24722. 
Seibert, F.B., and Nelson, J.W. (1942). Electrophoretic study of the blood protein 
response in tuberculosis. J Biol Chem 143, 29-38. 
Sekijima, Y., Dendle, M.A., and Kelly, J.W. (2006). Orally administered diflunisal stabilizes 
transthyretin against dissociation required for amyloidogenesis. Amyloid 13, 236-249. 
Sekijima, Y., Hammarström, P., Matsumura, M., Shimizu, Y., Iwata, M., Tokuda, T., Ikeda, 
S.-I., and Kelly, J.W. (2003). Energetic characteristics of the new transthyretin variant 
A25T may explain its atypical central nervous system pathology. Lab Invest 83, 409-417. 
Sekijima, Y., Kelly, J.W., and Ikeda, S. (2008). Pathogenesis of and therapeutic strategies 
to ameliorate the transthyretin amyloidoses. Curr Pharm Des 14, 3219-3230. 
Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarström, P., Miller, S.R., Sawkar, A.R., 
Balch, W.E., and Kelly, J.W. (2005). The biological and chemical basis for tissue-selective 
amyloid disease. Cell 121, 73-85. 
Selkoe, D.J. (2003). Folding proteins in fatal ways. Nature 426, 900-904. 
Sena-Esteves, M., Tebbets, J.C., Steffens, S., Crombleholme, T., and Flake, A.W. (2004). 
Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol 
Methods 122, 131-139. 
Senut, M.C., Suhr, S.T., Kaspar, B., and Gage, F.H. (2000). Intraneuronal aggregate 
formation and cell death after viral expression of expanded polyglutamine tracts in the 
adult rat brain. J Neurosci 20, 219-229. 
Serot, J.M., Christmann, D., Dubost, T., and Couturier, M. (1997). Cerebrospinal fluid 
transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatr 63, 
506-508. 
Shental-Bechor, D., and Levy, Y. (2008). Effect of glycosylation on protein folding: a close 
look at thermodynamic stabilization. Proc Natl Acad Sci U S A 105, 8256-8261. 
Sherman, M.Y., and Goldberg, A.L. (2001). Cellular defenses against unfolded proteins: a 
cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32. 
Shi, Q., Xu, H., Kleinman, W.A., and Gibson, G.E. (2008). Novel functions of the alpha-
ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in 
mitochondrial enzymes associated with Alzheimer's disease. Biochim Biophys Acta 1782, 
229-238. 
CHAPTER VI⏐References 
176 
Shore, G.C., Papa, F.R., and Oakes, S.A. (2011). Signaling cell death from the 
endoplasmic reticulum stress response. Curr Opin Cell Biol 23, 143-149. 
Simon, R., Lam, A., Li, M.C., Ngan, M., Menenzes, S., and Zhao, Y. (2007). Analysis of 
gene expression data using BRB-ArrayTools. Cancer Inform 3, 11-17. 
Simonato, M., Bennett, J., Boulis, N.M., Castro, M.G., Fink, D.J., Goins, W.F., Gray, S.J., 
Lowenstein, P.R., Vandenberghe, L.H., Wilson, T.J., et al. (2013). Progress in gene 
therapy for neurological disorders. Nat Rev Neurol 9, 277-291. 
Snyder, R.O., Miao, C., Meuse, L., Tubb, J., Donahue, B.A., Lin, H.F., Stafford, D.W., 
Patel, S., Thompson, A.R., Nichols, T., et al. (1999). Correction of hemophilia B in canine 
and murine models using recombinant adeno-associated viral vectors. Nat Med 5, 64-70. 
Soares, M.L., Centola, M., Chae, J., Saraiva, M.J., and Kastner, D.L. (2003). Human 
transthyretin intronic open reading frames are not independently expressed in vivo or part 
of functional transcripts. Biochim Biophys Acta 1626, 65-74. 
Socolow, E.L., Woeber, K.A., Purdy, R.H., Holloway, M.T., and Ingbar, S.H. (1965). 
Preparation of I-131-labeled human serum prealbumin and its metabolism in normal and 
sick patients. J Clin Invest 44, 1600-1609. 
Sonntag, F., Kother, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., 
Gerlach, B., Bottcher, B., Muller, O.J., et al. (2011). The assembly-activating protein 
promotes capsid assembly of different adeno-associated virus serotypes. J Virol 85, 
12686-12697. 
Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor promotes 
AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 107, 10220-10225. 
Soprano, D.R., Herbert, J., Soprano, K.J., Schon, E.A., and Goodman, D.S. (1985). 
Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. 
J Biol Chem 260, 11793-11798. 
Soprano, D.R., Soprano, K.J., and Goodman, D.S. (1986). Retinol-binding protein and 
transthyretin mRNA levels in visceral yolk sac and liver during fetal development in the rat. 
Proc Natl Acad Sci U S A 83, 7330-7334. 
Sörgjerd, K., Ghafouri, B., Jonsson, B.-H., Kelly, J.W., Blond, S.Y., and Hammarström, P. 
(2006). Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 
mitigates amyloidogenesis. J Mol Biol 356, 469-482. 
Sousa, J.C., Cardoso, I., Marques, F., Saraiva, M.J., and Palha, J.A. (2007a). 
Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 28, 713-718. 
Sousa, J.C., Grandela, C., Fernández-Ruiz, J., De Miguel, R., De Sousa, L., Magalhães, 
A.I., Saraiva, M.J., Sousa, N., and Palha, J.A. (2004). Transthyretin is involved in 
depression-like behaviour and exploratory activity. Journal of Neurochemistry 88, 1052-
1058. 
Sousa, J.C., Marques, F., Dias-Ferreira, E., Cerqueira, J.J., Sousa, N., and Palha, J.A. 
(2007b). Transthyretin influences spatial reference memory. Neurobiol Learn Mem 88, 
381-385. 
CHAPTER VI⏐References 
177 
Sousa, M.M., Berglund, L., and Saraiva, M.J. (2000a). Transthyretin in high density 
lipoproteins: association with apolipoprotein A-I. J Lipid Res 41, 58-65. 
Sousa, M.M., Cardoso, I., Fernandes, R., Guimarães, A., and Saraiva, M.J. (2001a). 
Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence 
for toxicity of nonfibrillar aggregates. Am J Pathol 159, 1993-2000. 
Sousa, M.M., do Amaral, J.B., Guimarães, A., and Saraiva, M.J. (2005). Up-regulation of 
the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated 
lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 19, 
124-126. 
Sousa, M.M., Du Yan, S., Fernandes, R., Guimaraes, A., Stern, D., and Saraiva, M.J. 
(2001b). Familial amyloid polyneuropathy: receptor for advanced glycation end products-
dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21, 
7576-7586. 
Sousa, M.M., Fernandes, R., Palha, J.A., Taboada, A., Vieira, P., and Saraiva, M.J. 
(2002). Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin 
Leu55Pro. Am J Pathol 161, 1935-1948. 
Sousa, M.M., Norden, A.G., Jacobsen, C., Willnow, T.E., Christensen, E.I., Thakker, R.V., 
Verroust, P.J., Moestrup, S.K., and Saraiva, M.J. (2000b). Evidence for the role of megalin 
in renal uptake of transthyretin. J Biol Chem 275, 38176-38181. 
Sousa, M.M., and Saraiva, M.J. (2001). Internalization of transthyretin. Evidence of a 
novel yet unidentified receptor-associated protein (RAP)-sensitive receptor. J Biol Chem 
276, 14420-14425. 
Sousa, M.M., and Saraiva, M.J. (2003). Neurodegeneration in familial amyloid 
polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71, 385-400. 
Sousa, M.M., and Saraiva, M.J. (2008). Transthyretin is not expressed by dorsal root 
ganglia cells. Experimental Neurology 214, 362-365. 
Sousa, M.M., Yan, S.D., Stern, D., and Saraiva, M.J. (2000c). Interaction of the receptor 
for advanced glycation end products (RAGE) with transthyretin triggers nuclear 
transcription factor kB (NF-kB) activation. Lab Invest 80, 1101-1110. 
Srivastava, A., Lusby, E.W., and Berns, K.I. (1983). Nucleotide sequence and 
organization of the adeno-associated virus 2 genome. J Virol 45, 555-564. 
Stabilini, R., Vergani, C., Agostoni, A., and Agostoni, R.P. (1968). Influence of age and 
sex on prealbumin levels. Clin Chim Acta 20, 358-359. 
Stangou, A.J., and Hawkins, P.N. (2004). Liver transplantation in transthyretin-related 
familial amyloid polyneuropathy. Curr Opin Neurol 17, 615-620. 
Stangou, A.J., Heaton, N.D., and Hawkins, P.N. (2005). Transmission of systemic 
transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 352, 
2356. 
Stein, T.D., Anders, N.J., DeCarli, C., Chan, S.L., Mattson, M.P., and Johnson, J.A. 
(2004). Neutralization of transthyretin reverses the neuroprotective effects of secreted 
CHAPTER VI⏐References 
178 
amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss 
of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24, 7707-7717. 
Suhr, O.B., Lang, K., Wikstrom, L., Anan, I., Ando, Y., El-Salhy, M., Holmgren, G., and 
Tashima, K. (2001). Scavenger treatment of free radical injury in familial amyloidotic 
polyneuropathy: a study on Swedish transplanted and non-transplanted patients. Scand J 
Clin Lab Invest 61, 11-18. 
Susuki, S., Sato, T., Miyata, M., Momohara, M., Suico, M.A., Shuto, T., Ando, Y., and Kai, 
H. (2009). The Endoplasmic Reticulum-associated Degradation of Transthyretin Variants 
Is Negatively Regulated by BiP in Mammalian Cells. J Biol Chem 284, 8312-8321. 
Takaoka, Y., Tashiro, F., Yi, S., Maeda, S., Shimada, K., Takahashi, K., Sakaki, Y., and 
Yamamura, K. (1997). Comparison of amyloid deposition in two lines of transgenic mouse 
that model familial amyloidotic polyneuropathy, type I. Transgenic Res 6, 261-269. 
Tanaka, K., Yamada, T., Ohyagi, Y., Asahara, H., Horiuchi, I., and Kira, J. (2001). 
Suppression of transthyretin expression by ribozymes: a possible therapy for familial 
amyloidotic polyneuropathy. J Neurol Sci 183, 79-84. 
Tanaka, Y., Ando, Y., Kumamoto, T., Miyazaki, A., Nakamura, M., Nakayama, M., Araki, 
S., and Ando, M. (1994). Changed affinity of apolipoprotein AII to high density lipoprotein 
(HDL) in patients with familial amyloidotic polyneuropathy (FAP) type I. Biochim Biophys 
Acta 1225, 311-316. 
Tawara, S., Nakazato, M., Kangawa, K., Matsuo, H., and Araki, S. (1983). Identification of 
amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). 
Biochem Biophys Res Commun 116, 880-888. 
Teixeira, A.C., and Saraiva, M.J. (2013). Presence of N-glycosylated transthyretin in 
plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. 
Journal of Cellular and Molecular Medicine 17, 429-435. 
Teixeira, P.F., Cerca, F., Santos, S.D., and Saraiva, M.J. (2006). Endoplasmic reticulum 
stress associated with extracellular aggregates. Evidence from transthyretin deposition in 
familial amyloid polyneuropathy. J Biol Chem 281, 21998-22003. 
Teng, M., Gallo, G., and Buxbaum, J. (1995). Is an amyloidogenic substrate enough? 
Transgenic mice producing human TTR Pro55 do not develop amyloid. Neuromuscul 
Disord 6. 
Teng, M.H., Yin, J.Y., Vidal, R., Ghiso, J., Kumar, A., Rabenou, R., Shah, A., Jacobson, 
D.R., Tagoe, C., Gallo, G., et al. (2001). Amyloid and nonfibrillar deposits in mice 
transgenic for wild-type human transthyretin: a possible model for senile systemic 
amyloidosis. Lab Invest 81, 385-396. 
Terasaki, T., and Hosoya, K. (2001). Conditionally immortalized cell lines as a new in vitro 
model for the study of barrier functions. Biol Pharm Bull 24, 111-118. 
Terazaki, H., Ando, Y., Fernandes, R., Yamamura, K.-i., Maeda, S., and Saraiva, M.J. 
(2006). Immunization in familial amyloidotic polyneuropathy: counteracting deposition by 
immunization with a Y78F TTR mutant. Lab Invest 86, 23-31. 
CHAPTER VI⏐References 
179 
Terazaki, H., Ando, Y., Misumi, S., Nakamura, M., Ando, E., Matsunaga, N., Shoji, S., 
Okuyama, M., Ideta, H., Nakagawa, K., et al. (1999). A novel compound heterozygote 
(FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol 
binding protein (RBP) levels. Biochem Biophys Res Commun 264, 365-370. 
Terazaki, H., Ando, Y., Suhr, O., Ohlsson, P.I., Obayashi, K., Yamashita, T., Yoshimatsu, 
S., Suga, M., Uchino, M., and Ando, M. (1998). Post-translational modification of 
transthyretin in plasma. Biochem Biophys Res Commun 249, 26-30. 
Thomas, P., and Smart, T.G. (2005). HEK293 cell line: a vehicle for the expression of 
recombinant proteins. J Pharmacol Toxicol Methods 51, 187-200. 
Tojo, K., Sekijima, Y., Kelly, J.W., and Ikeda, S. (2006). Diflunisal stabilizes familial 
amyloid polyneuropathy-associated transthyretin variant tetramers in serum against 
dissociation required for amyloidogenesis. Neurosci Res 56, 441-449. 
Tsuzuki, T., Mita, S., Maeda, S., Araki, S., and Shimada, K. (1985). Structure of the 
human prealbumin gene. J Biol Chem 260, 12224-12227. 
Ueda, M., Ando, Y., Hakamata, Y., Nakamura, M., Yamashita, T., Obayashi, K., Himeno, 
S., Inoue, S., Sato, Y., Kaneko, T., et al. (2007). A transgenic rat with the human ATTR 
V30M: a novel tool for analyses of ATTR metabolisms. Biochem Biophys Res Commun 
352, 299-304. 
Vahlquist, A. (1972). Metabolism of the vitamin-A-transporting protein complex: turnover 
of retinol-binding protein, prealbumin and vitamin A in a primate (Macaca Irus). Scand J 
Clin Lab Invest 30, 349-360. 
van Bennekum, A.M., Wei, S., Gamble, M.V., Vogel, S., Piantedosi, R., Gottesman, M., 
Episkopou, V., and Blaner, W.S. (2001). Biochemical basis for depressed serum retinol 
levels in transthyretin-deficient mice. J Biol Chem 276, 1107-1113. 
Vatassery, G.T., Quach, H.T., Smith, W.E., Benson, B.A., and Eckfeldt, J.H. (1991). A 
sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram 
amounts by ELISA. Clin Chim Acta 197, 19-25. 
Veerhuis, R., Janssen, I., De Groot, C.J., Van Muiswinkel, F.L., Hack, C.E., and 
Eikelenboom, P. (1999). Cytokines associated with amyloid plaques in Alzheimer's 
disease brain stimulate human glial and neuronal cell cultures to secrete early 
complement proteins, but not C1-inhibitor. Exp Neurol 160, 289-299. 
Vidal, R., Garzuly, F., Budka, H., Lalowski, M., Linke, R.P., Brittig, F., Frangione, B., and 
Wisniewski, T. (1996). Meningocerebrovascular amyloidosis associated with a novel 
transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 148, 361-366. 
Waits, R.P., Uemichi, T., Zeldenrust, S.R., Hull, M.T., Field, L., and Benson, M.D. (1995). 
Development of lines of transgenic mice expressing the human transthyretin Ser84 
variant. Neuromuscul Disord 6. 
Wang, L., Calcedo, R., Nichols, T.C., Bellinger, D.A., Dillow, A., Verma, I.M., and Wilson, 
J.M. (2005a). Sustained correction of disease in naive and AAV2-pretreated hemophilia B 
dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105, 3079-3086. 
CHAPTER VI⏐References 
180 
Wang, L., Figueredo, J., Calcedo, R., Lin, J., and Wilson, J.M. (2007). Cross-presentation 
of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not 
render hepatocytes effective cytolytic targets. Hum Gene Ther 18, 185-194. 
Wang, S., Thibault, G., and Ng, D.T. (2011). Routing misfolded proteins through the 
multivesicular body (MVB) pathway protects against proteotoxicity. J Biol Chem 286, 
29376-29387. 
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., and Xiao, X. 
(2005b). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. 
Nat Biotechnol 23, 321-328. 
Warrington, K.H., and Herzog, R.W. (2006). Treatment of human disease by adeno-
associated viral gene transfer. Hum Genet 119, 571-603. 
Wei, L., Kawano, H., Fu, X., Cui, D., Ito, S., Yamamura, K., Ishihara, T., Tokuda, T., 
Higuchi, K., and Maeda, S. (2004). Deposition of transthyretin amyloid is not accelerated 
by the same amyloid in vivo. Amyloid 11, 113-120. 
Wei, S., Episkopou, V., Piantedosi, R., Maeda, S., Shimada, K., Gottesman, M.E., and 
Blaner, W.S. (1995). Studies on the metabolism of retinol and retinol-binding protein in 
transthyretin-deficient mice produced by homologous recombination. J Biol Chem 270, 
866-870. 
Weisner, B., and Roethig, H.J. (1983). The concentration of prealbumin in cerebrospinal 
fluid (CSF), indicator of CSF circulation disorders. Eur Neurol 22, 96-105. 
Westermark, P., Sletten, K., Johansson, B., and Cornwell, G.G., 3rd (1990). Fibril in senile 
systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 87, 
2843-2845. 
Whitehead, A.S., Skinner, M., Bruns, G.A., Costello, W., Edge, M.D., Cohen, A.S., and 
Sipe, J.D. (1984). Cloning of human prealbumin complementary DNA. Localization of the 
gene to chromosome 18 and detection of a variant prealbumin allele in a family with 
familial amyloid polyneuropathy. Mol Biol Med 2, 411-423. 
Willnow, T.E. (1998). Receptor-associated protein (RAP): a specialized chaperone for 
endocytic receptors. Biol Chem 379, 1025-1031. 
Wu, J.W., Herman, M., Liu, L., Simoes, S., Acker, C.M., Figueroa, H., Steinberg, J.I., 
Margittai, M., Kayed, R., Zurzolo, C., et al. (2013). Small Misfolded Tau Species Are 
Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in 
Neurons. J Biol Chem 288, 1856-1870. 
Wu, Z., Asokan, A., and Samulski, R.J. (2006). Adeno-associated virus serotypes: vector 
toolkit for human gene therapy. Mol Ther 14, 316-327. 
Xiao, W., Berta, S.C., Lu, M.M., Moscioni, A.D., Tazelaar, J., and Wilson, J.M. (1998). 
Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 72, 10222-
10226. 
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. 
(2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene 
therapy. Proc Natl Acad Sci U S A 99, 10405-10410. 
CHAPTER VI⏐References 
181 
Xu, C., Bailly-Maitre, B., and Reed, J.C. (2005). Endoplasmic reticulum stress: cell life and 
death decisions. J Clin Invest 115, 2656-2664. 
Yan, Z., Zhang, Y., Duan, D., and Engelhardt, J.F. (2000). Trans-splicing vectors expand 
the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 97, 6716-
6721. 
Zaiss, A.K., Liu, Q., Bowen, G.P., Wong, N.C., Bartlett, J.S., and Muruve, D.A. (2002). 
Differential activation of innate immune responses by adenovirus and adeno-associated 
virus vectors. J Virol 76, 4580-4590. 
Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV 
serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol 
Ther 16, 1073-1080. 
  
  
 
 
 
 
 
 
 
 
 
 
 
Appendix I 
 
  
 
APPENDIX I 
185 
Legends for the movies presented as Supplemental Material for Chapter III 
Movie III.1: Animated series of time-lapse images taken with a spinning disc confocal 
microscope. TTR-V30M-TC uptake kinetics. SH-SY5Y cells are imaged in bright field; 
TTR-V30M-TC is green. Time 00:00 corresponds to approximately 2min after conditioned 
media addition to cells. Scale bar represents 10µm. 
 
Movie III.2: Animated series of time-lapse images taken with a SP5 confocal microscope. 
Co-localization of TTR-V30M-TC and lysosomes. TTR-V30M-TC is green; lysosomes are 
stained in red using LysoTracker Red DND-99. Time 00:00 corresponds to approximately 
2min after conditioned media addition to cells. Scale bar represents 10µm. 
 
Movie III.3: Animated series of time-lapse images taken with a SP5 confocal microscope. 
The effect of the modulator TUDCA in TTR V30M-TC uptake kinetics. TTR-V30M-TC is 
green; lysosomes are stained in red using LysoTracker Red DND-99. Time 00:00 
corresponds to approximately 2min after conditioned media addition to cells. Scale bar 
represents 10µm. 
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Differentially expressed genes in colon and DRG of scAAV8-TTR T119M animals 
referred in chapter IV 
Table AII.1. Genes found up-regulated in DRG of scAAV8-TTR T119M injected animals 
as compared to empty vector injected animals. Genes were considered up-regulated with 
fold change above 1.5 after class comparison assuming significances p<0.05. 
Up-regulated genes in DRG of scAAV8-TTR T119M injected animals 
GB accession 
number 
Fold 
Change 
Symbol Gene name Gene onthology 
AK078982 11.43 Adam28 disintegrin and 
metalloproteinase domain-
containing protein 28 isoform 1 
precursor 
metallopeptidase 
activity 
AK030621 7.49 Ppfia2 protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein 
(liprin), alpha 2 
Cell-cell 
communication 
NM_007490 3.69 Art2a-ps ADP-ribosyltransferase 2a, 
pseudogene 
cell signaling 
ENSMUST000001
18280 
3.58 Gng5 guanine nucleotide binding 
protein (G protein), gamma 5 
GPCR signaling 
NM_029568 2.86 Mfap4 microfibrillar-associated protein 
4 
ECM 
NM_147000 2.73 Olfr173 olfactory receptor 173 GPCR signaling 
AK036657 2.62 Ikzf3 IKAROS family zinc finger 3 Immune system 
NM_021405 2.56 Cst10 cystatin 10 (chondrocytes) Endochondral 
Ossification 
NM_011613 2.56 Tnfsf11 tumor necrosis factor (ligand) 
superfamily, member 11 
Immune system 
NM_001033978 2.54 H2-Eb2 histocompatibility 2, class II 
antigen E beta2 
Immune system 
NM_177868 2.47 Fhad1 forkhead-associated (FHA) 
phosphopeptide binding domain 
1 
platelet activation 
NM_010389 2.44 H2-Ob histocompatibility 2, O region 
beta locus 
Immune system 
NM_133353 2.39 Oosp1 oocyte secreted protein 1 cell diffrentiation 
NM_010743 2.35 Il1rl1 interleukin 1 receptor-like 1 Immune system 
NM_029122 2.33 Iqca IQ motif containing with AAA 
domain 
nucleotide 
binding 
NM_031252 2.32 Il23a interleukin 23, alpha subunit 
p19 
Immune system 
NM_029453 2.32 Wdr64 WD repeat domain 64 ND 
AK049727 2.32 Fam172a family with sequence similarity 
172, member A 
ND 
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AK087099 2.23 Thoc5 THO complex 5 RNA transport 
NM_145835 2.22 Lctl lactase-like carbohydrate 
metabolic 
process 
AK047533 2.22 Mgat4c mannosyl (alpha-1,3-)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, 
isozyme C (putative) 
N-Glycan 
biosynthesis 
AK044324 2.21 Rnf38 ring finger protein 38 ND 
AK042055 2.15 Eea1 early endosome antigen 1 Endocytosis 
NM_021472 2.15 Rnase4 ribonuclease, RNase A family 4 nuclease activity 
NM_010742 2.14 Ly6d lymphocyte antigen 6 complex, 
locus D 
Immune system 
AK083309 2.14 Arsb arylsulfatase B ECM 
M29475 2.14 Rag1 recombination activating gene 1 Immune system 
NM_133365 2.12 Dnahc5 dynein, axonemal, heavy chain 
5 
Cytoskeleton 
AK089392 2.12 Cenpc1 centromere protein C1 cell division 
ENSMUST000000
41621 
2.11 Lipt1 lipoyltransferase 1 Lipoic acid 
metabolism 
AK087919 2.11 Ttc26 tetratricopeptide repeat domain 
26 
Cell-cell 
communication 
NM_181858 2.10 Cd59b CD59b antigen Hematopoietic 
cell lineage, 
AJ293625 2.09 Slirp SRA stem-loop interacting RNA 
binding protein 
RNA binding 
NM_008524 2.08 Lum lumican Glycosaminoglyc
an metabolism 
AK017792 2.07 Slc9a9 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 9 
ion channel 
activity 
AK048865 2.07 Frmd5 FERM domain containing 5 Cytoskeleton 
AK136546 2.04 Cdc14a CDC14 cell division cycle 14A cell division 
AK031027 2.03 Neil3 nei like 3 (E. coli) DNA repair 
ENSMUST000001
47041 
2.02 Arhgef38 Rho guanine nucleotide 
exchange factor (GEF) 38 
RhoGTPase 
signaling 
AK052660 2.02 Lgr4 leucine-rich repeat-containing G 
protein-coupled receptor 4 
GPCR signaling 
AK090196 2.01 Pou3f4 POU domain, class 3, 
transcription factor 4 
DNA binding 
AK029954 1.97 Rbm6 RNA binding motif protein 6 RNA binding 
NM_205810 1.97 Mrgprb1 MAS-related GPR, member B1 GPCR signaling 
NM_021359 1.96 Itgb6 integrin beta 6 ECM 
AK042026 1.95 Mcph1 microcephaly, primary 
autosomal recessive 1 
cell division 
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NM_027651 1.95 Tmem30c transmembrane protein 30C cell cycle 
NM_029267 1.93 Boll bol, boule-like (Drosophila) mRNA 
processing 
NM_016925 1.92 Fanca Fanconi anemia, 
complementation group A 
DNA repair 
AK016718 1.92 Tekt3 tektin 3 Cytoskeleton 
AK048265 1.92 Shprh SNF2 histone linker PHD RING 
helicase 
DNA repair 
BC025027 1.91 Plce1 phospholipase C, epsilon 1 Calcium signaling 
pathway 
AK050778 1.90 Kif11 kinesin family member 11 Immune system 
NM_146790 1.90 Olfr1238 olfactory receptor 1238 GPCR signaling 
NM_030070 1.89 Lrrc9 leucine rich repeat containing 9 Cell-cell 
communication 
NM_134243 1.87 Vmn1r211 vomeronasal 1 receptor 211 GPCR signaling 
AK020772 1.87 Itk IL2 inducible T cell kinase Immune system 
NM_010745 1.86 Ly86 lymphocyte antigen 86 Immune system 
NM_146468 1.85 Olfr1391 olfactory receptor 1391 GPCR signaling 
AK032949 1.84 Asxl3 additional sex combs like 3 
(Drosophila) 
regulation of 
transcription 
NM_009385 1.83 Nkx2-1 NK2 homeobox 1 DNA binding 
AK011368 1.83 Arhgap26 Rho GTPase activating protein 
26 
Rho GTPase 
signaling 
AK035122 1.83 Zmym6 zinc finger, MYM-type 6 Cytoskeleton 
AK038964 1.83 Rnf144b ring finger protein 144B Immune system 
NM_134203 1.83 Vmn1r73 vomeronasal 1 receptor 73 GPCR signaling 
NM_001145806 1.81 Capn8 calpain 8 Calcium signaling 
pathway 
NM_176831 1.78 Ppcdc phosphopantothenoylcysteine 
decarboxylase 
Metabolism of 
vitamins 
AK043586 1.77 Sgpp1 sphingosine-1-phosphate 
phosphatase 1 
Metabolism of 
lipids 
NM_134090 1.74 Kdelr3 KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 3 
Activation of 
Chaperone 
AK054510 1.73 Kdr kinase insert domain protein 
receptor 
endocytosis 
NM_022026 1.72 Aqp9 aquaporin 9 Transmembrane 
transport  
NM_177446 1.72 Scgb2b24 secretoglobin, family 2B, 
member 24 
Immune system 
NM_178897 1.72 Tyw1 tRNA-yW synthesizing protein 1 
homolog (S. cerevisiae) 
RNA processing 
NM_146505 1.72 Olfr148 olfactory receptor 148 GPCR signaling 
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AK079794 1.71 Dapp1 dual adaptor for 
phosphotyrosine and 3-
phosphoinositides 1 
Immune system 
ENSMUST000000
00574 
1.70 Adora3 adenosine A3 receptor GPCR signaling 
NM_001002896 1.70 Bfsp2 beaded filament structural 
protein 2, phakinin 
cytoskeleton 
AK029066 1.69 Vps13b vacuolar protein sorting 13B 
(yeast) 
protein transport 
NM_146771 1.68 Olfr1176 olfactory receptor 1176 GPCR signaling 
NM_011261 1.68 Reln reelin ECM 
NM_001081270 1.68 Dscaml1 Down syndrome cell adhesion 
molecule like 1 
Cell-cell 
communication 
NM_175512 1.68 Dhrs9 dehydrogenase/reductase 
(SDR family) member 9 
Retinol 
metabolism 
NM_007954 1.66 Ces1c carboxylesterase 1C Drug metabolism 
NM_015758 1.66 Foxe3 forkhead box E3 DNA binding 
NM_009137 1.64 Ccl22 chemokine (C-C motif) ligand 
22 
Immune system 
AK085153 1.62 Galm galactose mutarotase Glycolysis 
NM_175677 1.62 Trim12c tripartite motif-containing 12C metal ion binding 
AK052292 1.60 Ednra endothelin receptor type A GPCR signaling 
NM_010512 1.60 Igf1 insulin-like growth factor 1 IGF1R signaling 
cascade 
NM_008663 1.60 Myo7a myosin VIIA cytoskeleton 
AK041015 1.59 Slc38a11 solute carrier family 38, 
member 11 
ion channel 
activity 
AK164634 1.58 Lox lysyl oxidase ECM 
NM_194357 1.58 Bpifb3 BPI fold containing family B, 
member 3 
Metabolism of 
lipids 
NM_011606 1.58 Clec3b C-type lectin domain family 3, 
member b 
Heparin binding 
NM_029674 1.56 Got1l1 glutamic-oxaloacetic 
transaminase 1-like 1 
aminoacid 
metabolism 
NM_146197 1.55 Acsm2 acyl-CoA synthetase medium-
chain family member 2 
aminoacid 
metabolism 
NM_013784 1.54 Pign phosphatidylinositol glycan 
anchor biosynthesis, class N 
GPI-anchor 
biosynthesis, 
AK038116 1.53 Itsn2 intersectin 2 Rho GTPase 
signaling 
NM_146495 1.53 Olfr474 olfactory receptor 474 GPCR signaling 
NM_010387 1.53 H2-DMb1 histocompatibility 2, class II, 
locus Mb1 
Immune system 
NM_008608 1.53 Mmp14 matrix metallopeptidase 14 
(membrane-inserted) 
ECM 
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AK045060 1.53 Eya4 eyes absent 4 homolog 
(Drosophila) 
DNA repair 
NM_010927 1.52 Nos2 nitric oxide synthase 2, 
inducible 
Calcium signaling 
pathway 
NM_009969 1.51 Csf2 colony stimulating factor 2 
(granulocyte-macrophage) 
Immune system 
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Table AII.2. Genes found down-regulated in DRG of scAAV8-TTR T119M injected 
animals as compared to empty vector injected animals. Genes were considered down-
regulated with fold change below 0.5 after class comparison assuming significances 
p<0.05. 
Down-regulated genes in DRG of scAAV8-TTR T119M injected animals 
GB accession 
number 
Fold 
Change 
Symbol Gene name Gene onthology 
NM_173869 -2.82 Stfa2l1 stefin A2 like 1 negative regulation 
of peptidase 
activity 
NM_001082545 -2.68 Stfa2 stefin A2 negative regulation 
of peptidase 
activity 
NM_146714 -2.65 Olfr248 olfactory receptor 248 GPCR signaling 
NM_183038 -2.52 Defb39 defensin beta 39 immune system 
AK018143 -2.04 Cgn cingulin cell-cell 
comunication 
NM_146289 -1.93 Olfr113 olfactory receptor 113 GPCR signaling 
AK035797 -1.90 Adamts18 a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 motif, 18 
metallopeptidase 
activity 
NM_010648 -1.86 Klra3 killer cell lectin-like receptor, 
subfamily A, member 3 
immune system 
BC024834 -1.83 Dixdc1 DIX domain containing 1 cytoskeleton 
NM_153109 -1.83 Tgif2lx1 TGFB-induced factor 
homeobox 2-like, X-linked 1 
cell diferentiation 
NM_147039 -1.81 Olfr1414 olfactory receptor 1414 GPCR signaling 
AK017898 -1.80 Tcrb-J T cell receptor beta, joining 
region 
immune system 
NM_182992 -1.79 Mypn myopalladin cytoskeleton 
AF054581 -1.75 Il2ra interleukin 2 receptor, alpha 
chain 
immune system 
NM_001038604 -1.71 Clec5a C-type lectin domain family 5, 
member a 
immune system 
NM_177823 -1.70 Ubash3a ubiquitin associated and SH3 
domain containing, A 
Ubiquitin pathway 
NM_177775 -1.70 Esyt3 extended synaptotagmin-like 
protein 3 
calcium signaling 
NM_147083 -1.69 Olfr622 olfactory receptor 622 GPCR signaling 
AK032524 -1.66 Camk2d calcium/calmodulin-
dependent protein kinase II, 
delta 
calcium signaling 
NM_013605 -1.60 Muc1 mucin 1, transmembrane Metabolism of 
proteins 
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NM_001011812 -1.58 Olfr951 olfactory receptor 951 GPCR signaling 
NM_207253 -1.57 Olfr1371 olfactory receptor 1371 GPCR signaling 
NM_001081252 -1.57 Uggt2 UDP-glucose glycoprotein 
glucosyltransferase 2 
Metabolism of 
proteins 
NM_181852 -1.56 Prl2c5 prolactin family 2, subfamily 
c, member 5 
immune system 
NM_011566 -1.56 Tead3 TEA domain family member 3 Metabolism of 
lipids 
NM_183307 -1.54 Ccdc63 coiled-coil domain containing 
63 
ND 
NM_008588 -1.54 Mesp1 mesoderm posterior 1 DNA binding 
NM_134247 -1.53 Acot4 acyl-CoA thioesterase 4 Biosynthesis of 
unsaturated fatty 
acids 
AK033284 -1.52 Cep128 centrosomal protein 128 cell division 
NM_010314 -1.52 Gngt1 guanine nucleotide binding 
protein (G protein), gamma 
transducing activity 
polypeptide 1 
GPCR signaling 
ENSMUST000000
70720 
-1.51 Sorcs2 sortilin-related VPS10 
domain containing receptor 2 
neuropeptide 
receptor activity 
NM_146540 -1.51 Olfr1364 olfactory receptor 1364 GPCR signaling 
NM_029971 -1.50 Pmch pro-melanin-concentrating 
hormone 
GPCR signaling 
BC030180 -1.50 Ptk2 PTK2 protein tyrosine kinase 
2 
immune system 
AK044226 -1.49 Helz helicase with zinc finger 
domain 
nucleotide binding 
NM_028529 -1.47 Nipsnap3a nipsnap homolog 3A (C. 
elegans) 
mitochondria 
AK038792 -1.44 Nwd1 NACHT and WD repeat 
domain containing 1 
ATP binding 
NM_018731 -1.42 Atp4a ATPase, H+/K+ exchanging, 
gastric, alpha polypeptide 
ion channel activity 
AK009704 -1.41 Sox7 SRY-box containing gene 7 DNA binding 
NM_001011842 -1.40 Olfr1474 olfactory receptor 1474 GPCR signaling 
AK082040 -1.40 Slc35a3 solute carrier family 35 (UDP-
N-acetylglucosamine (UDP-
GlcNAc) transporter), 
member 3 
Transmembrane 
transport 
NM_080641 -1.39 Bhlhe23 basic helix-loop-helix family, 
member e23 
development 
AK014557 -1.39 Ttll4 tubulin tyrosine ligase-like 
family, member 4 
cytoskeleton 
AK164127 -1.37 Ppil4 peptidylprolyl isomerase 
(cyclophilin)-like 4 
RNA binding 
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BC021830 -1.36 B4galt3 UDP-Gal:betaGlcNAc beta 
1,4-galactosyltransferase, 
polypeptide 3 
N-Glycan 
biosynthesis 
AK049811 -1.35 Sybu syntabulin (syntaxin-
interacting) 
cytoskeleton 
NM_019586 -1.35 Ube2j1 ubiquitin-conjugating enzyme 
E2J 1 
Ubiquitin pathway 
AK087054 -1.34 Rasal2 RAS protein activator like 2 RhoGTPase 
signaling 
NM_146962 -1.31 Olfr541 olfactory receptor 541 GPCR signaling 
NM_144903 -1.31 Aldob aldolase B, fructose-
bisphosphate 
Glycolysis 
AK084485 -1.30 Mfsd8 major facilitator superfamily 
domain containing 8 
Lysosomal activity 
NM_001011756 -1.27 Olfr948 olfactory receptor 948 GPCR signaling 
NM_030104 -1.26 Tmem247 transmembrane protein 247 ND 
ENSMUST000000
51089 
-1.26 Hist2h2bb histone cluster 2, H2bb cell cycle 
NM_180958 -1.25 Ccdc79 coiled-coil domain containing 
79 
DNA binding 
NM_146286 -1.24 Olfr981 olfactory receptor 981 GPCR signaling 
NM_030228 -1.23 Gas2l1 growth arrest-specific 2 like 1 cell cycle 
NM_013821 -1.23 Hsd3b6 hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and 
steroid delta-isomerase 6 
Metabolism of 
lipids 
NM_153097 -1.22 Trim60 tripartite motif-containing 60 metal ion binding 
AK042290 -1.21 Ipp IAP promoted placental gene cytoskeleton 
AK084671 -1.21 Galnt18 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransfera
se 18 
O-glycan 
biosynthesis 
NM_080510 -1.19 Trim69 tripartite motif-containing 69 metal ion binding 
NM_009380 -1.18 Thrb thyroid hormone receptor 
beta 
Gene Expression, 
NM_013780 -1.18 Npas3 neuronal PAS domain protein 
3 
transcription factor 
AK039166 -1.17 Snx21 sorting nexin family member 
21 
intracellular traffic 
AK038837 -1.17 Rhof ras homolog gene family, 
member f 
RhoGTPase 
signaling 
XM_138106 -1.17 Samd15 sterile alpha motif domain 
containing 15 
ND 
NM_138684 -1.17 Wfdc12 WAP four-disulfide core 
domain 12 
immune system 
NM_010555 -1.16 Il1r2 interleukin 1 receptor, type II immune system 
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NM_023500 -1.14 Xk Kell blood group precursor 
(McLeod phenotype) 
homolog 
amino acid 
transport 
NM_028660 -1.14 Klk9 kallikrein related-peptidase 9 ECM 
NM_146600 -1.13 Olfr700 olfactory receptor 700 GPCR signaling 
NM_175936 -1.12 Vmn2r81 vomeronasal 2, receptor 81 GPCR signaling 
NM_033269 -1.10 Chrm3 cholinergic receptor, 
muscarinic 3, cardiac 
calcium signaling 
AK020384 -1.10 Zfp142 zinc finger protein 142 transcription 
NM_174852 -1.10 Phf12 PHD finger protein 12 transcription 
NM_008995 -1.09 Pex5 peroxisomal biogenesis 
factor 5 
Peroxisome 
NM_019931 -1.08 Kcnd3 potassium voltage-gated 
channel, Shal-related family, 
member 3 
ion channel activity 
NM_201410 -1.07 Ugt1a6b UDP glucuronosyltransferase 
1 family, polypeptide A6B 
Metabolism of 
lipids 
AK048832 -1.07 Trank1 tetratricopeptide repeat and 
ankyrin repeat containing 1 
DNA binding 
NM_027960 -1.07 Dpep3 dipeptidase 3 metallopeptidase 
activity 
NM_007820 -1.07 Cyp3a16 cytochrome P450, family 3, 
subfamily a, polypeptide 16 
Biological 
oxidations 
AK017065 -1.07 Slc29a3 solute carrier family 29 
(nucleoside transporters), 
member 3 
Transmembrane 
transport 
NM_007588 -1.06 Calcr calcitonin receptor GPCR signaling 
NM_001013616 -1.06 Trim6 tripartite motif-containing 6 metal ion binding 
NM_177293 -1.05 Mtap7d3 MAP7 domain containing 3 cytoskeleton 
NM_031170 -1.04 Krt8 keratin 8 EGFR1 Signaling 
Pathway 
NM_001162865 -1.04 Cylc2 cylicin, basic protein of sperm 
head cytoskeleton 2 
cytoskeleton 
NM_021453 -1.03 Pga5 pepsinogen 5, group I Protein digestion 
NM_001012392 -1.02 Bpifb1 BPI fold containing family B, 
member 1 
lipid binding 
AK031754 -1.01 Ccser1 coiled-coil serine rich 1 cytoskeleton 
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Table AII.3. Genes found up-regulated in colon of scAAV8-TTR T119M injected animals 
as compared to empty vector injected animals. Genes were considered up-regulated with 
fold change over 1.5 after class comparison assuming significances p<0.05. 
Up-regulated genes in colon of scAAV8-TTR T119M injected animals 
GB accession 
number 
Fold 
Change 
Symbol Gene name Gene onthology 
AK031940 6.95 Enah enabled homolog 
(Drosophila) 
Immune system 
AK019950 6.35 Rrp15 ribosomal RNA processing 
15 homolog (S. cerevisiae) 
RNA processing 
AK041010 6.18 LOC6203
06 
similar to Glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH) 
Glycolysis 
NM_009872 6.10 Cdk5r2 cyclin-dependent kinase 5, 
regulatory subunit 2 (p39) 
Development 
AK084857 5.79 Bsdc1 BSD domain containing 1 ND 
NM_013806 5.77 Abcc2 ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 2 
ABC transporters 
AK014557 5.65 Ttll4 tubulin tyrosine ligase-like 
family, member 4 
Cell-cell interaction 
NM_025867 5.34 Serpinb11 serine (or cysteine) 
peptidase inhibitor, clade B 
(ovalbumin), member 11 
Peptidase inhibitor 
activity 
NM_146284 4.82 Olfr780 olfactory receptor 780 GPCR signaling 
AK037656 4.82 Colq collagen-like tail subunit 
(single strand of 
homotrimer) of asymmetric 
acetylcholinesterase 
Heparin binding 
NM_146491 4.76 Olfr1410 olfactory receptor 1410 GPCR signaling 
NM_009685 4.72 Apbb1 amyloid beta (A4) precursor 
protein-binding, family B, 
member 1 
ND 
NM_009508 4.59 Slc32a1 solute carrier family 32 
(GABA vesicular 
transporter), member 1 
Signal transmission 
AK147309 4.57 Pafah1b1 platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 1 
Cell division 
AK085209 4.51 Rab3gap1 RAB3 GTPase activating 
protein subunit 1 
Rho GTPases 
AK044079 4.39 Wwc2 WW, C2 and coiled-coil 
domain containing 2 
ND 
AK078650 4.11 Mosc2 mitochondrial amidoxime 
reducing component 2 
Lipid synthesis 
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AK164517 3.94 Slc35d1 solute carrier family 35 
(UDP-glucuronic acid/UDP-
N-acetylgalactosamine dual 
transporter), member D1 
Signal transmission 
AK079051 3.93 Arcn1 archain 1 Membrane Trafficking 
NM_147038 3.89 Olfr1416 olfactory receptor 1416 GPCR signaling 
AK012373 3.88 Qk quaking RNA processing 
NM_177261 3.87 Kndc1 kinase non-catalytic C-lobe 
domain (KIND) containing 1 
ND 
AK014475 3.74 Brd8 bromodomain containing 8 Gene regulation 
NM_009500 3.73 Vav2 vav 2 oncogene GPCR signaling 
NM_001012765 3.72 Adcy5 adenylate cyclase 5 GPCR signaling 
AK036956 3.68 Mpp7 membrane protein, 
palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
cell-cell interaction 
AK036508 3.68 Nr2c2 nuclear receptor subfamily 
2, group C, member 2 
Immune system 
BC034290 3.61 Lrrc29 leucine rich repeat 
containing 29 
Ubiquitin pathway 
NM_029660 3.59 Rbmxl2 RNA binding motif protein, 
X-linked-like 2 
RNA processing 
AK043857 3.50 Wipi2 WD repeat domain, 
phosphoinositide interacting 
2 
Autophagy 
AK084851 3.45 Ascc3 activating signal 
cointegrator 1 complex 
subunit 3 
RNA processing 
NM_172125 3.27 Adam1b a disintegrin and 
metallopeptidase domain 1b 
Metallopeptidase 
activity 
NM_029721 3.21 Snx27 sorting nexin family member 
27 
Cell-cell interaction 
AK078580 3.19 Gtpbp10 GTP-binding protein 10 
(putative) 
GTP binding 
NM_008398 3.11 Itga7 integrin alpha 7 Cell division 
NM_013468 3.11 Ankrd1 ankyrin repeat domain 1 
(cardiac muscle) 
Metabolism of lipids 
and lipoproteins 
NM_001001809 3.10 Olfr218 olfactory receptor 218 GPCR signaling 
NM_009948 3.09 Cpt1b carnitine 
palmitoyltransferase 1b, 
muscle 
Metabolism of lipids 
and lipoproteins 
AK032770 3.07 Apbb2 amyloid beta (A4) precursor 
protein-binding, family B, 
member 2 
ND 
NM_009867 3.05 Cdh4 cadherin 4 Cell-cell interaction 
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AK045633 2.99 Smug1 single-strand selective 
monofunctional uracil DNA 
glycosylase 
DNA repair 
AK038845 2.99 Crebl2 cAMP responsive element 
binding protein-like 2 
RNA processing 
NM_026580 2.94 Otub2 OTU domain, ubiquitin 
aldehyde binding 2 
Ubiquitin pathway 
AK052176 2.94 Efr3a EFR3 homolog A (S. 
cerevisiae) 
cell-cell interaction 
AK040413 2.88 Sntb2 syntrophin, basic 2 Cytoskeleton 
NM_013900 2.87 Mfi2 antigen p97 (melanoma 
associated) identified by 
monoclonal antibodies 
133.2 and 96.5 
Ion channel activity 
NM_010866 2.85 Myod1 myogenic differentiation 1 Development 
AK033284 2.82 Cep128 centrosomal protein 128 Cell division 
AK042238 2.80 Tgs1 trimethylguanosine 
synthase homolog (S. 
cerevisiae) 
Metabolism of lipids 
and lipoproteins 
AK020704 2.73 Fam115a family with sequence 
similarity 115, member A 
ND 
NM_178051 2.70 Mterfd2 MTERF domain containing 
2 
RNA processing 
AK032172 2.69 Pabpn1 poly(A) binding protein, 
nuclear 1 
RNA processing 
NM_152813 2.67 Plcd3 phospholipase C, delta 3 Inositol phosphate 
metabolism 
NM_011365 2.65 Itsn2 intersectin 2 Rho GTPases 
AK081212 2.61 Marveld1 MARVEL (membrane-
associating) domain 
containing 1 
Cell division 
NM_010021 2.60 Dazl deleted in azoospermia-like RNA processing 
AK018652 2.60 Saps3 protein phosphatase 6, 
regulatory subunit 3 
Regulation of 
phosphoprotein 
phosphatase activity 
AK028953 2.59 Apool apolipoprotein O-like ND 
L00919 2.57 Epb4.1 erythrocyte protein band 4.1 Cell-cell interaction 
NM_025890 2.57 Khdc3 KH domain containing 3, 
subcortical maternal 
complex member 
Cell division 
AK040524 2.56 Gns glucosamine (N-acetyl)-6-
sulfatase 
Heparin binding 
NM_011725 2.53 Xlr X-linked lymphocyte-
regulated complex 
Cell division 
NM_026763 2.52 Col6a4 collagen, type VI, alpha 4 Cell-cell interaction 
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AK086376 2.52 Caprin1 cell cycle associated protein 
1 
Cell division 
AK048571 2.50 Snapc3 small nuclear RNA 
activating complex, 
polypeptide 3 
RNA processing 
NM_001077499 2.49 Scn8a sodium channel, voltage-
gated, type VIII, alpha 
Development 
AK039509 2.45 Micu1 mitochondrial calcium 
uptake 1 
Calcium ion import 
NM_172385 2.42 Zfp536 zinc finger protein 536 RNA processing 
AK077918 2.40 Fan1 FANCD2/FANCI-associated 
nuclease 1 
Endonuclease activity 
AK030810 2.40 Cdk6 cyclin-dependent kinase 6 Cell division 
AK148314 2.38 Ppt1 palmitoyl-protein 
thioesterase 1 
Lysosomal activity 
NM_146772 2.37 Olfr1189 olfactory receptor 1189 GPCR signaling 
NM_011299 2.36 Rps6ka2 ribosomal protein S6 
kinase, polypeptide 2 
Immune system 
AK081803 2.32 Abi2 abl-interactor 2 Cell division 
AK078969 2.31 Rhbdl2 rhomboid, veinlet-like 2 
(Drosophila) 
Peptidase activity 
AK049588 2.29 Nipbl Nipped-B homolog 
(Drosophila) 
Cell division 
AK050084 2.27 Phf21a PHD finger protein 21A Hemostasis 
AK014060 2.27 Spag9 sperm associated antigen 9 Development 
AK085110 2.27 R3hdm1 R3H domain containing 1 RNA processing 
AK078743 2.24 Hmgcs1 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 
Metabolism of lipids 
and lipoproteins 
AK147417 2.23 Rimbp2 RIMS binding protein 2 Cell-cell interaction 
AK141428 2.23 Crbn cereblon Ubiquitin pathway 
NM_016868 2.23 Hif3a hypoxia inducible factor 3, 
alpha subunit 
Cellular response to 
hypoxia 
AK005318 2.22 Pot1a protection of telomeres 1A Cell division 
AK089360 2.22 Rps28 ribosomal protein S28 RNA processing 
AK148740 2.20 Mbnl2 muscleblind-like 2 RNA processing 
NM_018814 2.18 Pcnx pecanex homolog 
(Drosophila) 
Development 
AK050977 2.17 Cep78 centrosomal protein 78 Cell division 
AK029333 2.17 Iqce IQ motif containing E Rho GTPases 
AK053501 2.12 Ddef1 ArfGAP with SH3 domain, 
ankyrin repeat and PH 
domain1 
Endocytosis 
NM_177340 2.09 Synpo synaptopodin Cell division 
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NM_019725 2.07 Tle2 transducin-like enhancer of 
split 2, homolog of 
Drosophila E(spl) 
Signal Transduction 
NM_008227 2.06 Hcn3 hyperpolarization-activated, 
cyclic nucleotide-gated K+ 3 
Ion channel activity 
NM_011445 2.06 Sox6 SRY-box containing gene 6 RNA processing 
NM_172122 2.05 Crocc ciliary rootlet coiled-coil, 
rootletin 
Cell division 
AK019431 2.03 Sft2d3 SFT2 domain containing 3 Cell-cell interaction 
AK053217 2.01 Ubn2 ubinuclein 2 ND 
NM_080448 1.99 Srgap3 SLIT-ROBO Rho GTPase 
activating protein 3 
Rho GTPases 
NM_027055 1.99 Spaca4 sperm acrosome associated 
4 
Development 
NM_175181 1.96 Prr5l proline rich 5 like ND 
AK034024 1.95 Tmem117 transmembrane protein 117 ND 
NM_021877 1.94 Hr hairless RNA processing 
NM_008615 1.92 Me1 malic enzyme 1, NADP(+)-
dependent, cytosolic 
Metabolism of lipids 
and lipoproteins 
NM_011584 1.89 Nr1d2 nuclear receptor subfamily 
1, group D, member 2 
Gene regulation 
NM_013930 1.89 Aass aminoadipate-semialdehyde 
synthase 
Lysine catabolism 
NM_021466 1.88 Taf1a TATA box binding protein 
(Tbp)-associated factor, 
RNA polymerase I, A 
RNA processing 
AK013250 1.88 Ndfip2 Nedd4 family interacting 
protein 2 
Signal Transduction 
AK014613 1.88 Appbp2 amyloid beta precursor 
protein (cytoplasmic tail) 
binding protein 2 
ND 
NM_144819 1.86 Ccdc92 coiled-coil domain 
containing 92 
Cell division 
NM_175007 1.85 Amph amphiphysin Rho GTPases 
AK048355 1.84 Atad5 ATPase family, AAA 
domain containing 5 
Response to DNA 
damage stimulus 
NM_172779 1.84 Ddx26b DEAD/H (Asp-Glu-Ala-
Asp/His) box polypeptide 
26B 
ND 
AK029299 1.82 Slc22a15 solute carrier family 22 
(organic anion/cation 
transporter), member 15 
Ion channel activity 
NM_011858 1.82 Tenm4 teneurin transmembrane 
protein 4 
Cell differentiation 
NM_028523 1.79 Dcbld2 discoidin, CUB and LCCL 
domain containing 2 
Cell-cell interaction 
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AK021217 1.79 Jakmip1 janus kinase and 
microtubule interacting 
protein 1 
RNA processing 
AJ293625 1.78 Slirp SRA stem-loop interacting 
RNA binding protein 
RNA processing 
NM_145746 1.78 Odf4 outer dense fiber of sperm 
tails 4 
Development 
NM_201365 1.76 Fam178b family with sequence 
similarity 178, member B 
ND 
AK052698 1.74 Pkhd1 polycystic kidney and 
hepatic disease 1 
Cell division 
NM_053250 1.71 Crip3 cysteine-rich protein 3 Immune system 
NM_001081347 1.69 Rhobtb1 Rho-related BTB domain 
containing 1 
Rho GTPases 
NM_025774 1.69 Prkrip1 Prkr interacting protein 1 
(IL11 inducible) 
RNA processing 
AK084615 1.67 Fam20b family with sequence 
similarity 20, member B 
Rho GTPases 
AB078345 1.67 Centg3 ArfGAP with GTPase 
domain, ankyrin repeat and 
PH domain 3 
Rho GTPases 
NM_198886 1.66 Zbtb12 zinc finger and BTB domain 
containing 12 
Cell division 
NM_007547 1.66 Sirpa signal-regulatory protein 
alpha 
Immune system 
AK155624 1.65 Tmem184
b 
transmembrane protein 
184b 
ND 
NM_183186 1.60 Foxn3 forkhead box N3 RNA processing 
NM_153555 1.60 Dcaf8 DDB1 and CUL4 associated 
factor 8 
Ubiquitin pathway 
NM_007911 1.59 Efnb3 ephrin B3 Cell differentiation 
AK005461 1.58 Tbc1d5 TBC1 domain family, 
member 5 
Rho GTPases 
NM_009413 1.57 Tpd52l1 tumor protein D52-like 1 Membrane trafficking 
NM_178888 1.56 Garnl3 GTPase activating 
RANGAP domain-like 3 
Rho GTPases 
NM_010453 1.53 Hoxa5 homeobox A5 Development 
NM_010549 1.50 Il11ra1 interleukin 11 receptor, 
alpha chain 1 
Jak-STAT signaling 
pathway 
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Table AII.4. Genes found down-regulated in colon of scAAV8-TTR T119M injected 
animals as compared to empty vector injected animals. Genes were considered down-
regulated with fold change below 0.5 after class comparison assuming significances 
p<0.05. 
Down-regulated genes in colon of scAAV8-TTR T119M injected animals 
GB accession 
number 
Fold 
Change 
Symbol Gene name Gene onthology 
NM_177356 -2.81 Lamp3 lysosomal-associated 
membrane protein 3 
Lysosomal activity 
NM_011407 -2.57 Slfn1 schlafen 1 Immune system 
NM_023493 -2.47 Cml5 camello-like 5 Cell-Cell 
communication 
NM_011337 -2.39 Ccl3 chemokine (C-C motif) ligand 3 GPCR signaling 
pathway 
NM_177634 -2.33 H2-
M10.4 
histocompatibility 2, M region 
locus 10.4 
Immune system 
AK084109 -2.28 Trpc4 transient receptor potential 
cation channel, subfamily C, 
member 4 
Ion channel 
activity 
NM_146666 -2.25 Olfr736 olfactory receptor 736 GPCR signaling 
pathway 
NM_009401 -2.11 Tnfrsf8 tumor necrosis factor receptor 
superfamily, member 8 
Immune system 
NM_009477 -1.96 Upp1 uridine phosphorylase 1 Metabolism of 
nucleotides 
NM_011107 -1.94 Pla2g1b phospholipase A2, group IB, 
pancreas 
Metabolism of 
lipids and 
lipoproteins 
NM_029021 -1.93 Ocstamp osteoclast stimulatory 
transmembrane protein 
Immune system 
NM_029766 -1.93 Dtl denticleless homolog 
(Drosophila) 
Retinoic acid-
regulated nuclear 
matrix-associated 
protein 
NM_183391 -1.90 Tnfsf18 tumor necrosis factor (ligand) 
superfamily, member 18 
Immune system 
NM_010900 -1.88 Nfatc2ip nuclear factor of activated T 
cells, cytoplasmic, calcineurin 
dependent 2 interacting protein 
Immune system 
AK007357 -1.86 Pnlip pancreatic lipase Metabolism of 
lipids and 
lipoproteins 
NM_011999 -1.83 Clec4a2 C-type lectin domain family 4, 
member a2 
Immune system 
NM_022983 -1.79 Edg7 lysophosphatidic acid receptor 
3 
GPCR signaling 
pathway 
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NM_007440 -1.77 Alox12 arachidonate 12-lipoxygenase Metabolism of 
lipids and 
lipoproteins 
NM_011627 -1.75 Tpbg trophoblast glycoprotein Cell-Cell 
communication 
NM_030172 -1.74 Efcab11 EF-hand calcium binding 
domain 11 
Calcium binding 
AK087873 -1.74 Nlrp9c NLR family, pyrin domain 
containing 9C 
Immune system 
AK014229 -1.72 Vps51 vacuolar protein sorting 51 
homolog (S. cerevisiae) 
Autophagy 
NM_173770 -1.68 Fam69c family with sequence similarity 
69, member C 
Cell-Cell 
communication 
NM_170758 -1.65 Cd300a CD300A antigen Immune system 
NM_008462 -1.59 Klra2 killer cell lectin-like receptor, 
subfamily A, member 2 
Immune system 
NM_144890 -1.54 Bpifb5 BPI fold containing family B, 
member 5 
Metabolism of 
lipids and 
lipoproteins 
NM_008685 -1.51 Nfe2 nuclear factor, erythroid 
derived 2 
Cell-Cell 
communication 
NM_183000 -1.42 Accn3 acid-sensing (proton-gated) 
ion channel 3 
Ion channel 
activity 
NM_010903 -1.39 Nfe2l3 nuclear factor, erythroid 
derived 2, like 3 
Cell-Cell 
communication 
NM_025658 -1.37 Ms4a4d membrane-spanning 4-
domains, subfamily A, member 
4D 
Cell-Cell 
communication 
AK021362 -1.36 Nxpe4 neurexophilin and PC-esterase 
domain family, member 4 
Immune system 
NM_007975 -1.28 F2rl3 coagulation factor II (thrombin) 
receptor-like 3 
GPCR 
downstream 
signaling, 
organism-specific 
biosystem  
NM_027893 -1.25 Pvrl4 poliovirus receptor-related 4 Cell-Cell 
communication 
NM_010142 -1.22 Ephb2 Eph receptor B2 Development 
NM_183179 -1.14 Kcnv2 potassium channel, subfamily 
V, member 2 
Ion channel 
activity 
NM_133996 -1.13 Apon apolipoprotein N ND 
NM_001081278 -1.12 Tbc1d4 TBC1 domain family, member 
4 
Insulin Signaling 
NM_011932 -1.12 Dapp1 dual adaptor for 
phosphotyrosine and 3-
phosphoinositides 1 
Immune system 
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AK050232 -1.11 Piezo2 piezo-type mechanosensitive 
ion channel component 2; 
Fam38b 
Ion channel 
activity 
NM_001033177 -1.11 Krt76 keratin 76 ND 
NM_007555 -1.07 Bmp5 bone morphogenetic protein 5 Cell proliferation 
AK048153 -1.05 Ophn1 oligophrenin 1 Rho GTPases 
NM_145955 -1.04 Mcmbp MCM (minichromosome 
maintenance deficient) binding 
protein 
DNA replication 
NM_010369 -1.04 Gypa glycophorin A ND 
NM_010188 -1.04 Fcgr3 Fc receptor, IgG, low affinity III Immune system 
NM_134110 -1.04 Kcne2 potassium voltage-gated 
channel, Isk-related subfamily, 
gene 2 
Ion channel 
activity 
NM_031195 -1.02 Msr1 macrophage scavenger 
receptor 1 
Immune system 
AK148229 -1.01 Neu1 neuraminidase 1 Lysosomal activity 
NM_020268 -1.00 Klk1b27 kallikrein 1-related peptidase 
b27 
ECM 
NM_010654 -1.00 Klrd1 killer cell lectin-like receptor, 
subfamily D, member 1; CD94 
Immune system 
 
  
 
 
